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Preamble
It is important that the medical profession play a significant
role in critically evaluating the use of diagnostic procedures
and therapies as they are introduced and tested in the
detection, management, or prevention of disease states. Rig-
orous and expert analysis of the available data documenting
absolute and relative benefits and risks of those procedures
and therapies can produce helpful guidelines that improve the
effectiveness of care, optimize patient outcomes, and favor-
ably affect the overall cost of care by focusing resources on
the most effective strategies.
The American College of Cardiology Foundation (ACCF)
and the American Heart Association (AHA) have jointly
engaged in the production of such guidelines in the area of
cardiovascular disease since 1980. The ACC/AHA Task
Force on Practice Guidelines, whose charge is to develop,
update, or revise practice guidelines for important cardiovas-
cular diseases and procedures, directs this effort. The Task
Force is pleased to have this guideline developed in conjunc-
tion with the European Society of Cardiology (ESC). Writing
committees are charged with the task of performing an
assessment of the evidence and acting as an independent
group of authors to develop or update written recommenda-
tions for clinical practice.
Experts in the subject under consideration have been
selected from all 3 organizations to examine subject-specific
data and write guidelines. The process includes additional
representatives from other medical practitioner and specialty
groups when appropriate. Writing committees are specifically
charged to perform a formal literature review, weigh the
strength of evidence for or against a particular treatment or
procedure, and include estimates of expected health outcomes
where data exist. Patient-specific modifiers, comorbidities,
and issues of patient preference that might influence the
choice of particular tests or therapies are considered as well as
frequency of follow-up and cost-effectiveness. When avail-
able, information from studies on cost will be considered;
however, review of data on efficacy and clinical outcomes
will constitute the primary basis for preparing recommenda-
tions in these guidelines.
The ACC/AHA Task Force on Practice Guidelines and the
ESC Committee for Practice Guidelines make every effort to
avoid any actual, potential, or perceived conflict of interest
that might arise as a result of an outside relationship or
personal interest of the writing committee. Specifically, all
members of the Writing Committee and peer reviewers of
the document are asked to provide disclosure statements
of all such relationships that might be perceived as real or
potential conflicts of interest. Writing committee members
are also strongly encouraged to declare a previous relation-
ship with industry that might be perceived as relevant to
guideline development. If a writing committee member de-
velops a new relationship with industry during their tenure,
they are required to notify guideline staff in writing. The
continued participation of the writing committee member will
be reviewed. These statements are reviewed by the parent
Task Force, reported orally to all members of the writing
committee at each meeting, and updated and reviewed by the
writing committee as changes occur. Please refer to the
methodology manuals for further description of the policies
used in guideline development, including relationships with
industry, available online at the ACC, AHA, and ESC World
Wide Web sites (http://www.acc.org/clinical/manual/manual
_introltr.htm, http://circ.ahajournals.org/manual/, and http://
www.escardio.org/knowledge/guidelines/Rules/). Please see
Appendix I for author relationships with industry and Appen-
dix II for peer reviewer relationships with industry that are
pertinent to these guidelines.
These practice guidelines are intended to assist healthcare
providers in clinical decision making by describing a range of
generally acceptable approaches for the diagnosis, manage-
ment, and prevention of specific diseases and conditions.
These guidelines attempt to define practices that meet the
needs of most patients in most circumstances. These guide-
line recommendations reflect a consensus of expert opinion
after a thorough review of the available, current scientific
evidence and are intended to improve patient care. If these
guidelines are used as the basis for regulatory/payer deci-
sions, the ultimate goal is quality of care and serving the
patient’s best interests. The ultimate judgment regarding care
of a particular patient must be made by the healthcare
provider and the patient in light of all of the circumstances
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presented by that patient. There are circumstances in which
deviations from these guidelines are appropriate.
The guidelines will be reviewed annually by the ACC/AHA
Task Force on Practice Guidelines and the ESC Committee for
Practice Guidelines and will be considered current unless they
are updated, revised, or sunsetted and withdrawn from distribu-
tion. The executive summary and recommendations are pub-
lished in the August 15, 2006, issues of the Journal of the
American College of Cardiology and Circulation and the August
16, 2006, issue of the European Heart Journal. The full-text
guidelines are published in the August 15, 2006, issues of the
Journal of the American College of Cardiology and Circulation
and the September 2006 issue of Europace, as well as posted on
the ACC (www.acc.org), AHA (www.americanheart.org), and
ESC (www.escardio.org) World Wide Web sites. Copies of the
full-text guidelines and the executive summary are available
from all 3 organizations.
Sidney C. Smith Jr, MD, FACC, FAHA, FESC, Chair,
ACC/AHA Task Force on Practice Guidelines
Silvia G. Priori, MD, PhD, FESC, Chair, ESC Committee
for Practice Guidelines
1. Introduction
1.1. Organization of Committee and
Evidence Review
Atrial fibrillation (AF) is the most common sustained cardiac
rhythm disturbance, increasing in prevalence with age. AF is
often associated with structural heart disease, although a
substantial proportion of patients with AF have no detectable
heart disease. Hemodynamic impairment and thromboem-
bolic events related to AF result in significant morbidity,
mortality, and cost. Accordingly, the American College of
Cardiology (ACC), the American Heart Association (AHA),
and the European Society of Cardiology (ESC) created a
committee to establish guidelines for optimum management
of this frequent and complex arrhythmia.
The committee was composed of members representing the
ACC, AHA, and ESC, as well as the European Heart Rhythm
Association (EHRA) and the Heart Rhythm Society (HRS).
This document was reviewed by 2 official reviewers nomi-
nated by the ACC, 2 official reviewers nominated by the
AHA, and 2 official reviewers nominated by the ESC, as well
as by the ACCF Clinical Electrophysiology Committee, the
AHA ECG and Arrhythmias Committee, the AHA Stroke
Review Committee, EHRA, HRS, and numerous additional
content reviewers nominated by the writing committee. The
document was approved for publication by the governing
bodies of the ACC, AHA, and ESC and officially endorsed by
the EHRA and the HRS.
The ACC/AHA/ESC Writing Committee to Revise the
2001 Guidelines for the Management of Patients With Atrial
Fibrillation conducted a comprehensive review of the rele-
vant literature from 2001 to 2006. Literature searches were
conducted in the following databases: PubMed/MEDLINE
and the Cochrane Library (including the Cochrane Database
of Systematic Reviews and the Cochrane Controlled Trials
Registry). Searches focused on English-language sources and
studies in human subjects. Articles related to animal experi-
mentation were cited when the information was important to
understanding pathophysiological concepts pertinent to
patient management and comparable data were not avail-
able from human studies. Major search terms included
atrial fibrillation, age, atrial remodeling, atrioventricular
conduction, atrioventricular node, cardioversion, classifi-
cation, clinical trial, complications, concealed conduction,
cost-effectiveness, defibrillator, demographics, epidemiol-
ogy, experimental, heart failure (HF), hemodynamics,
human, hyperthyroidism, hypothyroidism, meta-analysis,
myocardial infarction, pharmacology, postoperative, preg-
nancy, pulmonary disease, quality of life, rate control,
rhythm control, risks, sinus rhythm, symptoms, and
tachycardia-mediated cardiomyopathy. The complete list
of search terms is beyond the scope of this section.
Classification of Recommendations and Level of Evidence
are expressed in the ACC/AHA/ESC format as follows and
described in Table 1. Recommendations are evidence based
and derived primarily from published data.
Classification of Recommendations
● Class I: Conditions for which there is evidence and/or
general agreement that a given procedure/therapy is bene-
ficial, useful, and effective.
● Class II: Conditions for which there is conflicting evidence
and/or a divergence of opinion about the usefulness/
efficacy of performing the procedure/therapy.
 Class IIa: Weight of evidence/opinion is in favor of
usefulness/efficacy.
 Class IIb: Usefulness/efficacy is less well established by
evidence/opinion.
● Class III: Conditions for which there is evidence and/or
general agreement that a procedure/therapy is not useful or
effective and in some cases may be harmful.
Level of Evidence
The weight of evidence was ranked from highest (A) to
lowest (C), as follows:
● Level of Evidence A: Data derived from multiple random-
ized clinical trials or meta-analyses.
● Level of Evidence B: Data derived from a single random-
ized trial or nonrandomized studies.
● Level of Evidence C: Only consensus opinion of experts,
case studies, or standard-of-care.
1.2. Contents of These Guidelines
These guidelines first present a comprehensive review of the
latest information about the definition, classification, epide-
miology, pathophysiological mechanisms, and clinical char-
acteristics of AF. The management of this complex and
potentially dangerous arrhythmia is then reviewed. This
includes prevention of AF, control of heart rate, prevention of
thromboembolism, and conversion to and maintenance of
sinus rhythm. The treatment algorithms include pharmaco-
logical and nonpharmacological antiarrhythmic approaches,
as well as antithrombotic strategies most appropriate for
particular clinical conditions. Overall, this is a consensus
document that attempts to reconcile evidence and opinion
from both sides of the Atlantic Ocean. The pharmacological
and nonpharmacological antiarrhythmic approaches may in-
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TABLE 1. Applying Classification of Recommendations and Level of Evidence†
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Class I Class IIa Class IIb Class III
Benefit  Risk Benefit  Risk Benefit  Risk Risk  Benefit
Additional studies with focused objectives
needed
Additional studies with broad objectives needed;
additional registry data would be helpful
No additional studies needed
Procedure/treatment SHOULD be
performed/administered
IT IS REASONABLE to perform
procedure/administer treatment
Procedure/treatment MAY BE CONSIDERED Procedure/treatment should NOT be
performed/administered SINCE IT IS NOT HELPFUL
AND MAY BE HARMFUL
Level A
Multiple (3 to 5) population
risk strata evaluated*
General consistency of
direction and magnitude of
effect
• Recommendation that procedure or
treatment is useful/effective
• Sufficient evidence from multiple
randomized trials or meta-analyses
• Recommendation in favor of treatment or
procedure being useful/effective
• Some conflicting evidence from multiple
randomized trials or meta-analyses
• Recommendation’s usefulness/efficacy less well
established
•Greater conflicting evidence from multiple
randomized trials or meta-analyses
• Recommendation that procedure or treatment is
not useful/effective and may be harmful
• Sufficient evidence from multiple randomized trials
or meta-analyses
Level B
Limited (2 to 3) population risk
strata evaluated*
• Recommendation that procedure or
treatment is useful/effective
• Limited evidence from single randomized
trial or nonrandomized studies
• Recommendation in favor of treatment or
procedure being useful/effective
• Some conflicting evidence from single
randomized trial or nonrandomized studies
• Recommendation’s usefulness/efficacy less well
established
•Greater conflicting evidence from single
randomized trial or nonrandomized studies
• Recommendation that procedure or treatment is
not useful/effective and may be harmful
• Limited evidence from single randomized trial or
nonrandomized studies
Level C
Very limited (1 to 2) population
risk strata evaluated*
• Recommendation that procedure or
treatment is useful/effective
•Only expert opinion, case studies, or
standard-of-care
• Recommendation in favor of treatment or
procedure being useful/effective
•Only diverging expert opinion, case studies, or
standard-of-care
• Recommendation’s usefulness/efficacy less well
established
•Only diverging expert opinion, case studies, or
standard-of-care
• Recommendation that procedure or treatment is
not useful/effective and may be harmful
•Only expert opinion, case studies, or
standard-of-care
*Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as gender, age, history of diabetes, history of prior myocardial infarction, history of heart failure, and prior aspirin use. A
recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Even though randomized trials are not
available, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.
†In 2003, the ACC/AHA Task Force on Practice Guidelines developed a list of suggested phrases to use when writing recommendations. All guideline recommendations have been written in full sentences that express a complete
thought, such that a recommendation, even if separated and presented apart from the rest of the document (including headings above sets of recommendations), would still convey the full intent of the recommendation. It is hoped that this
will increase readers’ comprehension of the guidelines and will allow queries at the individual recommendation level.
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clude some drugs and devices that do not have the approval
of all government regulatory agencies. Additional informa-
tion may be obtained from the package inserts when the drug
or device has been approved for the stated indication.
Because atrial flutter can precede or coexist with AF,
special consideration is given to this arrhythmia in each
section. There are important differences in the mechanisms of
AF and atrial flutter, and the body of evidence available to
support therapeutic recommendations is distinct for the 2
arrhythmias. Atrial flutter is not addressed comprehensively
in these guidelines but is addressed in the ACC/AHA/ESC
Guidelines on the Management of Patients with Supraven-
tricular Arrhythmias (1).
1.3. Changes Since the Initial Publication of These
Guidelines in 2001
In developing this revision of the guidelines, the Writing
Committee considered evidence published since 2001 and
drafted revised recommendations where appropriate to incor-
porate results from major clinical trials such as those that
compared rhythm-control and rate-control approaches to
long-term management. The text has been reorganized to
reflect the implications for patient care, beginning with
recognition of AF and its pathogenesis and the general
priorities of rate control, prevention of thromboembolism,
and methods available for use in selected patients to correct
the arrhythmia and maintain normal sinus rhythm. Advances
in catheter-based ablation technologies have been incorpo-
rated into expanded sections and recommendations, with the
recognition that that such vital details as patient selection,
optimum catheter positioning, absolute rates of treatment
success, and the frequency of complications remain incom-
pletely defined. Sections on drug therapy have been con-
densed and confined to human studies with compounds that
have been approved for clinical use in North America and/or
Europe. Accumulating evidence from clinical studies on the
emerging role of angiotensin inhibition to reduce the occur-
rence and complications of AF and information on ap-
proaches to the primary prevention of AF are addressed
comprehensively in the text, as these may evolve further in
the years ahead to form the basis for recommendations
affecting patient care. Finally, data on specific aspects of
management of patients who are prone to develop AF in
special circumstances have become more robust, allowing
formulation of recommendations based on a higher level of
evidence than in the first edition of these guidelines. An
example is the completion of a relatively large randomized
trial addressing prophylactic administration of antiarrhythmic
medication for patients undergoing cardiac surgery. In devel-
oping the updated recommendations, every effort was made
to maintain consistency with other ACC/AHA and ESC
practice guidelines addressing, for example, the management
of patients undergoing myocardial revascularization
procedures.
2. Definition
2.1. Atrial Fibrillation
AF is a supraventricular tachyarrhythmia characterized by
uncoordinated atrial activation with consequent deterioration
of atrial mechanical function. On the electrocardiogram
(ECG), AF is characterized by the replacement of consistent
P waves by rapid oscillations or fibrillatory waves that vary in
amplitude, shape, and timing, associated with an irregular,
frequently rapid ventricular response when atrioventricular
(AV) conduction is intact (2) (Fig. 1). The ventricular
response to AF depends on electrophysiological (EP) prop-
erties of the AV node and other conducting tissues, the level
of vagal and sympathetic tone, the presence or absence of
accessory conduction pathways, and the action of drugs (3).
Regular cardiac cycles (R-R intervals) are possible in the
presence of AV block or ventricular or AV junctional
tachycardia. In patients with implanted pacemakers, diagno-
sis of AF may require temporary inhibition of the pacemaker
to expose atrial fibrillatory activity (4). A rapid, irregular,
sustained, wide-QRS-complex tachycardia strongly suggests
AF with conduction over an accessory pathway or AF with
underlying bundle-branch block. Extremely rapid rates (over
200 beats per minute) suggest the presence of an accessory
pathway or ventricular tachycardia.
2.2. Related Arrhythmias
AF may occur in isolation or in association with other
arrhythmias, most commonly atrial flutter or atrial
tachycardia. Atrial flutter may arise during treatment with
antiarrhythmic agents prescribed to prevent recurrent AF.
Atrial flutter in the typical form is characterized by a
saw-tooth pattern of regular atrial activation called flutter (ƒ)
waves on the ECG, particularly visible in leads II, III, aVF,
and V1 (Fig. 2). In the untreated state, the atrial rate in atrial
flutter typically ranges from 240 to 320 beats per minute, with
ƒ waves inverted in ECG leads II, III, and aVF and upright in
lead V1. The direction of activation in the right atrium (RA)
may be reversed, resulting in ƒ waves that are upright in leads
II, III, and aVF and inverted in lead V1. Atrial flutter
commonly occurs with 2:1 AV block, resulting in a regular or
irregular ventricular rate of 120 to 160 beats per minute (most
characteristically about 150 beats per minute). Atrial flutter
may degenerate into AF and AF may convert to atrial flutter.
The ECG pattern may fluctuate between atrial flutter and AF,
reflecting changing activation of the atria. Atrial flutter is
usually readily distinguished from AF, but when atrial activ-
ity is prominent on the ECG in more than 1 lead, AF may be
misdiagnosed as atrial flutter (5).
Focal atrial tachycardias, AV reentrant tachycardias, and
AV nodal reentrant tachycardias may also trigger AF. In other
atrial tachycardias, P waves may be readily identified and are
separated by an isoelectric baseline in 1 or more ECG leads.
The morphology of the P waves may help localize the origin
of the tachycardias.
3. Classification
Various classification systems have been proposed for AF.
One is based on the ECG presentation (2–4). Another is
based on epicardial (6) or endocavitary recordings or non-
contact mapping of atrial electrical activity. Several clinical
classification schemes have also been proposed, but none
fully accounts for all aspects of AF (7–10). To be clinically
useful, a classification system must be based on a sufficient
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Figure 1. Electrocardiogram showing atrial fibrillation with a controlled rate of ventricular response. P waves are replaced by fibrillatory
waves and the ventricular response is completely irregular.
Figure 2. Electrocardiogram showing typical atrial flutter with variable atrioventricular conduction. Note the saw-tooth pattern, F waves,
particularly visible in leads II, III, and aVF, without an isoelectric baseline between deflections.
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number of features and carry specific therapeutic
implications.
Assorted labels have been used to describe the pattern of
AF, including acute, chronic, paroxysmal, intermittent, con-
stant, persistent, and permanent, but the vagaries of defini-
tions make it difficult to compare studies of AF or the
effectiveness of therapeutic strategies based on these desig-
nations. Although the pattern of the arrhythmia can change
over time, it may be of clinical value to characterize the
arrhythmia at a given moment. The classification scheme
recommended in this document represents a consensus driven
by a desire for simplicity and clinical relevance.
The clinician should distinguish a first-detected episode of
AF, whether or not it is symptomatic or self-limited, recog-
nizing that there may be uncertainty about the duration of the
episode and about previous undetected episodes (Fig. 3).
When a patient has had 2 or more episodes, AF is considered
recurrent. If the arrhythmia terminates spontaneously, recur-
rent AF is designated paroxysmal; when sustained beyond
7 d, AF is designated persistent. Termination with pharma-
cological therapy or direct-current cardioversion does not
change the designation. First-detected AF may be either
paroxysmal or persistent AF. The category of persistent AF
also includes cases of long-standing AF (e.g., greater than
1 y), usually leading to permanent AF, in which cardioversion
has failed or has not been attempted.
These categories are not mutually exclusive in a particular
patient, who may have several episodes of paroxysmal AF
and occasional persistent AF, or the reverse. Regarding
paroxysmal and persistent AF, it is practical to categorize a
given patient by the most frequent presentation. The defini-
tion of permanent AF is often arbitrary. The duration of AF
refers both to individual episodes and to how long the patient
has been affected by the arrhythmia. Thus, a patient with
paroxysmal AF may have episodes that last seconds to hours
occurring repeatedly for years.
Episodes of AF briefer than 30 s may be important in
certain clinical situations involving symptomatic patients,
pre-excitation or in assessing the effectiveness of therapeutic
interventions. This terminology applies to episodes of AF that
last more than 30 s without a reversible cause. Secondary AF
that occurs in the setting of acute myocardial infarction (MI),
cardiac surgery, pericarditis, myocarditis, hyperthyroidism,
pulmonary embolism, pneumonia, or other acute pulmonary
disease is considered separately. In these settings, AF is not
the primary problem, and treatment of the underlying disorder
concurrently with management of the episode of AF usually
terminates the arrhythmia without recurrence. Conversely,
because AF is common, it may occur independently of a
concurrent disorder like well-controlled hypothyroidism, and
then the general principles for management of the arrhythmia
apply.
The term “lone AF” has been variously defined but
generally applies to young individuals (under 60 y of age)
without clinical or echocardiographic evidence of cardiopul-
monary disease, including hypertension (11). These patients
have a favorable prognosis with respect to thromboembolism
and mortality. Over time, patients may move out of the lone
AF category due to aging or development of cardiac abnor-
malities such as enlargement of the left atrium (LA. Then, the
risks of thromboembolism and mortality rise accordingly. By
convention, the term “nonvalvular AF” is restricted to cases
in which the rhythm disturbance occurs in the absence of
rheumatic mitral valve disease, a prosthetic heart valve, or
mitral valve repair.
4. Epidemiology and Prognosis
AF is the most common arrhythmia in clinical practice,
accounting for approximately one-third of hospitalizations for
cardiac rhythm disturbances. Most data regarding the epide-
miology, prognosis, and quality of life in AF have been
obtained in the United States and western Europe. It has been
estimated that 2.2 million people in America and 4.5 million
in the European Union have paroxysmal or persistent AF
(12). During the past 20 y, there has been a 66% increase in
hospital admissions for AF (13–15) due to a combination of
factors including the aging of the population, a rising preva-
lence of chronic heart disease, and more frequent diagnosis
through use of ambulatory monitoring devices. AF is an
extremely costly public health problem (16,17), with hospi-
Figure 3. Patterns of atrial fibrillation (AF). 1, Epi-
sodes that generally last 7 d or less (most less
than 24 h); 2, episodes that usually last longer than
7 d; 3, cardioversion failed or not attempted; and
4, both paroxysmal and persistent AF may be
recurrent.
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talizations as the primary cost driver (52%), followed by
drugs (23%), consultations (9%), further investigations (8%),
loss of work (6%), and paramedical procedures (2%). Glo-
bally, the annual cost per patient is close to €3000 (approx-
imately U.S. $3600) (16). Considering the prevalence of AF,
the total societal burden is huge, for example, about €13.5
billion (approximately U.S. $15.7 billion) in the European
Union.
4.1. Prevalence
The estimated prevalence of AF is 0.4% to 1% in the general
population, increasing with age (18,19). Cross-sectional stud-
ies have found a lower prevalence in those below the age of
60 y, increasing to 8% in those older than 80 y (Fig. 4)
(20–22). The age-adjusted prevalence of AF is higher in men,
(22,23) in whom the prevalence has more than doubled from
the 1970s to the 1990s, while the prevalence in women has
remained unchanged (24). The median age of AF patients is
about 75 y. Approximately 70% are between 65 and 85 y old.
The overall number of men and women with AF is about
equal, but approximately 60% of AF patients over 75 y are
female. Based on limited data, the age-adjusted risk of
developing AF in blacks seems less than half that in whites
(18,25,26). AF is less common among African-American
than Caucasian patients with heart failure (HF).
In population-based studies, patients with no history of
cardiopulmonary disease account for fewer than 12% of all
cases of AF (11,22,27,28). In some series, however, the
observed proportion of lone AF was over 30% (29,30).
These differences may depend on selection bias when
recruiting patients seen in clinical practice compared with
population-based observations. In the Euro Heart Survey on
AF (31), the prevalence of idiopathic AF amounted to 10%,
with an expected highest value of 15% in paroxysmal AF,
14% in first-detected AF, 10% in persistent AF, and only 4%
in permanent AF. Essential hypertension, ischemic heart
disease, HF (Table 2), valvular heart disease, and diabetes are
the most prominent conditions associated with AF (14).
4.2. Incidence
In prospective studies, the incidence of AF increases from
less than 0.1% per year in those under 40 y old to exceed
1.5% per year in women and 2% in men older than 80 (Fig.
5) (25,32,33). The age-adjusted incidence increased over a
30-y period in the Framingham Study (32), and this may have
implications for the future impact of AF (34). During 38 y of
follow-up in the Framingham Study, 20.6% of men who
developed AF had HF at inclusion versus 3.2% of those
without AF; the corresponding incidences in women were
26.0% and 2.9% (35). In patients referred for treatment of HF,
the 2- to 3-y incidence of AF was 5% to 10% (25,36,37). The
incidence of AF may be lower in HF patients treated with
angiotensin inhibitors (38–40). Similarly, angiotensin inhibition
may be associated with a reduced incidence of AF in patients
with hypertension (41,42), although this may be confined to
those with left ventricular hypertrophy (LVH) (43–45).
Figure 4. Estimated age-specific prevalence of atrial fibrillation
(AF) based on 4 population-based surveys. Prevalence, age,
distribution, and gender of patients with AF analysis and impli-
cations. Modified with permission from Feinberg WM, Black-
shear JL, Laupacis A, et al. Prevalence, age distribution, and
gender of patients with atrial fibrillation. Analysis and implica-
tions. Arch Intern Med 1995;155:469–73 (19). Copyright © 1995,
American Medical Association. All rights reserved.
TABLE 2. Prevalence of AF in Patients With Heart Failure as
Reflected in Several Heart Failure Trials
Predominant
NYHA Class
Prevalence of
AF (%) Study
I 4 SOLVD–Prevention (1992)(14a)
II-III 10 to 26 SOLVD–Treatment (1991) (14b)
CHF-STAT (1995) (14c)
MERIT-HF (1999) (14d)
DIAMOND-CHF (1999) (501)
II-IV 12 to 27 CHARM (2003) Val-HeFT (2003) (848)
III-IV 20 to 29 Middlekauff (1991) (14e)
Stevenson (1996) GESICA (1994) (14f)
IV 50 CONSENSUS (1987) (14g)
AF indicates atrial fibrillation; NYHA, New York Heart Association; SOLVD,
Studies Of Left Ventricular Dysfunction; CHF-STAT, Survival Trial of Antiarrhyth-
mic Therapy in Congestive Heart Failure; MERIT-HF, Metropolol CR/XL Ran-
domized Intervention Trial in Congestive Heart Failure; DIAMOND-CHF, Danish
Investigations of Arrhythmia and Mortality on Dofetilide–Congestive Heart
Failure; CHARM, Candesartan in Heart failure, Assessment of Reduction in
Mortality and morbidity; Val-HeFT, Valsartan Heart Failure Trial; GESICA, Grupo
Estudio de la Sobrevida en la Insufficienca Cardiaca en Argentina (V); and
CONSENSUS, Co-operative North Scandinavian Enalapril Survival Study.
Figure 5. Incidence of atrial fibrillation in 2 American epidemio-
logical studies. Framingham indicates the Framingham Heart
Study. Data are from Wolf PA, Abbott RD, Kannel WB. Atrial
fibrillation: a major contributor to stroke in the elderly. The Fra-
mingham Study. Arch Intern Med 1987;147:1561–4 (32). CHS
indicates the Cardiovascular Health Study. Data are from Psaty
BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors
for atrial fibrillation in older adults. Circulation 1997;96:2455–61
(25); and Furberg CD, Psaty BM, Manolio TA, et al. Prevalence
of atrial fibrillation in elderly subjects (the Cardiovascular Health
Study). Am J Cardiol 1994;74:236–41, (22) and Farrell B, God-
win J, Richards S, et al. The United Kingdom transient isch-
aemic attack (UK-TIA) aspirin trial: final results. J Neurol Neuro-
surg Psychiatry 1991;54:1044–54 (46).
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4.3. Prognosis
AF is associated with an increased long-term risk of stroke,
(47), HF, and all-cause mortality, especially in women (48).
The mortality rate of patients with AF is about double that of
patients in normal sinus rhythm and linked to the severity of
underlying heart disease (20,23,33) (Fig. 6). About two-thirds
of the 3.7% mortality over 8.6 mo in the Etude en Activité
Libérale sur la Fibrillation Auriculaire Study (ALFA) was
attributed to cardiovascular causes (29). Table 3 shows a list
of associated heart diseases in the population of the ALFA
study (29).
Mortality in the Veterans Administration Heart Failure
Trials (V-HeFT) was not increased among patients with
concomitant AF, (49) whereas in the Studies of Left Ventric-
ular Dysfunction (SOLVD), mortality was 34% for those with
AF versus 23% for patients in sinus rhythm (p less than
0.001) (50). The difference was attributed mainly to deaths
due to HF rather than to thromboembolism. AF was a strong
independent risk factor for mortality and major morbidity in
large HF trials. In the Carvedilol Or Metoprolol European
Trial (COMET), there was no difference in all-cause mortal-
ity in those with AF at entry, but mortality increased in those
who developed AF during follow-up (51). In the Val-HeFT
cohort of patients with chronic HF, development of AF was
associated with significantly worse outcomes (40). HF pro-
motes AF, AF aggravates HF, and individuals with either
condition who develop the alternate condition share a poor
prognosis (52). Thus, managing the association is a major
challenge (53) and the need for randomized trials to investi-
gate the impact of AF on the prognosis in HF is apparent.
The rate of ischemic stroke among patients with nonval-
vular AF averages 5% per year, 2 to 7 times that of people
without AF (20,21,29,32,33,47) (Fig. 6). One of every 6
strokes occurs in a patient with AF (54). Additionally, when
transient ischemic attacks (TIAs) and clinically “silent”
strokes detected by brain imaging are considered, the rate of
brain ischemia accompanying nonvalvular AF exceeds 7%
per year (35,55–58) In patients with rheumatic heart disease
and AF in the Framingham Heart Study, stroke risk was
increased 17-fold compared with age-matched controls (59),
and attributable risk was 5 times greater than that in those
with nonrheumatic AF (21). In the Manitoba Follow-up
Study, AF doubled the risk of stroke independently of other
risk factors (33), and the relative risks for stroke in nonrheu-
matic AF were 6.9% and 2.3% in the Whitehall and the
Regional Heart studies, respectively. Among AF patients
from general practices in France, the Etude en Activité
Libe´rale sur le Fibrillation Auriculaire (ALFA) study found a
2.4% incidence of thromboembolism over a mean of 8.6 mo
of follow-up (29). The risk of stroke increases with age; in the
Framingham Study, the annual risk of stroke attributable to
AF was 1.5% in participants 50 to 59 y old and 23.5% in
those aged 80 to 89 y (21).
Figure 6. Relative risk of stroke and mortality in patients with
atrial fibrillation (AF) compared with patients without AF. Source
data from the Framingham Heart Study (Kannel WB, Abbott RD,
Savage DD, et al. Coronary heart disease and atrial fibrillation:
the Framingham Study. Am Heart J 1983;106:389–96), (23) the
Regional Heart Study and the Whitehall study (Flegel KM,
Shipley MJ, Rose G. Risk of stroke in non-rheumatic atrial
fibrillation), and the Manitoba study (Krahn AD, Manfreda J, Tate
RB, et al. The natural history of atrial fibrillation: incidence, risk
factors, and prognosis in the Manitoba Follow-Up Study.
Am J Med 1995;98:476–84) (33).
TABLE 3. Demographics and Associated Conditions Among
Patients With Atrial Fibrillation in the ALFA Study
Total
Population
Paroxysmal
AF
Chronic
AF
Recent-
Onset
AF
No. of patients 756 167 389 200
Age, y 69 66 70 68
Male/female ratio 1 1 2 1
Time from first episode
of AF (mo)
47 39 66 NA
Underlying heart disease (%)
Coronary artery disease 17 12 18 19
Hypertensive heart disease 21 17 22 25
Valvular (rheumatic) 15 10 20 12
Dilated cardiomyopathy 9 2 13 9
Hypertrophic cardiomyopathy 5 3 4 9
Other 9 14 9 7
None 29 46 23 28
Other predisposing
or associated
factors (%)
Hyperthyroidism 3 4 2 5
Hypertension 39 35 38 46
Bronchopulmonary disease 11 10 13 10
Diabetes 11 7 13 9
Congestive HF 30 14 43 18
Prior embolic events 8 8 11 4
Left atrial size (mm) 44 40 47 42
Left ventricular ejection
fraction (%)
59 63 57 58
Persistent atrial fibrillation (AF) includes both recent-onset and chronic AF.
Recent-onset AF was defined as persistent AF lasting greater than or equal to
7 and less than 30 d. Chronic AF was defined as persistent AF of more than
30-d duration. Patients in whom the diagnosis was definite and those in whom
it was probable were included. Modified with permission from Levy S, Maarek
M, Coumel P, et al. Characterization of different subsets of atrial fibrillation in
general practice in France: the ALFA Study, The College of French Cardiolo-
gists. Circulation 1999;99:3028–35 (29). © 1999 American Heart Association.
ALFA indicates Etude en Activité Libérale sur la Fibrillation Auriculaire; HF,
heart failure; and NA, not applicable or unavailable.
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5. Pathophysiological Mechanisms
5.1. Atrial Factors
5.1.1. Atrial Pathology as a Cause of Atrial Fibrillation
The most frequent pathoanatomic changes in AF are atrial
fibrosis and loss of atrial muscle mass. Histological exami-
nation of atrial tissue of patients with AF has shown patchy
fibrosis juxtaposed with normal atrial fibers, which may
account for nonhomogeneity of conduction (60–62). The
sinoatrial (SA) and AV nodes may also be involved, account-
ing for the sick sinus syndrome and AV block. It is difficult
to distinguish between changes due to AF and those due to
associated heart disease, but fibrosis may precede the onset of
AF (63).
Biopsy of the LA posterior wall during mitral valve
surgery revealed mild to moderate fibrosis in specimens
obtained from patients with sinus rhythm or AF of relatively
short duration, compared with severe fibrosis and substantial
loss of muscle mass in those from patients with long-standing
AF. Patients with mild or moderate fibrosis responded more
successfully to cardioversion than did those with severe
fibrosis, which was thought to contribute to persistent AF in
cases of valvular heart disease (64). In atrial tissue specimens
from 53 explanted hearts from transplantation recipients with
dilated cardiomyopathy, 19 of whom had permanent, 18
persistent, and 16 no documented AF, extracellular matrix
remodeling including selective downregulation of atrial
insulin-like growth factor II mRNA-binding protein 2
(IMP-2) and upregulation of matrix metalloproteinase 2
(MMP-2) and type 1 collagen volume fraction (CVF-1) were
associated with sustained AF (65).
Atrial biopsies from patients undergoing cardiac surgery
revealed apoptosis (66) that may lead to replacement of atrial
myocytes by interstitial fibrosis, loss of myofibrils, accumu-
lation of glycogen granules, disruption of cell coupling at gap
junctions (67), and organelle aggregates (68). The concentra-
tion of membrane-bound glycoproteins that regulate cell-cell
and cell-matrix interactions (disintegrin and metalloprotein-
ases) in human atrial myocardium has been reported to
double during AF. Increased disintegrin and metalloprotein-
ase activity may contribute to atrial dilation in patients with
long-standing AF.
Atrial fibrosis may be caused by genetic defects like lamin
AC gene mutations (69). Other triggers of fibrosis include
inflammation (70) as seen in cardiac sarcoidosis (71) and
autoimmune disorders (72). In one study, histological
changes consistent with myocarditis were reported in 66% of
atrial biopsy specimens from patients with lone AF (62), but
it is uncertain whether these inflammatory changes were a
cause or consequence of AF. Autoimmune activity is sug-
gested by high serum levels of antibodies against myosin
heavy chains in patients with paroxysmal AF who have no
identified heart disease (72). Apart from fibrosis, atrial
pathological findings in patients with AF include amyloid-
osis, (73,74). hemochromatosis (75), and endomyocardial
fibrosis (75,76). Fibrosis is also triggered by atrial dilation in
any type of heart disease associated with AF, including
valvular disease, hypertension, HF, or coronary atherosclero-
sis (77). Stretch activates several molecular pathways, includ-
ing the renin-angiotensin-aldosterone system (RAAS). Both
angiotensin II and transforming growth factor-beta1 (TGF-
beta1) are upregulated in response to stretch, and these
molecules induce production of connective tissue growth
factor (CTGF) (70). Atrial tissue from patients with persistent
AF undergoing open-heart surgery demonstrated increased
amounts of extracellular signal-regulated kinase messenger
RNA (ERK-2-mRNA), and expression of angiotensin-
converting enzyme (ACE) was increased 3-fold during per-
sistent AF (78). A study of 250 patients with AF and an equal
number of controls demonstrated the association of RAAS
gene polymorphisms with this type of AF (79).
Several RAAS pathways are activated in experimental
(78,80–84) as well as human AF (78,85), and ACE inhibition
and angiotensin II receptor blockade had the potential to
prevent AF by reducing fibrosis (84,86).
In experimental studies of HF, atrial dilation and interstitial
fibrosis facilitates sustained AF (86–92). The regional elec-
trical silence (suggesting scar), voltage reduction, and con-
duction slowing described in patients with HF (93) are similar
to changes in the atria that occur as a consequence of aging.
AF is associated with delayed interatrial conduction and
dispersion of the atrial refractory period (94). Thus, AF seems
to cause a variety of alterations in the atrial architecture and
function that contribute to remodeling and perpetuation of the
arrhythmia. Despite these pathological changes in the atria,
however, isolation of the pulmonary veins (PVs) will prevent
AF in many such patients with paroxysmal AF.
5.1.1.1. Pathological Changes Caused by Atrial Fibrillation
Just as atrial stretch may cause AF, AF can cause atrial
dilation through loss of contractility and increased compli-
ance (61). Stretch-related growth mechanisms and fibrosis
increase the extracellular matrix, especially during prolonged
periods of AF. Fibrosis is not the primary feature of AF-
induced structural remodeling (95,96), although accumula-
tion of extracellular matrix and fibrosis are associated with
more pronounced myocytic changes once dilation occurs due
to AF or associated heart disease (90,97). These changes
closely resemble those in ventricular myocytes in the hiber-
nating myocardium associated with chronic ischemia (98).
Among these features are an increase in cell size, perinuclear
glycogen accumulation, loss of sarcoplasmic reticulum and
sarcomeres (myolysis). Changes in gap junction distribution
and expression are inconsistent (61,99), and may be less
important than fibrosis or shortened refractoriness in promot-
ing AF. Loss of sarcomeres and contractility seems to protect
myocytes against the high metabolic stress associated with
rapid rates. In fact, in the absence of other pathophysiological
factors, the high atrial rate typical of AF may cause ischemia
that affects myocytes more than the extracellular matrix and
interstitial tissues.
Aside from changes in atrial dimensions that occur over
time, data on human atrial structural remodeling are limited
(96,100) and difficult to distinguish from degenerative
changes related to aging and associated heart disease (96).
One study that compared atrial tissue specimens from patients
with paroxysmal and persistent lone AF found degenerative
contraction bands in patients with either pattern of AF, while
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myolysis and mitochondria hibernation were limited to those
with persistent AF. The activity of calpain I, a proteolytic
enzyme activated in response to cytosolic calcium overload,
was upregulated in both groups and correlated with ion
channel protein and structural and electrical remodeling.
Hence, calpain activation may link calcium overload to
cellular adaptation in patients with AF (341).
5.1.2. Mechanisms of Atrial Fibrillation
The onset and maintenance of a tachyarrhythmia require both
an initiating event and an anatomical substrate. With respect
to AF, the situation is often complex, and available data
support a “focal” mechanism involving automaticity or mul-
tiple reentrant wavelets. These mechanisms are not mutually
exclusive and may at various times coexist in the same patient
(Fig. 7).
5.1.2.1. Automatic Focus Theory
A focal origin of AF is supported by experimental models of
aconitine and pacing-induced AF (102,103) in which the
arrhythmia persists only in isolated regions of atrial myocar-
dium. This theory received minimal attention until the im-
portant observation that a focal source for AF could be
identified in humans and ablation of this source could
extinguish AF (104). While PVs are the most frequent source
of these rapidly atrial impulses, foci have also been found in
the superior vena cava, ligament of Marshall, left posterior
free wall, crista terminalis, and coronary sinus (79,104–110).
In histological studies, cardiac muscle with preserved
electrical properties extends into the PV (106,111–116), and
the primacy of PVs as triggers of AF has prompted substan-
tial research into the anatomical and EP properties of these
structures. Atrial tissue on the PV of patients with AF has
shorter refractory periods than in control patients or other
parts of the atria in patients with AF (117,118). The refractory
period is shorter in atrial tissue in the distal PV than at the
PV-LA junction. Decremental conduction in PV is more
frequent in AF patients than in controls, and AF is more
readily induced during pacing in the PV than in the LA. This
heterogeneity of conduction may promote reentry and form a
substrate for sustained AF (119). Programmed electrical
stimulation in PV isolated by catheter ablation initiated
sustained pulmonary venous tachycardia, probably as a con-
sequence of reentry (120). Rapidly firing atrial automatic foci
may be responsible for these PV triggers, with an anatomical
substrate for reentry vested within the PV.
Whether the source for AF is an automatic focus or a
microreentrant circuit, rapid local activation in the LA cannot
extend to the RA in an organized way. Experiments involving
acetylcholine-induced AF in Langendorf-perfused sheep
hearts demonstrated a dominant fibrillation frequency in the
LA with decreasing frequency as activation progressed to the
RA. A similar phenomenon has been shown in patients with
paroxysmal AF (121). Such variation in conduction leads to
disorganized atrial activation, which could explain the ECG
appearance of a chaotic atrial rhythm (122). The existence of
triggers for AF does not negate the role of substrate modifi-
cation. In some patients with persistent AF, disruption of the
muscular connections between the PV and the LA may
terminate the arrhythmia. In others, AF persists following
isolation of the supposed trigger but does not recur after
cardioversion. Thus, in some patients with abnormal triggers,
sustained AF may depend on an appropriate anatomical
substrate.
5.1.2.2. Multiple-Wavelet Hypothesis
The multiple-wavelet hypothesis as the mechanism of reen-
trant AF was advanced by Moe and colleagues (123), who
proposed that fractionation of wavefronts propagating
through the atria results in self-perpetuating “daughter wave-
lets.” In this model, the number of wavelets at any time
depends on the refractory period, mass, and conduction
velocity in different parts of the atria. A large atrial mass with
a short refractory period and delayed conduction increases the
number of wavelets, favoring sustained AF. Simultaneous
recordings from multiple electrodes supported the multiple-
wavelet hypothesis in human subjects (127).
For many years, the multiple-wavelet hypothesis was the
dominant theory explaining the mechanism of AF, but the data
presented above and from experimental (127a) and clinical
(127b,127c) mapping studies challenge this notion. Even so, a
number of other observations support the importance of an
abnormal atrial substrate in the maintenance of AF. For over
25 y, EP studies in humans have implicated atrial vulnerability in
the pathogenesis of AF (128–132). In one study of 43 patients
without structural heart disease, 18 of whom had paroxysmal
AF, the coefficient of dispersion of atrial refractoriness was
significantly greater in the patients with AF (128). Furthermore,
in 16 of 18 patients with a history of AF, the arrhythmia was
induced with a single extrastimulus, while a more aggressive
pacing protocol was required in 23 of 25 control patients without
Figure 7. Posterior view of principal electrophysio-
logical mechanisms of atrial fibrillation. A, Focal acti-
vation. The initiating focus (indicated by the star)
often lies within the region of the pulmonary veins.
The resulting wavelets represent fibrillatory conduc-
tion, as in multiple-wavelet reentry. B, Multiple-
wavelet reentry. Wavelets (indicated by arrows) ran-
domly reenter tissue previously activated by the
same or another wavelet. The routes the wavelets
travel vary. Reproduced with permission from
Konings KT, Kirchhof CJ, Smeets JR, et al.
High-density mapping of electrically induced atrial
fibrillation in humans. Circulation 1994;89:1665–80
(101). LA indicates left atrium; PV, pulmonary vein;
ICV, inferior vena cava; SCV, superior vena cava;
and RA, right atrium.
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previously documented AF. In patients with idiopathic paroxys-
mal AF, widespread distribution of abnormal electrograms in the
RA predicted development of persistent AF, suggesting an
abnormal substrate (132). In patients with persistent AF who had
undergone conversion to sinus rhythm, there was significant
prolongation of intra-atrial conduction compared with a control
group, especially among those who developed recurrent AF after
cardioversion (130).
Patients with a history of paroxysmal AF, even those with
lone AF, have abnormal atrial refractoriness and conduction
compared with patients without AF. An abnormal signal-
averaged P-wave ECG reflects slowed intra-atrial conduction
and shorter wavelengths of reentrant impulses. The resulting
increase in wavelet density promotes the onset and mainte-
nance of AF. Among patients with HF, prolongation of the P
wave was more frequent in those prone to paroxysmal AF
(133). In specimens of RA appendage tissue obtained from
patients undergoing open-heart surgery, P-wave duration was
correlated with amyloid deposition (73). Because many of
these observations were made prior to the onset of clinical
AF, the findings cannot be ascribed to atrial remodeling that
occurs as a consequence of AF. Atrial refractoriness increases
with age in both men and women, but concurrent age-related
fibrosis lengthens effective intra-atrial conduction pathways.
This, coupled with the shorter wavelengths of reentrant
impulses, increases the likelihood that AF will develop
(134,135). Nonuniform alterations of refractoriness and con-
duction throughout the atria may provide a milieu for the
maintenance of AF. However, the degree to which changes in
the atrial architecture contribute to the initiation and mainte-
nance of AF is not known. Isolation of the PV may prevent
recurrent AF even in patients with substantial abnormalities
in atrial size and function. Finally, the duration of episodes of
AF correlates with both a decrease in atrial refractoriness and
shortening of the AF cycle length, attesting to the importance
of electrical remodeling in the maintenance of AF (136). The
anatomical and electrophysiological substrates are detailed in
Table 4.
5.1.3. Atrial Electrical Remodeling
Pharmacological or direct-current cardioversion of AF has a
higher success rate when AF has been present for less than
24 h, (137) whereas more prolonged AF makes restoring and
maintaining sinus rhythm less likely. These observations gave
rise to the adage “atrial fibrillation begets atrial fibrillation.”
The notion that AF is self-perpetuating takes experimental
support from a goat model using an automatic atrial fibrillator
that detected spontaneous termination of AF and reinduced
the arrhythmia by electrical stimulation (138). Initially, elec-
trically induced AF terminated spontaneously. After repeated
inductions, however, the episodes became progressively more
sustained until AF persisted at a more rapid atrial rate (138).
The increasing propensity to AF was related to progressive
shortening of effective refractory periods with increasing
episode duration, a phenomenon known as EP remodeling.
These measurements support clinical observations (139) that
the short atrial effective refractory period in patients with
paroxysmal AF fails to adapt to rate, particularly during
bradycardia. Confirmation came from recordings of action
TABLE 4. Anatomical and Electrophysiological Substrates Promoting the Initiation and/or Maintenance of
Atrial Fibrillation
Substrates*
Diseases Anatomical Cellular Electrophysiological
Part A. Substrate develops during sinus rhythm (remodeling related to stretch and dilatation. The main pathways involve the
RAAS, TGF-beta, and CTGF.
Hypertension Atrial dilatation Myolysis Conduction abnormalities
Heart failure PV dilatation Apoptosis, necrosis ERP dispersion
Coronary disease Fibrosis Channel expression change Ectopic activity
Valvular disease
Part B. Substrate develops due to tachycardia (tachycardia-related remodeling, downregulation of calcium channel and calcium
handling.
Focal AF None or† None or† Ectopic activity
Atrial flutter Atrial dilatation Calcium channel downregulation Microreentry
PV dilatation Myolysis Short ERP‡
Large PV sleeves Connexin downregulation ERP dispersion§
Reduced contractility Adrenergic supersensitivity Slowed conduction
Fibrosis Changed sympathetic innervation
*Substrate develops either while in sinus rhythm, usually caused by ventricular remodeling, atrial pressure overload and subsequent atrial
dilatation (Part A), or due to the rapid atrial rate during atrial fibrillation (AF), according to the principle that “AF begets AF” (Part B.
†The listed changes may only occur with prolonged episodes of AF at high atrial rate.
‡Short ERP and slow conduction may produce short wavelength, thereby promoting further AF.
§ERP dispersion together with spontaneous or stretch-induced ectopic activity may initiate AF. Long ERPs occur in Bachmann’s
bundle among other tissues.
The reduction of atrial contractility during AF may enhance atrial dilatation, leading to persistent AF.
CTGF indicates connective tissue growth factor; ERP, effective refractory period; PV, pulmonary vein; RAAS, renin-angiotensin-al-
dosterone system; and TGF-beta, transforming growth factor-beta1.
e162 Fuster et al. JACC Vol. 48, No. 4, 2006
ACC/AHA/ESC Practice Guidelines August 15, 2006:e149–246
potentials in isolated fibrillating atrial tissue and from pa-
tients after cardioversion (140). The duration of atrial
monophasic action potentials was shorter after cardioversion
and correlated with the instability of sinus rhythm (141).
Tachycardia-induced AF may result from AV node reentry,
an accessory pathway, atrial tachycardia, or atrial flutter (142–
144). After a period of rapid atrial rate, electrical remodeling
stimulates progressive intracellular calcium loading that leads
to inactivation of the calcium current (145,146). Reduction of
the calcium current in turn shortens the action potential
duration and atrial refractory period, which may promote
sustained AF. The role of potassium currents in this situation
is less clear (145). Electrical remodeling has also been
demonstrated in PV myocytes subjected to sustained rapid
atrial pacing, resulting in shorter action potential durations
and both early and delayed afterdepolarizations (147).
In addition to remodeling and changes in electrical refrac-
toriness, prolonged AF disturbs atrial contractile function.
With persistent AF, recovery of atrial contraction can be
delayed for days or weeks following the restoration of sinus
rhythm, which has important implications for the duration of
anticoagulation after cardioversion. (See Section 8.1.4, Pre-
venting Thromboembolism.) Both canine and preliminary
human data suggest that prolonged AF may also lengthen
sinus node recovery time (148,149). The implication is that
AF may be partly responsible for sinus node dysfunction in
some patients with the tachycardia-bradycardia syndrome.
Reversal of electrical remodeling in human atria may occur
at different rates depending on the region of the atrium
studied (150). When tested at various times after cardiover-
sion, the effective refractory period of the lateral RA in-
creased within 1 h after cardioversion, while that in the
coronary sinus was delayed for 1 wk. In another study,
recovery of normal atrial refractoriness after cardioversion of
persistent AF was complete within 3 to 4 d (151), after which
there was no difference in refractoriness between the RA
appendage and the distal coronary sinus. The disparities
between studies may reflect patient factors or the duration or
pattern of AF before cardioversion.
5.1.4. Counteracting Atrial Electrical Remodeling
Data are accumulating on the importance of the RAAS in the
genesis of AF (145). Irbesartan plus amiodarone was associ-
ated with a lower incidence of recurrent AF after cardiover-
sion than amiodarone alone, (39) and use of angiotensin
inhibitors and diuretics significantly reduced the incidence of
AF after catheter ablation of atrial flutter (152). Amiodarone
may reverse electrical remodeling even when AF is ongoing,
(153) and this explains how amiodarone can convert persis-
tent AF to sinus rhythm. Inhibition of the RAAS, alone or in
combination with other therapies, may therefore prevent the
onset or maintenance of AF (43) through several mecha-
nisms. These include hemodynamic changes (lower atrial
pressure and wall stress), prevention of structural remodeling
(fibrosis, dilation, and hypertrophy) in both the LA and left
ventricle (LV), inhibition of neurohumoral activation, re-
duced blood pressure, prevention or amelioration of HF, and
avoidance of hypokalemia. Treatment with trandolapril re-
duced the incidence of AF in patients with LV dysfunction
following acute MI (36), but it remains to be clarified whether
the antiarrhythmic effect of these agents is related to reversal
of structural or electrical remodeling in the atria or to these
other mechanisms.
5.1.5. Other Factors Contributing to Atrial Fibrillation
Other factors potentially involved in the induction or main-
tenance of AF include inflammation, autonomic nervous
system activity, atrial ischemia (154), atrial dilation (155),
anisotropic conduction, (156) and structural changes associ-
ated with aging (3). It has been postulated that oxidative
stress and inflammation may be involved in the genesis of AF
(157–159). In a case-control study, levels of C-reactive
protein (CRP), a marker of systemic inflammation, were
higher in patients with atrial arrhythmias than in those
without rhythm disturbances (159), and those with persistent
AF had higher CRP levels than those with paroxysmal AF. In
a population-based cohort of nearly 6000 patients, AF was
more prevalent among patients in the highest quartile for CRP
than those in the lowest quartile. In patients without AF at
baseline, CRP levels were associated with the future devel-
opment of AF (158).
The effects of HMG CoA-reductase inhibitors (“statins”),
which have both anti-inflammatory and antioxidant proper-
ties, on electrical remodeling have been evaluated in a canine
model of atrial tachycardia (160) but have not been ade-
quately studied in human subjects. In the experimental model,
tachycardia-related electrical remodeling was suppressed by
pretreatment with simvastatin but not by the antioxidant
vitamins C and E. The mechanism responsible for the salutary
effect of simvastatin requires further investigation, and the
utility of drugs in the statin class to prevent clinical AF has
not yet been established.
Increased sympathetic or parasympathetic tone has been
implicated in the initiation of AF. Autonomic ganglia con-
taining parasympathetic and sympathetic fibers are present on
the epicardial surface of both the RA and LA, clustered on the
posterior wall near the ostia of the PV, superior vena cava
(SVC), and coronary sinus. In animal models, parasympa-
thetic stimulation shortens atrial and PV refractory periods,
potentiating initiation and maintenance of AF (161,162), and
vagal denervation of the atria prevents induction of AF (163).
In 297 patients with paroxysmal AF, vagal denervation
concomitant with extensive endocardial catheter ablation was
associated with significant reduction in subsequent AF in a
third of cases (162). Pure autonomic initiation of clinical AF
is uncommon and seen only in situations of high sympathetic
or high vagal tone, but recordings of heart rate variability
(HRV) disclose autonomic perturbations in some patients that
precede the onset of AF (164–169).
There is a strong association between obstructive sleep
apnea, hypertension, and AF (170). It is likely that LV
diastolic dysfunction plays a role in the genesis of AF, either
by increasing pressure that affects stretch receptors in PV
triggers and other areas of the atria or by inducing direct
structural changes in atrial myocardium (171,172). Familial
factors are discussed in Section 6.1.5.
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5.2. Atrioventricular Conduction
5.2.1. General Aspects
In the absence of an accessory pathway or His-Purkinje dys-
function, the AV node limits conduction during AF (144).
Multiple atrial inputs to the AV node have been identified, 2 of
which seem dominant: one directed posteriorly via the crista
terminalis and the other aimed anteriorly via the interatrial
septum. Other factors affecting AV conduction are the intrinsic
refractoriness of the AV node, concealed conduction, and
autonomic tone. Concealed conduction, which occurs when
atrial impulses traverse part of the AV node but are not
conducted to the ventricles, plays a prominent role in determin-
ing the ventricular response during AF (173,174). These im-
pulses alter AV nodal refractoriness, slowing or blocking sub-
sequent atrial impulses, and may explain the irregularity of
ventricular response during AF (125). When the atrial rate is
relatively slow during AF, the ventricular rate tends to rise.
Conversely, a higher atrial rate is associated with slower ven-
tricular rate.
Increased parasympathetic and reduced sympathetic tone
exert negative dromotropic effects on AV nodal conduction,
while the opposite is true in states of decreased parasympa-
thetic and increased sympathetic tone (173,175,176). Vagal
tone also enhances the negative chronotropic effects of
concealed conduction in the AV node (175,176). Fluctuations
in autonomic tone can produce disparate ventricular re-
sponses to AF in a given patient as exemplified by a slow
ventricular rate during sleep but accelerated ventricular re-
sponse during exercise. Digitalis, which slows the ventricular
rate during AF predominantly by increasing vagal tone, is
more effective for controlling heart rate at rest in AF but less
effective during activity. Wide swings in rate due to varia-
tions in autonomic tone may create a therapeutic challenge.
Conducted QRS complexes are narrow during AF unless
there is fixed or rate-related bundle-branch block or accessory
pathway. Aberrant conduction is common and facilitated by
the irregularity of the ventricular response. When a long
interval is followed by a relatively short interval, the QRS
complex that closes the short interval is often aberrantly
conducted (Ashman phenomenon) (177).
5.2.2. Atrioventricular Conduction in Patients With
Preexcitation Syndromes
Conduction across an accessory pathway during AF can result in
a dangerously rapid ventricular rate (3,178,179). Whereas a
substantial increase in sympathetic tone may increase the pre-
excited ventricular response, alterations in vagal tone have little
effect on conduction over accessory pathways.
Transition of AV reentry into AF in patients with the
Wolff-Parkinson-White (WPW) syndrome can produce a
rapid ventricular response that degenerates into ventricular
fibrillation, leading to death (178,180). Intravenous adminis-
tration of drugs such as digitalis, verapamil, or diltiazem,
which lengthen refractoriness and slow conduction across the
AV node, does not block conduction over the accessory
pathway and may accelerate the ventricular rate. Hence, these
agents are contraindicated in this situation (181). Although
the potential for beta blockers to potentiate conduction across
the accessory pathway is controversial, caution should be
exercised in the use of these agents as well as in patients with
AF associated with preexcitation.
5.3. Myocardial and Hemodynamic Consequences
of Atrial Fibrillation
Among factors that affect the hemodynamic function during
AF are loss of synchronous atrial mechanical activity, irreg-
ular ventricular response, rapid heart rate, and impaired
coronary arterial blood flow. Loss of atrial contraction may
markedly decrease cardiac output, especially when diastolic
ventricular filling is impaired by mitral stenosis, hyperten-
sion, hypertrophic cardiomyopathy (HCM), or restrictive
cardiomyopathy. Hemodynamic impairment due to variation
in R-R intervals during AF has been demonstrated in a canine
model with complete heart block, in which cardiac output fell
by approximately 9% during irregular ventricular pacing at
the same mean cycle length as a regularly paced rhythm
(182). In patients undergoing AV nodal ablation, irregular
right ventricular (RV) pacing at the same rate as regular
ventricular pacing resulted in a 15% reduction in cardiac
output (183). Myocardial contractility is not constant during
AF because of force-interval relationships associated with
variations in cycle length (184). Although one might expect
restoration of sinus rhythm to improve these hemodynamic
characteristics, this is not always the case (185,186).
Myocardial blood flow is determined by the presence or
absence of coronary obstructive disease, the difference be-
tween aortic diastolic pressure and LV end-diastolic pressure
(myocardial perfusion pressure), coronary vascular resis-
tance, and the duration of diastole. AF may adversely impact
all of these factors. An irregular ventricular rhythm is
associated with coronary blood flow compared with a regular
rhythm at the same average rate (186). Animal studies have
consistently shown that the decrease in coronary flow caused
by experimentally induced AF relates to an increase in
coronary vascular resistance mediated by sympathetic activa-
tion of alpha-adrenergic receptors that is less pronounced
than during regular atrial pacing at the same ventricular rate
(187). Similarly, coronary blood flow is lower during AF than
during regular atrial pacing in patients with angiographically
normal coronary arteries (188). The reduced coronary flow
reserve during AF may be particularly important in patients
with coronary artery disease (CAD), in whom compensatory
coronary vasodilation is limited. These findings may explain
why patients without previous angina sometimes develop
chest discomfort with the onset of AF.
In patients with persistent AF, mean LA volume increased
over time from 45 to 64 cm3 while RA volume increased from
49 to 66 cm3 (189). Restoration and maintenance of sinus
rhythm decreased atrial volumes (190). Moreover, transesopha-
geal echocardiography (TEE) has demonstrated that contractile
function and blood flow velocity in the LA appendage (LAA)
recover after cardioversion, consistent with a reversible atrial
cardiomyopathy in patients with AF (191,192).
Beyond its effects on atrial function, a persistently elevated
ventricular rate during AF—greater than or equal to 130
beats per minute in one study (193)—can produce dilated
ventricular cardiomyopathy (tachycardia-induced cardiomy-
opathy) (3,193–196). It is critically important to recognize
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this cause of cardiomyopathy, in which HF is a consequence
rather than the cause of AF. Control of the ventricular rate
may lead to reversal of the myopathic process. In one study,
the median LV ejection fraction increased with rate control
from 25% to 52% (194). This phenomenon also has implica-
tions for timing measurements of ventricular performance in
patients with AF. A reduced ejection fraction during or in the
weeks following tachycardia may not reliably predict ventric-
ular function once the rate has been consistently controlled. A
variety of hypotheses have been proposed to explain
tachycardia-mediated cardiomyopathy: myocardial energy
depletion, ischemia, abnormal calcium regulation, and re-
modeling, but the actual mechanisms are still unclear (197).
Because of the relationship between LA and LV pressure,
a rapid ventricular rate during AF may adversely impact
mitral valve function, increasing mitral regurgitation. In
addition, tachycardia may be associated with rate-related
intraventricular conduction delay (including left bundle-
branch block), which further compromises the synchrony of
LV wall motion and reduces cardiac output. Such conduction
disturbances may exacerbate mitral regurgitation and limit
ventricular filling. Controlling the ventricular rate may re-
verse these effects.
5.4. Thromboembolism
Although ischemic stroke and systemic arterial occlusion in
AF are generally attributed to embolism of thrombus from the
LA, the pathogenesis of thromboembolism is complex (198).
Up to 25% of strokes in patients with AF may be due to
intrinsic cerebrovascular diseases, other cardiac sources of
embolism, or atheromatous pathology in the proximal aorta
(199,200). In patients 80 to 89 y old, 36% of strokes occur in
those with AF. The annual risk of stroke for octogenarians
with AF is in the range of 3% to 8% per year, depending on
associated stroke risk factors (21). About half of all elderly
AF patients have hypertension (a major risk factor for
cerebrovascular disease) (47), and approximately 12% harbor
carotid artery stenosis (201). Carotid atherosclerosis is not
substantially more prevalent in AF patients with stroke than
in patients without AF and is probably a relatively minor
contributing epidemiological factor (202).
5.4.1. Pathophysiology of Thrombus Formation
Thrombotic material associated with AF arises most frequently
in the LAA, which cannot be regularly examined by precordial
(transthoracic) echocardiography (203). Doppler TEE is a more
sensitive and specific method to assess LAA function (204) and
to detect thrombus formation. Thrombi are more often encoun-
tered in AF patients with ischemic stroke than in those without
stroke (205). Although clinical management is based on the
presumption that thrombus formation requires continuation of
AF for approximately 48 h, thrombi have been identified by
TEE within shorter intervals (206,207). Thrombus formation
begins with Virchow’s triad of stasis, endothelial dysfunction,
and a hypercoagulable state. Serial TEE studies of the LA (208)
and LAA (209) during conversion of AF to sinus rhythm
demonstrated reduced LAA flow velocities related to loss of
organized mechanical contraction during AF. Stunning of the
LAA (210) seems responsible for an increased risk of thrombo-
embolic events after successful cardioversion, regardless of
whether the method is electrical, pharmacological, or spontane-
ous (210). Atrial stunning is at a maximum immediately after
cardioversion, with progressive improvement of atrial transport
function within a few days but sometimes as long as 3 to 4 wk,
depending on the duration of AF (210,211). This corroborates
the observation that following cardioversion, more than 80% of
thromboembolic events occur during the first 3 d and almost all
occur within 10 d (212). Atrial stunning is more pronounced in
patients with AF associated with ischemic heart disease than in
those with hypertensive heart disease or lone AF (210). Al-
though stunning may be milder with certain associated condi-
tions or a short duration of AF, anticoagulation is recommended
during cardioversion in all patients with AF lasting longer than
48 h or of unknown duration, including lone AF except when
anticoagulation is contraindicated.
Decreased flow within the LA/LAA during AF has been
associated with spontaneous echo contrast (SEC), thrombus
formation, and embolic events (213–218). Specifically, SEC,
or “smoke,” a swirling haze of variable density, may be
detected by transthoracic or transesophageal echocardio-
graphic imaging of the cardiac chambers and great vessels
under low-flow conditions (219). This phenomenon relates to
fibrinogen-mediated erythrocyte aggregation (220) and is not
resolved by anticoagulation (221). There is evidence that SEC
is a marker of stasis caused by AF (222–224). Independent
predictors of SEC in patients with AF include LA enlarge-
ment, reduced LAA flow velocity, (213,225). LV dysfunc-
tion, fibrinogen level (218), and hematocrit (217,218). The
utility of SEC for prospective thromboembolic risk stratifi-
cation beyond that achieved by clinical assessment alone has,
however, not been confirmed.
LAA flow velocities are lower in patients with atrial flutter
than are usually seen during sinus rhythm but higher than in
AF. Whether this accounts for any lower prevalence of LAA
thrombus or thromboembolism associated with atrial flutter is
uncertain. As in AF, atrial flutter is associated with low
appendage emptying velocities following cardioversion with
the potential for thromboembolism (226,227) and anticoagu-
lation is similarly recommended. (See Section 8.1.4.1.3,
Therapeutic Implications.)
Although endothelial dysfunction has been difficult to
demonstrate as distinctly contributing to thrombus formation
in AF, it may, along with stasis, contribute to a hypercoagu-
lable state. Systemic and/or atrial tissue levels of P-selectin
and von Willebrand factor are elevated in some patients (228–
233), and AF has been associated with biochemical markers
of coagulation and platelet activation that reflect a systemic
hypercoagulable state (228,234–236). Persistent and parox-
ysmal AF have been associated with increased systemic
fibrinogen and fibrin D-dimer levels, indicating active intra-
vascular thrombogenesis (228,236,237). Elevated
thromboglobulin and platelet factor 4 levels in selected
patients with AF indicate platelet activation, (235,238,239)
but these data are less robust, in line with the lower efficacy
of platelet-inhibitor drugs for prevention of thromboembo-
lism in clinical trials. Fibrin D-dimer levels are higher in
patients with AF than in patients in sinus rhythm, irrespective
of underlying heart disease (240). The levels of some markers
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of coagulation fall to normal during anticoagulation therapy
(234), and some increase immediately after conversion to sinus
rhythm and then normalize (241). These biochemical markers do
not, however, distinguish a secondary reaction to intravascular
coagulation from a primary hypercoagulable state.
C-reactive protein (CRP) is increased in patients with AF
compared with controls (159,242) and correlates with clinical
and echocardiographic stroke risk factors (243). Although
these findings do not imply a causal relationship, the associ-
ation may indicate that a thromboembolic milieu in the LA
may involve mechanisms linked to inflammation (243).
In patients with rheumatic mitral stenosis undergoing
trans-septal catheterization for balloon valvuloplasty, levels
of fibrinopeptide A, thrombin–antithrombin III complex, and
prothrombin fragment F1.2 are increased in the LA compared
with the RA and femoral vein, indicating regional activation
of the coagulation system (244,245). Whether such elevations
are related to AF, for example, through atrial pressure
overload or due to another mechanism has not been deter-
mined. Regional coagulopathy is associated with SEC in the
LA and hence with atrial stasis (245).
Contrary to the prevalent concept that systemic anticoag-
ulation for 4 wk results in organization and endocardial
adherence of LAA thrombus, TEE studies have verified
resolution of thrombus in the majority of patients (246).
Similar observations have defined the dynamic nature of
LA/LAA dysfunction following conversion of AF, providing
a mechanistic rationale for anticoagulation for several weeks
before and after successful cardioversion. Conversely, in-
creased flow within the LA in patients with mitral regurgita-
tion has been associated with less prevalent LA SEC
(247,248) and fewer thromboembolic events, even in the
presence of LA enlargement (249).
5.4.2. Clinical Implications
Because the pathophysiology of thromboembolism in patients
with AF is uncertain, the mechanisms linking risk factors to
ischemic stroke in patients with AF are incompletely defined.
The strong association between hypertension and stroke in
AF is probably mediated primarily by embolism originating
in the LAA (200), but hypertension also increases the risk of
noncardioembolic strokes in patients with AF (200,250).
Hypertension in patients with AF is associated with reduced
LAA flow velocity, SEC, and thrombus formation
(225,251,252). Ventricular diastolic dysfunction might under-
lie the effect of hypertension on LA dynamics, but this
relationship is still speculative (253,254). Whether control of
hypertension lowers the risk for cardioembolic stroke in
patients with AF is a vital question, because LV diastolic
abnormalities associated with hypertension in the elderly are
often multifactorial and difficult to reverse (254,255).
The increasing stroke risk in patients with AF with advanc-
ing age is also multifactorial. In patients with AF, aging is
associated with LA enlargement, reduced LAA flow velocity,
and SEC, all of which predispose to LA thrombus formation
(225,251,256). Aging is a risk factor for atherosclerosis, and
plaques in the aortic arch are associated with stroke indepen-
dent of AF (257). Levels of prothrombin activation fragment
F1.2, an index of thrombin generation, increase with age in
the general population (258–260) as well as in those with AF
(12,261), suggesting an age-related prothrombotic diathesis.
In the Stroke Prevention in Atrial Fibrillation (SPAF) studies,
age was a more potent risk factor when combined with other
risk factors such as hypertension or female gender (261,262),
placing women over age 75 y with AF at particular risk for
cardioembolic strokes (263).
LV systolic dysfunction, as indicated by a history of HF or
echocardiographic assessment, predicts ischemic stroke in
patients with AF who receive no antithrombotic therapy (264–
267) but not in moderate-risk patients given aspirin (261,268).
Mechanistic inferences are contradictory; LV systolic dys-
function has been associated both with LA thrombus and with
noncardioembolic strokes in patients with AF (200,269).
In summary, complex thromboembolic mechanisms are
operative in AF and involve the interplay of risk factors
related to atrial stasis, endothelial dysfunction, and systemic
and possibly local hypercoagulability.
6. Causes, Associated Conditions, Clinical
Manifestations, and Quality of Life
6.1. Causes and Associated Conditions
6.1.1. Reversible Causes of Atrial Fibrillation
AF may be related to acute, temporary causes, including
alcohol intake (“holiday heart syndrome”), surgery, electro-
cution, MI, pericarditis, myocarditis, pulmonary embolism or
other pulmonary diseases, hyperthyroidism, and other meta-
bolic disorders. In such cases, successful treatment of the
underlying condition often eliminates AF. AF that develops
in the setting of acute MI portends an adverse prognosis
compared with preinfarct AF or sinus rhythm (270,271). AF
may be associated with atrial flutter, the WPW syndrome, or
AV nodal reentrant tachycardias, and treatment of the pri-
mary arrhythmias reduces or eliminates the incidence of
recurrent AF (172). AF is a common early postoperative
complication of cardiac or thoracic surgery.
6.1.2. Atrial Fibrillation Without Associated
Heart Disease
AF is often an electrical manifestation of underlying cardiac
disease. Nonetheless, approximately 30% to 45% of cases of
paroxysmal AF and 20% to 25% of cases of persistent AF
occur in younger patients without demonstrable underlying
disease (“lone AF”) (27,29). AF can present as an isolated
(104) or familial arrhythmia, although a responsible underly-
ing disease may appear over time (272). Although AF may
occur without underlying heart disease in the elderly, the
changes in cardiac structure and function that accompany
aging, such as an increase in myocardial stiffness, may be
associated with AF, just as heart disease in older patients may
be coincidental and unrelated to AF.
6.1.3. Medical Conditions Associated With
Atrial Fibrillation
Obesity is an important risk factor for development of AF
(273–275). After adjusting for clinical risk factors, the excess
risk of AF appears mediated by LA dilation, because there is
a graded increase in LA size as BMI increases from normal to
the overweight and obese categories (273). Weight reduction
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has been linked to regression of LA enlargement (273,276).
These findings suggest a physiological link between obesity,
AF, and stroke and raise the intriguing possibility that weight
reduction may decrease the risk of AF.
6.1.4. Atrial Fibrillation With Associated Heart Disease
Specific cardiovascular conditions associated with AF in-
clude valvular heart disease (most often, mitral valve dis-
ease), HF, CAD, and hypertension, particularly when LVH is
present. In addition, AF may be associated with HCM, dilated
cardiomyopathy, or congenital heart disease, especially atrial
septal defect in adults. Potential etiologies also include
restrictive cardiomyopathies (e.g., amyloidosis, hemochro-
matosis, and endomyocardial fibrosis), cardiac tumors, and
constrictive pericarditis. Other heart diseases, such as mitral
valve prolapse with or without mitral regurgitation, calcifi-
cation of the mitral annulus, cor pulmonale, and idiopathic
dilation of the RA, have been associated with a high inci-
dence of AF. AF is commonly encountered in patients with
sleep apnea syndrome, but whether the arrhythmia is pro-
voked by hypoxia, another biochemical abnormality, changes
in pulmonary dynamics or RA factors, changes in autonomic
tone, or systemic hypertension has not been determined.
Table 5 lists etiologies and factors predisposing patients to
AF. (For a list of associated heart diseases in the ALFA study,
see Table 3.)
6.1.5. Familial (Genetic) Atrial Fibrillation
Familial AF, defined as lone AF running in a family, is more
common than previously recognized but should be distin-
guished from AF secondary to other genetic diseases like
familial cardiomyopathies. The likelihood of developing AF
is increased among those whose parents had AF, suggesting a
familial susceptibility to the arrhythmia, but the mechanisms
associated with transmission are not necessarily electrical,
because the relationship has also been seen in patients who
have a family history of hypertension, diabetes, or HF (277).
The molecular defects responsible for familial AF are
largely unknown. Specific chromosomal loci (278) have been
linked to AF in some families, suggesting distinct genetic
mutations (279). Two mutations associated with gain of
function leading to short atrial refractoriness have been
discovered in several Chinese families (280,281).
6.1.6. Autonomic Influences in Atrial Fibrillation
Autonomic influences play an important role in the initiation
of AF. The noninvasive measurement of autonomic tone in
humans has been augmented by measures of HRV (282),
which reflect changes in the relative autonomic modulation of
heart rate rather than the absolute level of sympathetic or
parasympathetic tone. It appears that the balance between
sympathetic and vagal influences is as important as absolute
sympathetic or parasympathetic tone as a predictor of AF.
Fluctuations in autonomic tone as measured by HRV occur
prior to the development of AF. Vagal predominance in the
minutes preceding the onset of AF has been observed in some
patients with structurally normal hearts, while in others there
is a shift toward sympathetic predominance (283,284). Al-
though Coumel (285) recognized that certain patients could
be characterized in terms of a vagal or adrenergic form of AF,
these cases likely represent the extremes of either influence. In
general, vagally mediated AF occurs at night or after meals,
while adrenergically induced AF typically occurs during the
daytime in patients with organic heart disease (286). Vagally
mediated AF is the more common form, and in such cases
adrenergic blocking drugs or digitalis sometimes worsens symp-
toms and anticholinergic agents such as disopyramide are
sometimes helpful to prevent recurrent AF. Classification of AF
as of either the vagal or adrenergic form has only limited impact
on management. For AF of the adrenergic type, beta blockers are
the initial treatment of choice.
6.2. Clinical Manifestations
AF has a heterogeneous clinical presentation, occurring in the
presence or absence of detectable heart disease. An episode of
AF may be self-limited or require medical intervention for
TABLE 5. Etiologies and Factors Predisposing Patients to AF
Electrophysiological abnormalities
Enhanced automaticity (focal AF)
Conduction abnormality (reentry)
Atrial pressure elevation
Mitral or tricuspid valve disease
Myocardial disease (primary or secondary, leading to systolic or diastolic
dysfunction)
Semilunar valvular abnormalities (causing ventricular hypertrophy)
Systemic or pulmonary hypertension (pulmonary embolism)
Intracardiac tumors or thrombi
Atrial ischemia
Coronary artery disease
Inflammatory or infiltrative atrial disease
Pericarditis
Amyloidosis
Myocarditis
Age-induced atrial fibrotic changes
Drugs
Alcohol
Caffeine
Endocrine disorders
Hyperthyroidism
Pheochromocytoma
Changes in autonomic tone
Increased parasympathetic activity
Increased sympathetic activity
Primary or metastatic disease in or adjacent to the atrial wall
Postoperative
Cardiac, pulmonary, or esophageal
Congenital heart disease
Neurogenic
Subarachnoid hemorrhage
Nonhemorrhagic, major stroke
Idiopathic (lone AF)
Familial AF
AF indicates atrial fibrillation.
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termination. Over time, the pattern of AF may be defined in
terms of the number of episodes, duration, frequency, mode
of onset, triggers, and response to therapy, but these features
may be impossible to discern when AF is first encountered in
an individual patient.
AF may be immediately recognized by sensation of
palpitations or by its hemodynamic or thromboembolic
consequences or follow an asymptomatic period of un-
known duration. Ambulatory ECG recordings and device-
based monitoring have revealed that an individual may
experience periods of both symptomatic and asymptomatic
AF (287–290). Patients in whom the arrhythmia has
become permanent often notice that palpitation decreases
with time and may become asymptomatic. This is partic-
ularly common among the elderly. Some patients experi-
ence symptoms only during paroxysmal AF or only inter-
mittently during sustained AF. When present, symptoms of
AF vary with the irregularity and rate of ventricular
response (291), underlying functional status, duration of
AF, and individual patient factors.
The initial presentation of AF may be an embolic compli-
cation or exacerbation of HF, but most patients complain of
palpitations, chest pain, dyspnea, fatigue, lightheadedness, or
syncope. Polyuria may be associated with the release of atrial
natriuretic peptide, particularly as episodes of AF begin or
terminate. AF associated with a sustained, rapid ventricular
response can lead to tachycardia-mediated cardiomyopathy,
especially in patients unaware of the arrhythmia.
Syncope is an uncommon complication of AF that can
occur upon conversion in patients with sinus node dysfunc-
tion or because of rapid ventricular rates in patients with
HCM, in patients with valvular aortic stenosis, or when an
accessory pathway is present.
6.3. Quality of Life
Although stroke certainly accounts for much of the func-
tional impairment associated with AF, available data
suggest that quality of life is considerably impaired in
patients with AF compared with age-matched controls.
Sustained sinus rhythm is associated with improved quality
of life and better exercise performance than AF in some
studies but not others (292–296). In the SPAF study
cohort, Ganiats et al (297) found the New York Heart
Association functional classification, originally developed
for HF, an insensitive index of quality of life in patients
with AF. In another study (298), 47 of 69 patients (68%)
with paroxysmal AF considered the arrhythmia disruptive
of lifestyle, but this perception was not associated with
either the frequency or duration of symptomatic episodes.
7. Clinical Evaluation
7.1. Basic Evaluation of the Patient With
Atrial Fibrillation
7.1.1. Clinical History and Physical Examination
The diagnosis of AF is based on history and clinical exami-
nation and confirmed by ECG recording, sometimes in the
form of bedside telemetry or ambulatory Holter recordings.
The initial evaluation of a patient with suspected or proved
AF involves characterizing the pattern of the arrhythmia as
paroxysmal or persistent, determining its cause, and defining
associated cardiac and extracardiac factors pertinent to the
etiology, tolerability, and history of prior management (Table
6). A thorough history will result in a well-planned, focused
workup that serves as an effective guide to therapy (3). The
workup of a patient with AF can usually take place and
therapy initiated in a single outpatient encounter. Delay
occurs when the rhythm has not been specifically docu-
mented and additional monitoring is necessary.
Typically, AF occurs in patients with underlying heart dis-
ease, such as hypertensive heart disease (33,299). (See Section 6,
Causes, Associated Conditions, Clinical Manifestations, and
Quality of Life.) Atherosclerotic or valvular heart diseases are
also common substrates, whereas pulmonary pathology, preex-
citation syndromes, and thyroid disease are less frequent cau-
ses (300). Because of reports of genetic transmission of AF, the
family history is important as well (272,301). Although various
environmental triggers can initiate episodes of AF, this aspect
may not emerge from the history given spontaneously by the
patient and often requires specific inquiry. Commonly men-
tioned triggers include alcohol, sleep deprivation, and emotional
stress, but vagally mediated AF may occur during sleep or after
a large meal and is more likely to arise during a period of rest
succeeded by a period of stress. Stimulants such as caffeine or
exercise may also precipitate AF.
The physical examination may suggest AF on the basis of
irregular pulse, irregular jugular venous pulsations, and vari-
ation in the intensity of the first heart sound or absence of a
fourth sound heard previously during sinus rhythm. Exami-
nation may also disclose associated valvular heart disease,
myocardial abnormalities, or HF. The findings are similar in
patients with atrial flutter, except that the rhythm may be
regular and rapid venous oscillations may occasionally be
visible in the jugular pulse.
7.1.2. Investigations
The diagnosis of AF requires ECG documentation by at least
a single-lead recording during the arrhythmia, which may be
facilitated by review of emergency department records,
Holter monitoring, or transtelephonic or telemetric record-
ings. A portable ECG recording tool may help establish the
diagnosis in cases of paroxysmal AF and provide a permanent
ECG record of the arrhythmia. In patients with implanted
pacemakers or defibrillators, the diagnostic and memory
functions may allow accurate and automatic detection of AF
(302). A chest radiograph may detect enlargement of the
cardiac chambers and HF but is valuable mostly to detect
intrinsic pulmonary pathology and evaluate the pulmonary
vasculature. It is less important than echocardiography for
routine evaluation of patients with AF. As part of the initial
evaluation, all patients with AF should have 2-dimensional,
Doppler echocardiography to assess LA and LV dimensions
and LV wall thickness and function and to exclude occult
valvular or pericardial disease and HCM. LV systolic and
diastolic performance helps guide decisions regarding antiar-
rhythmic and antithrombotic therapy. Thrombus should be
sought in the LA but is seldom detected without TEE
(203,303,304).
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TABLE 6. Clinical Evaluation in Patients With AF
Minimum evaluation
1. History and physical examination, to define
Presence and nature of symptoms associated with AF
Clinical type of AF (first episode, paroxysmal, persistent, or permanent)
Onset of the first symptomatic attack or date of discovery of AF
Frequency, duration, precipitating factors, and modes of termination of AF
Response to any pharmacological agents that have been administered
Presence of any underlying heart disease or other reversible conditions (e.g., hyperthyroidism or alcohol consumption)
2. Electrocardiogram, to identify
Rhythm (verify AF)
LV hypertrophy
P-wave duration and morphology or fibrillatory waves
Preexcitation
Bundle-branch block
Prior MI
Other atrial arrhythmias
To measure and follow the R-R, QRS, and QT intervals in conjunction with antiarrhythmic drug therapy
3. Transthoracic echocardiogram, to identify
Valvular heart disease
LA and RA size
LV size and function
Peak RV pressure (pulmonary hypertension)
LV hypertrophy
LA thrombus (low sensitivity)
Pericardial disease
4. Blood tests of thyroid, renal, and hepatic function
For a first episode of AF, when the ventricular rate is difficult to control
Additional testing
One or several tests may be necessary.
1. Six-minute walk test
If the adequacy of rate control is in question
2. Exercise testing
If the adequacy of rate control is in question (permanent AF)
To reproduce exercise-induced AF
To exclude ischemia before treatment of selected patients with a type IC antiarrhythmic drug
3. Holter monitoring or event recording
If diagnosis of the type of arrhythmia is in question
As a means of evaluating rate control
4. Transesophageal echocardiography
To identify LA thrombus (in the LA appendage)
To guide cardioversion
5. Electrophysiological study
To clarify the mechanism of wide-QRS-complex tachycardia
To identify a predisposing arrhythmia such as atrial flutter or paroxysmal supraventricular tachycardia
To seek sites for curative ablation or AV conduction block/modification
6. Chest radiograph, to evaluate
Lung parenchyma, when clinical findings suggest an abnormality
Pulmonary vasculature, when clinical findings suggest an abnormality
Type IC refers to the Vaughan Williams classification of antiarrhythmic drugs (see Table 19).
AF indicates atrial fibrillation; AV, atrioventricular; LA, left atrial; LV, left ventricular; MI, myocardial infarction; RA, right atrial; and
RV, right ventricular.
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Blood tests are routine but can be abbreviated. It is
important that thyroid, renal, and hepatic function, serum
electrolytes, and the hemogram be measured at least once in
the course of evaluating a patient with AF (305).
7.2. Additional Investigation of Selected Patients
With Atrial Fibrillation
Abnormalities in P-wave duration detected by signal-
averaged ECG during sinus rhythm that reflect slow intra-
atrial conduction are associated with an increased risk of
developing AF (133,306–308). The sensitivity and negative
predictive value of signal-averaged P-wave ECG are high, but
specificity and positive predictive value are low, limiting the
usefulness of this technique (309). Measurement of HRV has
failed to provide useful information for risk stratification (309).
Both B-type natriuretic peptide (assessed by measuring
BNP or N-terminal pro-BNP), which is produced mainly in
the ventricles, and atrial naturetic peptide (ANP), which is
produced primarily in the atria, are associated with AF.
Plasma levels of both peptides are elevated in patients with
paroxysmal and persistent AF and decrease rapidly after
restoration of sinus rhythm (310–313). Thus, the presence of
AF should be considered when interpreting plasma levels of
these peptides. In the absence of HF, there is an inverse
correlation between LA volume and ANP/BNP levels (251);
spontaneous conversion to sinus rhythm is associated with
higher ANP levels during AF and with smaller LA volumes
(311). In long-standing persistent AF, lower plasma ANP levels
may be related to degeneration of atrial myocytes (314). High
levels of BNP may be predictive of thromboembolism (315) and
recurrent AF (40,316), but further studies are needed to evaluate
the utility of BNP as a prognostic marker.
7.2.1. Electrocardiogram Monitoring and Exercise Testing
Prolonged or frequent monitoring may be necessary to reveal
episodes of asymptomatic AF, which may be a cause of
cryptogenic stroke. Ambulatory ECG (e.g., Holter) monitor-
ing is also useful to judge the adequacy of rate control. This
technology may provide valuable information to guide drug
dosage for rate control or rhythm management (317).
Exercise testing should be performed if myocardial ische-
mia is suspected and prior to initiating type IC antiarrhythmic
drug therapy. Another reason for exercise testing is to study
the adequacy of rate control across a full spectrum of activity,
not only at rest, in patients with persistent or permanent AF.
7.2.2. Transesophageal Echocardiography
TEE is not part of the standard initial investigation of patients
with AF. By placing a high-frequency ultrasound transducer
close to the heart, however, TEE provides high-quality
images of cardiac structure (318) and function (319). It is the
most sensitive and specific technique to detect sources and
potential mechanisms for cardiogenic embolism (320). The
technology has been used to stratify stroke risk in patients
with AF and to guide cardioversion. (See Section 8.1.4,
Preventing Thromboembolism.) Several TEE features have
been associated with thromboembolism in patients with
nonvalvular AF, including LA/LAA thrombus, LA/LAA
SEC, reduced LAA flow velocity, and aortic atheromatous
abnormalities (252). Although these features are associated
with cardiogenic embolism (268,321), prospective investiga-
tions are needed to compare these TEE findings with clinical
and transthoracic echocardiographic predictors of thrombo-
embolism. Detection of LA/LAA thrombus in the setting of
stroke or systemic embolism is convincing evidence of a
cardiogenic mechanism (207).
TEE of patients with AF before cardioversion has shown
LA or LAA thrombus in 5% to 15%, (304,321–323) but
thromboembolism after conversion to sinus rhythm has been
reported even when TEE did not show thrombus (324). These
events typically occur relatively soon after cardioversion in
patients who were not treated with anticoagulation, reinforc-
ing the need to maintain continuous therapeutic anticoagula-
tion in patients with AF undergoing cardioversion even when
no thrombus is identified. For patients with AF of greater than
48-h duration, a TEE-guided strategy or the traditional
strategy of anticoagulation for 4 wk before and 4 wk after
elective cardioversion resulted in similar rates of thromboembo-
lism (less than 1% during the 8 wk) (325). Contrast-enhanced
magnetic resonance imaging is an emerging technique for
detection of intracardiac thrombi that appears more sensitive
than precordial echocardiography and comparable to TEE (326).
7.2.3. Electrophysiological Study
An EP study can be helpful when AF is a consequence of
reentrant tachycardia such as atrial flutter, intra-atrial reentry,
or AV reentry involving an accessory pathway. Detection of
a delta wave on the surface ECG in a patient with a history of
AF or syncope is a firm indication for EP study and ablation
of the bypass tract. Some patients with documented atrial
flutter also have AF, and ablation of flutter can eliminate AF,
although this is not common and successful ablation of flutter
does not eliminate the possibility of developing AF in the
future (327). AF associated with rapid ventricular rates and
wide-complex QRS morphology may sometimes be misla-
beled as ventricular tachycardia, and an EP study will
differentiate the 2 arrhythmias. In short, EP testing is indi-
cated when ablative therapy of arrhythmias that trigger AF or
ablation of AF is planned.
In patients with AF who are candidates for ablation, an EP
study is critical to define the targeted site or sites of ablation
in the LA and/or right-sided structures. Evolving strategies in
the ablation of AF are discussed in Section 8.0.
8. Management
Management of patients with AF involves 3 objectives—rate
control, prevention of thromboembolism, and correction of
the rhythm disturbance, and these are not mutually exclusive.
The initial management decision involves primarily a rate-
control or rhythm-control strategy. Under the rate-control
strategy, the ventricular rate is controlled with no commit-
ment to restore or maintain sinus rhythm. The rhythm-control
strategy attempts restoration and/or maintenance of sinus
rhythm. The latter strategy also requires attention to rate
control. Depending on the patient’s course, the strategy
initially chosen may prove unsuccessful and the alternate
strategy is then adopted. Regardless of whether the rate-
control or rhythm-control strategy is pursued, attention must
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also be directed to antithrombotic therapy for prevention of
thromboembolism.
At the initial encounter, an overall management strategy
should be discussed with the patient, considering several
factors: (1) type and duration of AF, (2) severity and type of
symptoms, (3) associated cardiovascular disease, (4) patient
age, (5) associated medical conditions, (6) short-term and
long-term treatment goals, and (7) pharmacological and
nonpharmacological therapeutic options. A patient with a
first-documented episode of AF in whom rate control is
achieved does not require hospitalization.
DURATION AND PATTERN OF ATRIAL FIBRILLATION. As defined
in Section 3, AF may be categorized as paroxysmal
(self-terminating), persistent (requiring electrical or phar-
macological termination), or permanent (cardioversion im-
possible or futile). The duration since onset may be known
or unknown in an individual patient depending upon the
presence or absence of specific symptoms or ECG docu-
mentation of the arrhythmia.
TYPE AND SEVERITY OF SYMPTOMS. As described in Section
6.2, few arrhythmias present with such protean manifesta-
tions, some of which are subtle. Some patients with AF
become accommodated to a poor state of health and may
feel markedly better once sinus rhythm is restored. In
contrast, other patients have no or minimal symptoms
during AF and restoration of sinus rhythm would not
change their functional status. Before deciding on whether
a patient is truly asymptomatic, it may be helpful to ask
whether the patient has noticed a decline in activity over
time, especially when there is no other obvious
explanation.
ASSOCIATED CARDIOVASCULAR DISEASE. The likelihood that
symptoms may progress is typically related to the presence
of cardiovascular disease. The presence of ventricular
hypertrophy could, for example, lead to symptoms as
diastolic compliance worsens. Such a patient may not feel
different in sinus rhythm when initially evaluated but may
face difficulties in the future if left in AF until it becomes
difficult to restore sinus rhythm because of atrial
remodeling.
POTENTIAL FOR CHANGES IN CARDIAC FUNCTION RELATED TO
AGE. Before choosing rate control as a long-term strategy,
the clinician should consider how permanent AF is likely
to affect the patient in the future. In a patient with
asymptomatic persistent AF, attempts to restore sinus
rhythm may not be needed. Prospective studies like Rate
Control vs Electrical cardioversion for persistent atrial
fibrillation (RACE) and Atrial Fibrillation Follow-up In-
vestigation of Rhythm Management (AFFIRM) showed
that patients who could tolerate rate-controlled AF had
outcomes similar to those randomized to rhythm control.
However, these studies enrolled predominantly older pa-
tients (average 70 y), most of whom had persistent AF and
heart disease, and follow-up extended over just a few
years. Thus, the trial data do not necessarily apply to
younger patients without heart disease or to patients whose
dependency upon sinus rhythm is likely to change appre-
ciably over time. Among the latter may be patients in HF,
who are prone to deteriorate over time if left in AF. The
problem with allowing AF to persist for years is that it may
then be impossible to restore sinus rhythm as a conse-
quence of electrical and structural remodeling, which
preclude successful restoration or maintenance of sinus
rhythm and favor permanent AF. This makes it important
to ensure that a window of opportunity to maintain sinus
rhythm is not overlooked early in the course of manage-
ment of a patient with AF.
8.1. Pharmacological and Nonpharmacological
Therapeutic Options
Drugs and ablation are effective for both rate and rhythm
control, and in special circumstances surgery may be the
preferred option. Regardless of the approach, the need for
anticoagulation is based on stroke risk and not on whether
sinus rhythm is maintained. For rhythm control, drugs are
typically the first choice and LA ablation is a second-line
choice, especially in patients with symptomatic lone AF. In
some patients, especially young ones with very symptomatic
AF who need sinus rhythm, radiofrequency ablation may be
preferred over years of drug therapy. Patients with pre-
operative AF undergoing cardiac surgery face a unique
opportunity. While few patients are candidates for a stand-
alone surgical procedure to cure AF using the maze or LA
ablation techniques, these approaches can be an effective
adjunct to coronary bypass or valve repair surgery to prevent
recurrent postoperative AF. Applied in this way, AF may be
eliminated without significant additional risk. Because the
LAA is the site of over 95% of detected thrombi, this
structure should be removed from the circulation when
possible during cardiac surgery in patients at risk of devel-
oping postoperative AF, although this has not been proved to
prevent stroke (328).
Drugs are the primary treatment for rate control in most
patients with AF. While ablation of the AV conduction
system and permanent pacing (the “ablate and pace” strategy)
is an option that often yields remarkable symptomatic relief,
growing concern about the negative effect of long-term RV
pacing makes this a fallback rather than a primary treatment
strategy. LV pacing, on the other hand, may overcome many
of the adverse hemodynamic effects associated with RV
pacing.
8.1.1. Pharmacological Therapy
8.1.1.1. Drugs Modulating the Renin-Angiotensin-
Aldosterone System
Experimental and clinical studies have demonstrated that
ACE inhibitors and angiotensin receptor antagonists may
decrease the incidence of AF (36) (see Section 8.5, Primary
Prevention). ACE inhibitors decrease atrial pressure, reduce
the frequency of atrial premature beats, (329) reduce fibrosis,
(86) and may lower the relapse rate after cardioversion
(39,330,331) in patients with AF. These drugs can reduce
signal-averaged P-wave duration, the number of defibrillation
attempts required to restore sinus rhythm, and the number of
hospital readmissions for AF (332). Withdrawal of ACE-in-
hibitor medication is associated with postoperative AF in
patients undergoing coronary bypass surgery, (333) and
concurrent therapy with ACE-inhibitor and antiarrhythmic
agents enhances maintenance of sinus rhythm (334).
In patients with persistent AF and normal LV function, the
combination of enalapril or irbesartan plus amiodarone re-
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sulted in lower rates of recurrent AF after electrical conver-
sion than amiodarone alone (39,331). The role of treatment
with inhibitors of the RAAS in long-term maintenance of
sinus rhythm in patients at risk of developing recurrent AF
requires clarification in randomized trials before this ap-
proach can be routinely recommended.
8.1.1.2. HMG CoA-Reductase Inhibitors (Statins)
Available evidence supports the efficacy of statin-type cho-
lesterol-lowering agents in maintaining sinus rhythm in pa-
tients with persistent lone AF. Statins decrease the risk of
recurrences after successful direct-current cardioversion
without affecting the defibrillation threshold (335). The
mechanisms by which these drugs prevent AF recurrence are
poorly understood but include an inhibitory effect on the
progression of CAD, pleiotropic (anti-inflammatory and an-
tioxidant) effects, (336,337) and direct antiarrhythmic effects
involving alterations in transmembrane ion channels (338).
8.1.2. Heart Rate Control Versus Rhythm Control
8.1.2.1. Distinguishing Short-Term and Long-Term
Treatment Goals
The initial and subsequent management of symptomatic AF
may differ from one patient to another. For patients with
symptomatic AF lasting many weeks, initial therapy may be
anticoagulation and rate control, while the long-term goal is
to restore sinus rhythm. When cardioversion is contemplated
and the duration of AF is unknown or exceeds 48 h, patients
who do not require long-term anticoagulation may benefit
from short-term anticoagulation. If rate control offers inade-
quate symptomatic relief, restoration of sinus rhythm be-
comes a clear long-term goal. Early cardioversion may be
necessary if AF causes hypotension or worsening HF, making
the establishment of sinus rhythm a combined short- and
long-term therapeutic goal. In contrast, amelioration of symp-
toms by rate control in older patients may steer the clinician
away from attempts to restore sinus rhythm. In some circum-
stances, when the initiating pathophysiology of AF is revers-
ible, as for instance in the setting of thyrotoxicosis or after
cardiac surgery, no long-term therapy may be necessary.
8.1.2.2. Clinical Trials Comparing Rate Control and
Rhythm Control
Randomized trials comparing outcomes of rhythm- versus
rate-control strategies in patients with AF are summarized in
Tables 7 and 8. Among these, AFFIRM (Atrial Fibrillation
Follow-up Investigation of Rhythm Management) found no
difference in mortality or stroke rate between patients as-
signed to one strategy or the other. The RACE (Rate Control
vs. Electrical cardioversion for persistent atrial fibrillation)
trial found rate control not inferior to rhythm control for
prevention of death and morbidity. Clinically silent recur-
rences of AF in asymptomatic patients treated with antiar-
rhythmic drugs may be responsible for thromboembolic
events after withdrawal of anticoagulation. Hence, patients at
high risk for stroke may require anticoagulation regardless of
whether the rate-control or rhythm-control strategy is chosen,
but the AFFIRM trial was not designed to address this
question. While secondary analyses support this notion, (339)
the stroke rate in patients assigned to rhythm control who
stopped warfarin is uncertain, and additional research is
needed to address this important question.
Depending upon symptoms, rate control may be reasonable
initial therapy in older patients with persistent AF who have
hypertension or heart disease. For younger individuals, espe-
cially those with paroxysmal lone AF, rhythm control may be
a better initial approach. Often medications that exert both
antiarrhythmic and rate-controlling effects are required. Cath-
eter ablation should be considered to maintain sinus rhythm
in selected patients who failed to respond to antiarrhythmic
drug therapy (340).
8.1.2.3. Effect on Symptoms and Quality of Life
Information about the effects of antiarrhythmic and chrono-
tropic therapies on quality of life is inconsistent (292,294,295).
The AFFIRM (293,296), RACE (293,295), PIAF (Pharmaco-
logic Intervention in Atrial Fibrillation) (342), and STAF
(Strategies of Treatment of Atrial Fibrillation) (343) studies
found no differences in quality of life with rhythm control
compared with rate control. Rhythm control in the PIAF and
How to Treat Chronic Atrial Fibrillation (HOT CAFÉ) (344)
studies resulted in better exercise tolerance than rate control,
but this did not translate into improved quality of life. In the
Canadian Trial of Atrial Fibrillation (CTAF) study (347), there
was no difference between amiodarone and sotalol or
propafenone as assessed by responses to the Short Form-36
questionnaire, while a symptom severity scale showed benefit of
amiodarone over the other drugs. In the Sotalol Amiodarone
TABLE 7. Trials Comparing Rate Control and Rhythm Control Strategies in Patients With AF
Clinical Events (n)
Stroke/Embolism Death
Trial Reference Patients (n) AF Duration
Follow-Up
(y)
Age (mean
y SD) Patients in SR* Rate Rhythm Rate Rhythm
AFFIRM (2002) 296 4060 †/NR 3.5 709 35% vs. 63% (at 5 y) 88/2027 93/2033 310/2027 356/2033
RACE (2002) 293 522 1 to 399 d 2.3 689 10% vs. 39% (at 2.3 y) 7/256 16/266 18/256 18/266
PIAF (2000) 294 252 7 to 360 d 1 6110 10% vs. 56% (at 1 y) 0/125 2/127 2/125 2/127
STAF (2003) 343 200 63 mo 1.6 668 11% vs. 26% (at 2 y) 2/100 5/100 8/100 4/100
HOT CAFÉ (2004) 344 205 7 to 730 d 1.7 6111 NR vs. 64% 1/101 3/104 1/101 3/104
*Comparison between rate and rhythm control groups.
†Approximately one third of patients were enrolled with first episode of atrial fibrillation (AF).
AFFIRM indicates Atrial Fibrillation Follow-Up Investigation of Rhythm Management; HOT CAFE´, How to Treat Chronic Atrial Fibrillation; NR, not reported; PIAF,
Pharmacological Intervention in Atrial Fibrillation; RACE, Rate Control Versus Electrical Cardioversion for Persistent Atrial Fibrillation; SR, sinus rhythm; and STAF,
Strategies of Treatment of Atrial Fibrillation.
e172 Fuster et al. JACC Vol. 48, No. 4, 2006
ACC/AHA/ESC Practice Guidelines August 15, 2006:e149–246
Atrial Fibrillation Efficacy Trial (SAFE-T) (292), restoration
and maintenance of sinus rhythm in patients with AF signifi-
cantly improved quality of life in certain domains, but amiod-
arone was associated with a decrease in mental health function
compared with sotalol or placebo (292). Symptomatic improve-
ment has also been reported after the maze procedure in patients
with AF (348).
In a substudy of AFFIRM, there was no significant
association between achieved HR and quality-of-life mea-
surements, New York Heart Association functional class, or
6-min walking distance in patients with AF compared with
less well-controlled patients (345). On the whole, rate- and
rhythm-control strategies do not affect quality of life signif-
icantly or differently. Even when sinus rhythm can be
maintained, symptoms of associated cardiovascular condi-
tions may obscure changes in quality of life related to AF.
Clinicians must exercise judgment, however, in translating
shifts in quality of life in these study populations to the sense
of well-being experienced by individual patients. Patients
with similar health status may experience entirely different
qualitiy of life, and treatment must be tailored to each
individual, depending on the nature, intensity, and frequency
of symptoms, patient preferences, comorbid conditions, and
the ongoing response to treatment.
Long-term oral anticoagulant therapy with vitamin K
antagonists involves multiple drug interactions and frequent
blood testing, which influences quality of life in patients with
AF. Gage et al (349) quantified this as a mean 1.3% decrease
in utility, a measure of quality of life in quantitative decision
analysis. Some patients (16%) thought that their quality of
life would be greater with aspirin than with oral anticoagu-
lants, despite its lesser efficacy. Other investigators, using
decision analysis to assess patient preferences, found that
61% of 97 patients preferred anticoagulation to no treatment,
a smaller proportion than that for which published guidelines
recommend treatment (350). In the future, these comparisons
could be influenced by the development of more convenient
approaches to antithrombotic therapy.
8.1.2.4. Effects on Heart Failure
HF may develop or deteriorate during either type of treatment
for AF due to progression of underlying cardiac disease,
inadequate control of the ventricular rate at the time of
recurrent AF, or antiarrhythmic drug toxicity. Patients man-
aged with rate compared with rhythm control did not,
however, differ significantly in development or deterioration
of HF. In the AFFIRM study, 2.1% of those in the rate-
control group and 2.7% in the rhythm-control group devel-
oped AF after an average follow-up of 3.5 y. In the RACE
study, the incidence of hospitalization for HF was 3.5%
during a management strategy directed at rate control and
4.5% with rhythm control, during an average follow-up of
2.3 y. Similarly, there were no differences in the STAF or
HOT CAFE studies. The Atrial Fibrillation and Congestive
Heart Failure (AF-CHF) study (53) is currently investigating
this issue in a large number of patients.
8.1.2.5. Effects on Thromboembolic Complications
The majority of patients in the AFFIRM and RACE trials had
1 or more stroke risk factors in addition to AF, and the
rhythm-control strategy did not lower the stroke rate more
effectively than rate control and anticoagulation
(296,339,351) (see Table 7). One methodological concern is
that the success of rhythm control at maintaining sinus
rhythm was assessed by intermittent ECG recordings,
whereas longer-term monitoring might have identified pa-
tients at lower thromboembolic risk. Most strokes were
diagnosed after discontinuation of anticoagulation or at sub-
therapeutic intensity (International Normalized Ratio [INR]
below 2.0). In addition, while recurrent AF was detected in
only about one-third of those in the rhythm-control groups
who developed stroke, at the time of ischemic stroke, patients
in the rate-control groups typically had AF. Long-term oral
anticoagulation therefore seems appropriate for most patients
TABLE 8. General Characteristics of Rhythm Control and Rate Control Trials in Patients With AF
Patients Reaching Primary Endpoint (n)
Trial Reference
Patients
(n)
Mean
Age
(y)
Mean Length
of Follow-Up
(y)
Inclusion
Criteria
Primary
Endpoint
Rate
Control
Rhythm
Control p
PIAF (2000) 294 252 61.0 1.0 Persistent AF (7 to 360 d) Symptomatic improvement 76/125 (60.8%) 70/127 (55.1%) 0.317
RACE (2002) 293 522 68.0 2.3 Persistent AF or flutter for less than 1 y
and 1 to 2 cardioversions over 2 y and
oral anticoagulation
Composite: cardiovascular death, CHF,
severe bleeding, PM implantation,
thromboembolic events, severe adverse
effects of antiarrhythmic drugs
44/256 (17.2%) 60/266 (22.6%) 0.11
STAF (2002) 343 200 66.0 1.6 Persistent AF (longer than 4 wk and less
than 2 y), left atrial size greater than
45 mm, CHF NYHA II–IV, LVEF less than
45%
Composite: overall mortality,
cerebrovascular complications, CPR,
embolic events
10/100 (10.0%) 9/100 (9.0%) 0.99
AFFIRM
(2002)
296 4060 69.7 3.5 Paroxysmal AF or persistent AF, age 65 y
or older, or risk of stroke or death
All-cause mortality 310/2027 (25.9%) 356/2033 (26.7%) 0.08
HOT CAFÉ
(2004)
344 205 60.8 1.7 First clinically overt episode of persistent
AF (7 d or more and less than 2 y), 50 to
75 y old
Composite; death, thromboembolic
complications; intracranial or other major
hemorrhage
1/101 (1.0%) 4/104 (3.9%) Greater
than 0.71
Reprinted with permission from Pelargonio G, Prystowsky EN. Rate versus rhythm control in the management of patients with atrial fibrillation. Nat Clin Pract
Cardiovasc Med 2005;2:514–21 (346).
AF indicates atrial fibrillation; AFFIRM, Atrial Fibrillation Follow-up Investigation of Rhythm Management, CHF, congestive heart failure; CPR, cardiopulmonary
resuscitation; HOT CAFE´, How to Treat Chronic Atrial Fibrillation; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PIAF, Pharmacological
Intervention in Atrial Fibrillation; PM, pacemaker; RACE, Rate Control Versus Electrical Cardioversion for Persistent Atrial Fibrillation; and STAF, Strategies of Treatment
of Atrial Fibrillation.
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with AF who have risk factors for thromboembolism, regard-
less of treatment strategy and of whether AF is documented at
any given time.
8.1.2.6. Effects on Mortality and Hospitalization
In the AFFIRM study, a trend toward increased overall
mortality was observed in patients treated for rhythm control
compared with rate control after an average of 3.5 y (26.7%
vs. 25.9%, p  0.08) (296). The rhythm-control strategy was
associated with excess mortality among older patients, those
with HF, and those with CAD, but the tendency persisted
after adjustment for these covariates. A substudy suggested
that deleterious effects of antiarrhythmic drugs (mortality
increase of 49%) may have offset the benefits of sinus rhythm
(which was associated with a 53% reduction in mortality)
(352). Hospitalization was more frequent in the rhythm-
control arms in all trials, mainly due to admissions for
cardioversion. A substudy of RACE compared anticoagulated
patients in the rhythm-control group who sustained sinus
rhythm with patients in the rate-control group who had
permanent AF and found no benefit of rhythm control even in
this selected subgroup (353). The implication that adverse
drug effects in patients with underlying heart disease might
exert an adverse effect on morbidity and mortality that is not
overcome by maintaining sinus rhythm must be interpreted
cautiously because the comparisons of patient subgroups in
these secondary analyses are not based on randomization
(Table 9).
8.1.2.7. Implications of the Rhythm-Control Versus
Rate-Control Studies
Theoretically, rhythm control should have advantages over
rate control, yet a trend toward lower mortality was observed
in the rate-control arm of the AFFIRM study and did not
differ in the other trials from the outcome with the rhythm-
control strategy. This might suggest that attempts to restore
sinus rhythm with presently available antiarrhythmic drugs
are obsolete. The RACE and AFFIRM trials did not address
AF in younger, symptomatic patients with little underlying
heart disease, in whom restoration of sinus rhythm by
cardioversion antiarrhythmic drugs or nonpharmacological
interventions still must be considered a useful therapeutic
approach. One may conclude from these studies that rate
control is a reasonable strategy in elderly patients with
minimal symptoms related to AF. An effective method for
maintaining sinus rhythm with fewer side effects would
address a presently unmet need.
8.1.3. Rate Control During Atrial Fibrillation
CRITERIA FOR RATE CONTROL. In patients with AF, the ventric-
ular rate may accelerate excessively during exercise even
when it is well controlled at rest. In addition to allowing
adequate time for ventricular filling and avoiding rate-related
ischemia, enhancement of intraventricular conduction with
rate reduction may result in improved hemodynamics. It may
be useful to evaluate the heart rate response to submaximal or
maximal exercise or to monitor the rate over an extended
period (e.g., by 24-h Holter recording). In addition, rate
variability during AF provides information about the status of
the autonomic nervous system that may have independent
prognostic implications (356–359).
The definition of adequate rate control has been based
primarily on short-term hemodynamic benefits and has not
been well studied with respect to regularity or irregularity of
the ventricular response to AF, quality of life, or symptoms or
development of cardiomyopathy. No standard method for
assessment of heart rate control has been established to guide
management of patients with AF. Criteria for rate control vary
with patient age but usually involve achieving ventricular
rates between 60 and 80 beats per minute at rest and between
90 and 115 beats per minute during moderate exercise. For the
AFFIRM trial, adequate control was defined as an average
heart rate up to 80 beats per minute at rest and either an
average rate up to 100 beats per minute over at least 18-h
ambulatory Holter monitoring with no rate above 100% of the
maximum age-adjusted predicted exercise heart rate or a
maximum heart rate of 110 beats per minute during a 6-min
walk test (360). In the RACE trial, rate control was defined as
less than 100 beats per minute at rest. Only about 5% of
patients from these large clinical trials required AV ablation to
achieve heart rate control within these limits.
HEMODYNAMIC AND CLINICAL CONSEQUENCES OF RAPID RATE.
Patients who are symptomatic with rapid ventricular rates
during AF require prompt medical management, and car-
dioversion should be considered if symptomatic hypoten-
sion, angina, or HF is present. A sustained, uncontrolled
tachycardia may lead to deterioration of ventricular func-
TABLE 9. Comparison of Adverse Outcomes in Rhythm Control and Rate Control Trials in Patients With AF
Trial Reference
Deaths of All
Causes
(n rate/rhythm))
Deaths From
Cardiovascular
Causes
Deaths From
Noncardiovascular
Causes Stroke
Thromboembolic
Events Bleeding
RACE (2002) 293 36 18/18 ND ND 14/21 12/9
PIAF (2000) 294 4 1/1 1* ND ND ND
STAF (2003) 343 12 (8/4) 8/3 0/1 1/5 ND 8/11
AFFIRM (2002) 296 666 (310/356) 167/164 113/165 77/80 ND 107/96
HOT CAFÉ (2004) 344 4 (1/3) 0/2 1/1 0/3 ND 5/8
*Total number of patients not reported.
Reprinted with permission from Pelargonio G, Prystowsky EN. Rate versus rhythm control in the management of patients with atrial fibrillation. Nat Clin Pract
Cardiovasc Med 2005;2:514–21 (346).
AF indicates atrial fibrillation; AFFIRM, Atrial Fibrillation Follow-up Investigation of Rhythm Management; HOT CAFE´, How to Treat Chronic Atrial Fibrillation; ND, not
determined; PIAF, Pharmacological Intervention in Atrial Fibrillation; RACE, Rate Control Versus Electrical Cardioversion for Persistent Atrial Fibrillation; and STAF,
Strategies of Treatment of Atrial Fibrillation.
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tion (tachycardia-related cardiomyopathy) (361) and that
improves with adequate rate control. In the Ablate and
Pace Trial (APT), 25% of patients with AF who had an
ejection fraction below 45% displayed a greater than 15%
increase in ejection fraction after ablation (363).
Tachycardia-induced cardiomyopathy tends to resolve
within 6 mo of rate or rhythm control; when tachycardia
recurs, LV ejection fraction declines and HF develops over
a shorter period, and this is associated with a relatively
poor prognosis (364).
8.1.3.1. Pharmacological Rate Control During Atrial
Fibrillation
RECOMMENDATIONS
Class I
1. Measurement of the heart rate at rest and control
of the rate using pharmacological agents (either a
beta blocker or nondihydropyridine calcium chan-
nel antagonist, in most cases) are recommended
for patients with persistent or permanent AF.
(Level of Evidence: B)
2. In the absence of preexcitation, intravenous admin-
istration of beta blockers (esmolol, metoprolol, or
propranolol) or nondihydropyridine calcium chan-
nel antagonists (verapamil, diltiazem) is recom-
mended to slow the ventricular response to AF in the
acute setting, exercising caution in patients with
hypotension or HF. (Level of Evidence: B)
3. Intravenous administration of digoxin or amiod-
arone is recommended to control the heart rate in
patients with AF and HF who do not have an
accessory pathway. (Level of Evidence: B)
4. In patients who experience symptoms related to AF
during activity, the adequacy of heart rate control
should be assessed during exercise, adjusting phar-
macological treatment as necessary to keep the rate
in the physiological range. (Level of Evidence: C)
5. Digoxin is effective following oral administration
to control the heart rate at rest in patients with AF
and is indicated for patients with HF, LV dysfunc-
tion, or for sedentary individuals. (Level of Evi-
dence: C)
Class IIa
1. A combination of digoxin and either a beta blocker
or nondihydropyridine calcium channel antagonist
is reasonable to control the heart rate both at rest
and during exercise in patients with AF. The choice
of medication should be individualized and the dose
modulated to avoid bradycardia. (Level of Evidence:
B)
2. It is reasonable to use ablation of the AV node or
accessory pathway to control heart rate when phar-
macological therapy is insufficient or associated with
side effects. (Level of Evidence: B)
3. Intravenous amiodarone can be useful to control the
heart rate in patients with AF when other measures are
unsuccessful or contraindicated. (Level of Evidence: C)
4. When electrical cardioversion is not necessary in
patients with AF and an accessory pathway, intra-
venous procainamide or ibutilide is a reasonable
alternative. (Level of Evidence: C)
Class IIb
1. When the ventricular rate cannot be adequately con-
trolled both at rest and during exercise in patients with
AF using a beta blocker, nondihydropyridine calcium
channel antagonist, or digoxin, alone or in combina-
tion, oral amiodarone may be administered to control
the heart rate. (Level of Evidence: C)
2. Intravenous procainamide, disopyramide, ibutilide,
or amiodarone may be considered for hemodynam-
ically stable patients with AF involving conduction
over an accessory pathway. (Level of Evidence: B)
3. When the rate cannot be controlled with pharmaco-
logical agents or tachycardia-mediated cardiomyop-
athy is suspected, catheter-directed ablation of the
AV node may be considered in patients with AF to
control the heart rate. (Level of Evidence: C)
Class III
1. Digitalis should not be used as the sole agent to
control the rate of ventricular response in patients
with paroxysmal AF. (Level of Evidence: B)
2. Catheter ablation of the AV node should not be
attempted without a prior trial of medication to
control the ventricular rate in patients with AF.
(Level of Evidence: C)
3. In patients with decompensated HF and AF, intrave-
nous administration of a nondihydropyridine calcium
channel antagonist may exacerbate hemodynamic
compromise and is not recommended. (Level of Evi-
dence: C)
4. Intravenous administration of digitalis glycosides or
nondihydropyridine calcium channel antagonists to
patients with AF and a preexcitation syndrome may
paradoxically accelerate the ventricular response and
is not recommended. (Level of Evidence: C)
The main determinants of ventricular rate during AF are the
intrinsic conduction characteristics and refractoriness of the
AV node and sympathetic and parasympathetic tone. The
functional refractory period of the AV node correlates in-
versely with ventricular rate during AF, and drugs that
prolong the refractory period are generally effective for rate
control. The efficacy of pharmacological interventions de-
signed to achieve rate control in patients with AF has been
about 80% in clinical trials (365). There is no evidence that
pharmacological rate control has any adverse influence on
LV function, but bradycardia and heart block may occur as an
unwanted effect of beta blockers, amiodarone, digitalis gly-
cosides, or nondihydropyridine calcium channel antagonists,
particularly in patients with paroxysmal AF, especially the
elderly. When rapid control of the ventricular response to AF
is required or oral administration of medication is not
feasible, medication may be administered intravenously. Oth-
erwise, in hemodynamically stable patients with a rapid
ventricular response to AF, negative chronotropic medication
may be administered orally (Table 10). Combinations may be
necessary to achieve rate control in both acute and chronic
situations, but proper therapy requires careful dose titration.
Some patients develop symptomatic bradycardia that requires
permanent pacing. Nonpharmacological therapy should be
considered when pharmacological measures fail.
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8.1.3.1.1. BETA BLOCKERS. Intravenous beta blockade with
propranolol, atenolol, metoprolol, or esmolol is effective for
control of the rate of ventricular response to AF. These agents
may be particularly useful in states of high adrenergic tone
(e.g., postoperative AF). After noncardiac surgery, intrave-
nous esmolol produced more rapid conversion to sinus
rhythm than diltiazem, but rates after 2 and 12 h were similar
with both treatments (366).
TABLE 10. Intravenous and Orally Administered Pharmacological Agents for Heart Rate Control in Patients With Atrial Fibrillation
Drug
Class/LOE
Recommendation Loading Dose Onset Maintenance Dose Major Side Effects
ACUTE SETTING
Heart rate control in patients without accessory
pathway
Esmolol*† Class I, LOE C 500 mcg/kg IV over 1 min 5 min 60 to 200 mcg/kg/min IV 2BP, HB,2HR, asthma, HF
Metoprolol† Class I, LOE C 2.5 to 5 mg IV bolus over 2
min; up to 3 doses
5 min NA 2BP, HB,2HR, asthma, HF
Propranolol† Class I, LOE C 0.15 mg/kg IV 5 min NA 2BP, HB,2HR, asthma, HF
Diltiazem Class I, LOE B 0.25 mg/kg IV over 2 min 2 to 7 min 5 to 15 mg/h IV 2BP, HB, HF
Verapamil Class I, LOE B 0.075 to 0.15 mg/kg IV over 2
min
3 to 5 min NA 2BP, HB, HF
Heart rate control in patients with accessory
pathway§
Amiodarone‡ Class IIa, LOE C 150 mg over 10 min Days 0.5 to 1 mg/min IV 2BP, HB, pulmonary toxicity, skin
discoloration, hypothyroidism,
hyperthyroidism, corneal deposits,
optic neuropathy, warfarin
interaction, sinus bradycardia
Heart rate control in patients with heart failure and without accessory pathway
Digoxin Class I, LOE B 0.25 mg IV each 2 h, up to
1.5 mg
60 min or more§ 0.125 to 0.375 mg daily IV or
orally
Digitalis toxicity, HB,2HR
Amiodarone‡ Class IIa, LOE C 150 mg over 10 min Days 0.5 to 1 mg/min IV 2BP, HB, pulmonary toxicity, skin
discoloration, hypothyroidism,
hyperthyroidism, corneal deposits,
optic neuropathy, warfarin
interaction, sinus bradycardia
NON-ACUTE SETTING and CHRONIC MAINTENANCE THERAPY¶
Heart rate control
Metoprolol† Class I, LOE C Same as maintenance dose 4 to 6 h 25 to 100 mg twice a day,
orally
2BP, HB,2HR, asthma, HF
Propranolol† Class I, LOE C Same as maintenance dose 60 to 90 min 80 to 240 mg daily in divided
doses, orally
2BP, HB,2HR, asthma, HF
Diltiazem Class I, LOE B Same as maintenance dose 2 to 4 h 120 to 360 mg daily in
divided doses; slow release
available, orally
2BP, HB, HF
Verapamil Class I, LOE B Same as maintenance dose 1 to 2 h 120 to 360 mg daily in
divided doses; slow release
available, orally
2BP, HB, HF, digoxin interaction
Heart rate control in patients with heart failure and without accessory pathway
Digoxin Class I, LOE C 0.5 mg by mouth daily 2 days 0.125 to 0.375 mg daily,
orally
Digitalis toxicity, HB,2HR
Amiodarone‡ Class IIb, LOE C 800 mg daily for 1 wk, orally
600 mg daily for 1 wk, orally
400 mg daily for 4 to 6 wk,
orally
1 to 3 wk 200 mg daily, orally 2BP, HB, pulmonary toxicity, skin
discoloration, hypothyroidism,
hyperthyroidism, corneal deposits,
optic neuropathy, warfarin
interaction, sinus bradycardia
*Onset is variable and some effect occurs earlier.
†Only representative members of the type of beta-adrenergic antagonist drugs are included in the table, but other, similar agents could be used for this indication
in appropriate doses. Beta blockers are grouped in an order preceding the alphabetical listing of drugs.
‡Amiodarone can be useful to control the heart rate in patients with atrial fibrillation (AF) when other measures are unsuccessful or contraindicated.
§Conversion to sinus rhythm and catheter ablation of the accessory pathway are generally recommended; pharmacological therapy for rate control may be
appropriate in certain patients.
If rhythm cannot be converted or ablated and rate control is needed, intravenous (IV) amiodarone is recommended.
¶Adequacy of heart rate control should be assessed during physical activity as well as at rest.
2BP indicates hypotension; 2HR, bradycardia; HB, heart block; HF, heart failure; LOE, level of evidence; and NA, not applicable.
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In 7 of 12 comparisons, beta-adrenergic blockade proved
safe and effective for control of heart rate in patients with AF
and superior to placebo. Nadolol and atenolol were the most
efficacious of the drugs tested. Patients taking beta blockers
may experience slow rates at rest, or exercise tolerance may
be compromised when the rate response is blunted exces-
sively (367). Sotalol, a nonselective beta-blocking drug with
type III antiarrhythmic activity used for rhythm control, also
provides excellent rate control in the event of AF recurrence
(368) and may achieve lower heart rate than metoprolol
during exercise. Atenolol, metoprolol, and sotalol provide
better control of exercise-induced tachycardia than digoxin
(369,370). Carvedilol also lowers the ventricular rate at rest
and during exercise in such patients and reduces ventricular
ectopy (371). With or without digoxin in the AFFIRM study,
beta blockers were the most effective drug class for rate control,
achieving the specified heart rate endpoints in 70% of patients
compared with 54% with use of calcium channel blockers (360).
Beta blockers should be initiated cautiously in patients with AF
and HF who have reduced ejection fraction (372).
8.1.3.1.2. NONDIHYDROPYRIDINE CALCIUM CHANNEL ANTAGO-
NISTS. The nondihydropyridine calcium channel antagonist
agents verapamil and diltiazem are commonly used for
treatment of AF and are the only agents that have been
associated with an improvement in quality of life and exercise
tolerance. Intravenous bolus injection of either drug is effec-
tive to control the ventricular rate (367,373), although their
short duration of action usually requires continuous intrave-
nous infusion to maintain rate control. These agents should be
used cautiously or avoided in patients with HF due to systolic
dysfunction because of their negative inotropic effects. Eight
randomized studies comparing calcium channel blockers to
placebo (370) found significant decrease in heart rate with
diltiazem. Verapamil decreased heart rate both at rest (by 8 to
23 beats per minute) and during exercise (by 20 to 34 beats
per minute). Direct comparisons of verapamil and diltiazem
have demonstrated similar effectiveness, (374) with pre-
served or improved exercise tolerance in most patients (374).
These agents may be preferred for long-term use over beta
blockers in patients with bronchospasm or chronic obstruc-
tive pulmonary disease.
8.1.3.1.3. DIGOXIN. Although intravenous digoxin may slow
the ventricular response to AF at rest, there is a delay of at
least 60 min before onset of a therapeutic effect in most
patients, and the peak effect does not develop for up to 6 h.
Digoxin is no more effective than placebo in converting AF
to sinus rhythm and may perpetuate AF (375,376). Its
efficacy is reduced in states of high sympathetic tone, a
possible precipitant of paroxysmal AF. In a review of 139
episodes of paroxysmal AF detected by Holter monitoring,
there was no difference in the ventricular rates of patients
taking digoxin and those not taking this agent (376). Other
investigators, however, have reported that digoxin reduces
the frequency and severity of AF recurrences (30), and the
combination of digoxin and atenolol is effective for rate
control (377). Given the availability of more effective agents,
digoxin is no longer considered first-line therapy for rapid
management of AF, except in patients with HF or LV
dysfunction, or perhaps in patients who are so sedentary as to
obviate the need for rate control during activity.
Digoxin exerts only a transient rate-slowing effect in
patients with recent-onset AF (378), perhaps as a result of a
vagotonic effect on the AV node. In contrast to its limited
negative chronotropic effect in patients with paroxysmal AF,
digoxin is moderately effective in those with persistent AF,
particularly when HF is present (362,370). According to a
systematic review, digoxin administered alone slows the heart
rate more than placebo by an average of 4 to 21 beats per
minute at rest, but it does not slow heart rate during exercise
in patients with AF (367,370). The most frequent adverse
effects of digoxin are ventricular arrhythmias, atrioventricular
block, and sinus pauses, all of which are dose dependent.
Because of drug interactions, the serum digoxin concentration
may rise and toxic effects may be potentiated when verapamil
or antiarrhythmic agents such as propafenone or amiodarone
are administered concurrently.
8.1.3.1.4. ANTIARRHYTHMIC AGENTS. Amiodarone has both
sympatholytic and calcium antagonistic properties, depresses
AV conduction, and is effective for controlling the ventricular
rate in patients with AF. Intravenous amiodarone is generally
well tolerated in critically ill patients who develop rapid atrial
tachyarrhythmias refractory to conventional treatment, but effi-
cacy has not been sufficiently evaluated in this indication (379).
Amiodarone is considered a suitable alternative agent for heart
rate control when conventional measures are ineffective (379).
When conventional measures are ineffective, amiodarone may
be considered as an alternative agent for heart rate control in
patients with AF (379), but this represents an off-label use in the
United States and in some other countries and the potential
benefit must be carefully weighed against the considerable
potential toxicity of this drug. Patients given amiodarone who
did not convert from AF to sinus rhythm experienced substan-
tially lower ventricular rates than those treated with placebo,
(370) but important adverse effects make this agent a second-
line therapy for rate control. In one study, oral amiodarone
decreased the ventricular rate without affecting exercise capac-
ity, quality of life, or AF symptoms (380). High-dose oral
amiodarone loading can worsen hemodynamics in patients with
recent decompensation of HF or hypotension (381). Amiodarone
may cause potentially fatal toxicity, including pulmonary fibro-
sis, hepatic injury, and proarrhythmia.
Dofetilide and ibutilide are effective for conversion of
atrial flutter and AF but are not effective for control of the
ventricular rate. Propafenone exerts mild beta-blocking ef-
fects that may slow conduction across the AV node, but this
is seldom sufficient to control the rate in patients with AF,
and AV conduction may accelerate when the atrial rhythm
becomes slower and more regular, so other agents in addition
to propafenone are generally required to maintain control of
the heart rate when AF recurs.
8.1.3.1.5. COMBINATION THERAPY. Combinations of drugs
may be required to achieve adequate rate control in some
patients with AF, but care should be taken to avoid brady-
cardia (370). The addition of other drugs to digoxin is
commonly required to control the rate during exercise. The
combination of digoxin and atenolol produces a synergistic
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effect on the AV node (377), and the combination of digoxin
and pindolol provided better control during exercise than
digoxin alone or in combination with verapamil (382). In
general, the combination of digoxin and a beta blocker
appears more effective than the combination of digoxin with
a calcium channel antagonist (377).
8.1.3.1.6. SPECIAL CONSIDERATIONS IN PATIENTS WITH THE
WOLFF-PARKINSON-WHITE (WPW) SYNDROME. Intravenous
beta blockers, digitalis, adenosine, lidocaine, and nondihy-
dropyridine calcium channel antagonists, all of which slow
conduction across the AV node, are contraindicated in pa-
tients with the WPW syndrome and tachycardia associated
with ventricular preexcitation, because they can facilitate
antegrade conduction along the accessory pathway during AF
(3), resulting in acceleration of the ventricular rate, hypoten-
sion, or ventricular fibrillation (181). When the arrhythmia is
associated with hemodynamic compromise, however, early
direct-current cardioversion is indicated. In hemodynamically
stable patients with preexcitation, type I antiarrhythmic
agents or amiodarone may be administered intravenously.
Beta blockers and calcium channel blockers are reasonable
for oral chronic use (383).
8.1.3.2. Pharmacological Therapy to Control Heart Rate in
Patients With Both Atrial Fibrillation and Atrial Flutter
A patient treated with AV nodal blocking drugs whose ventric-
ular rate is well controlled during AF may experience a rise or
fall in rate if he or she develops atrial flutter. This is also true
when antiarrhythmic agents such as propafenone or flecainide
are used to prevent recurrent AF. These compounds may
increase the likelihood of 1:1 AV conduction during atrial
flutter, leading to a very rapid ventricular response. Thus, when
these agents are given for prophylaxis against recurrent parox-
ysmal AF or atrial flutter, AV nodal blocking drugs should be
routinely coadministered. An exception may be patients with
paroxysmal AF who have undergone catheter ablation of the
cavotricuspid isthmus to prevent atrial flutter.
8.1.3.3. Regulation of Atrioventricular Nodal Conduction
by Pacing
Because ventricular pacing prolongs the AV nodal refractory
period as a result of concealed retrograde penetration, it
eliminates longer ventricular cycles and may reduce the
number of short ventricular cycles related to rapid AV
conduction during AF. Pacing at approximately the mean
ventricular rate during spontaneous AV conduction can reg-
ulate the ventricular rhythm during AF (384). This may be
useful for patients with marked variability in ventricular rates
or for those who develop resting bradycardia during treatment
with medication. In some patients, the hemodynamic benefit
of revascularization may be offset by asynchronous ventric-
ular activation during RV pacing. At least 2 multicenter
studies examined a ventricular rate regularization algorithm.
In one study, patients with paroxysmal AF indicated a
preference for the paced regularization strategy, while pa-
tients with permanent AF showed no preference despite a
29% improvement of irregularity (385). In another study,
ventricular rate regularization did not improve quality of life
in patients with paroxysmal or permanent AF (386).
8.1.3.4. AV Nodal Ablation
AV nodal ablation in conjunction with permanent pacemaker
implantation provides highly effective control of the heart rate
and improves symptoms in selected patients with AF (363,387–
389). In general, patients most likely to benefit from this strategy
are those with symptoms or tachycardia-mediated cardiomyop-
athy related to rapid ventricular rate during AF that cannot be
controlled adequately with antiarrhythmic or negative chrono-
tropic medications. Meta-analysis of 21 studies published be-
tween 1989 and 1998 that included a total of 1181 patients
concluded that AV nodal ablation and permanent pacemaker
implantation significantly improved cardiac symptoms, quality
of life, and healthcare utilization for patients with symptomatic
AF refractory to medical treatment (389). In the APT, 156
patients with refractory AF displayed improvements in quality of
life, exercise capacity, and ventricular function over 1 y (363). In
a study of 56 patients with impaired LV function (ejection
fraction less than 40%), the mean ejection fraction improved
from 26% plus or minus 8% to 34% plus or minus 13% after AV
nodal ablation and pacemaker implantation and became normal
in 16 patients (29%) (390). Patients with persistent LV dysfunc-
tion after ablation were more likely to have structural heart
disease associated with less than 60% survival at 5 y. In small
randomized trials involving patients with paroxysmal (388) and
persistent (387). AF, significantly greater proportions experi-
enced improvement in symptoms and quality of life after AV
nodal ablation than with antiarrhythmic medication therapy. Of
2027 patients randomized to make control in the AFFIRM study,
AV nodal ablation was performed in 5% (360) after failure to
achieve adequate rate control with a mean of 2.4 plus or minus
0.7 medications. Another 147 patients required pacemaker
implantation because of symptomatic bradycardia. Catheter
ablation of inferior atrial inputs to the AV node slows the
ventricular rate during AF and improves symptoms without
pacemaker implantation (391,392). This technique has several
limitations, however, including inadvertent complete AV block
and a tendency of ventricular rate to rise over the 6 mo following
ablation. Two small, randomized trials comparing this type of
AV nodal modification with complete AV nodal ablation and
permanent pacemaker implantation demonstrated better symp-
tom relief with the complete interruption procedure. Thus, AV
nodal modification without pacemaker implantation is only
rarely used.
Ablation of the AV inputs in the atrium may improve the
reliability of the junctional escape mechanism (393). This
involves selective ablation of fast and slow AV nodal
pathways followed, if necessary, by ablation between these
inputs to achieve complete AV block. Complications of AV
nodal ablation include those associated with pacemaker
implantation, ventricular arrhythmias, thromboembolism as-
sociated with interruption of anticoagulation, the rare occur-
rence of LV dysfunction, and progression from paroxysmal to
persistent AF. The 1-y mortality rate after AV nodal ablation
and permanent pacemaker implantation is approximately
6.3% (95% confidence interval [CI] 5.5% to 7.2%), including
a 2.0% risk of sudden death (95% CI 1.5% to 2.6%).
Although a causal relationship between the procedure and
sudden death remains controversial, it has been suggested that
programming the pacemaker to a relatively high nominal rate
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(90 beats per minute) for the first month after ablation may
reduce the risk (394,395).
Although the symptomatic benefits of AV nodal ablation
are clear, limitations include the persistent need for antico-
agulation, loss of AV synchrony, and lifelong pacemaker
dependency. There is also a finite risk of sudden death due to
torsades de pointes or ventricular fibrillation (396). Patients
with abnormalities of diastolic ventricular compliance who
depend on AV synchrony to maintain cardiac output, such as
those with hypertrophic cardiomyopathy or hypertensive
heart disease, may experience persistent symptoms after AV
nodal ablation and pacemaker implantation. Hence, patients
should be counseled regarding each of these considerations
before proceeding with this irreversible measure.
The adverse hemodynamic effects of RV apical pacing
following AV nodal ablation have been a source of concern.
Compared with RV apical pacing, LV pacing significantly
improves indices of both LV systolic function (pressure-
volume loop, stroke work, ejection fraction, and dP/dt) and
diastolic filling (397). Acutely, LV pacing was associated
with a 6% increase in ejection fraction and a 17% decrease in
mitral regurgitation (398). The Post AV Node Ablation
Evaluation (PAVE) randomized 184 patients undergoing AV
nodal ablation because of permanent AF to standard RV
apical pacing or biventricular pacing (399). After 6 mo, the
biventricular pacing group walked 25.6 meters farther in 6
min (p  0.03), had greater peak oxygen consumption, and
had higher scores in 9 of 10 quality-of-life domains than the
RV pacing group. While there was no difference in LV
ejection fraction between the groups at baseline, the LV
ejection fraction remained stable in the biventricular pacing
group while it declined in the RV pacing group (46% vs.
41%, respectively; p  0.03). There was no significant dif-
ference in mortality. A subgroup analysis suggested that
functional improvements were confined to patients with LV
ejection fraction below 35% before ablation.
Patients with normal LV function or reversible LV dys-
function undergoing AV nodal ablation are most likely to
benefit from standard AV nodal ablation and pacemaker
implantation. For those with impaired LV function not due to
tachycardia, a biventricular pacemaker with or without defi-
brillator capability should be considered. Upgrading to a
biventricular device should be considered for patients with
HF and an RV pacing system who have undergone AV node
ablation (400).
8.1.4. Preventing Thromboembolism
For recommendations regarding antithrombotic therapy in
patients with AF undergoing cardioversion, see Section 8.2.7.
RECOMMENDATIONS
Class I
1. Antithrombotic therapy to prevent thromboembo-
lism is recommended for all patients with AF, except
those with lone AF or contraindications. (Level of
Evidence: A)
2. The selection of the antithrombotic agent should be
based upon the absolute risks of stroke and bleeding
and the relative risk and benefit for a given patient.
(Level of Evidence: A)
3. For patients without mechanical heart valves at high
risk of stroke, chronic oral anticoagulant therapy
with a vitamin K antagonist is recommended in a
dose adjusted to achieve the target intensity INR of
2.0 to 3.0, unless contraindicated. Factors associated
with highest risk for stroke in patients with AF are
prior thromboembolism (stroke, TIA, or systemic
embolism) and rheumatic mitral stenosis. (Level of
Evidence: A)
4. Anticoagulation with a vitamin K antagonist is rec-
ommended for patients with more than 1 moderate
risk factor. Such factors include age 75 y or greater,
hypertension, HF, impaired LV systolic function
(ejection fraction 35% or less or fractional shorten-
ing less than 25%), and diabetes mellitus. (Level of
Evidence: A)
5. INR should be determined at least weekly during
initiation of therapy and monthly when anticoagu-
lation is stable. (Level of Evidence: A)
6. Aspirin, 81–325 mg daily, is recommended as an
alternative to vitamin K antagonists in low-risk
patients or in those with contraindications to oral
anticoagulation. (Level of Evidence: A)
7. For patients with AF who have mechanical heart
valves, the target intensity of anticoagulation should
be based on the type of prosthesis, maintaining an
INR of at least 2.5. (Level of Evidence: B)
8. Antithrombotic therapy is recommended for pa-
tients with atrial flutter as for those with AF. (Level
of Evidence: C)
Class IIa
1. For primary prevention of thromboembolism in
patients with nonvalvular AF who have just 1 of the
following validated risk factors, antithrombotic
therapy with either aspirin or a vitamin K antago-
nist is reasonable, based upon an assessment of the
risk of bleeding complications, ability to safely sus-
tain adjusted chronic anticoagulation, and patient
preferences: age greater than or equal to 75 y (espe-
cially in female patients), hypertension, HF, im-
paired LV function, or diabetes mellitus. (Level of
Evidence: A)
2. For patients with nonvalvular AF who have 1 or
more of the following less well-validated risk factors,
antithrombotic therapy with either aspirin or a
vitamin K antagonist is reasonable for prevention of
thromboembolism: age 65 to 74 y, female gender, or
CAD. The choice of agent should be based upon the
risk of bleeding complications, ability to safely sus-
tain adjusted chronic anticoagulation, and patient
preferences. (Level of Evidence: B)
3. It is reasonable to select antithrombotic therapy
using the same criteria irrespective of the pattern
(i.e., paroxysmal, persistent, or permanent) of AF.
(Level of Evidence: B)
4. In patients with AF who do not have mechanical
prosthetic heart valves, it is reasonable to interrupt
anticoagulation for up to 1 wk without substituting
heparin for surgical or diagnostic procedures that
carry a risk of bleeding. (Level of Evidence: C)
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5. It is reasonable to reevaluate the need for anticoag-
ulation at regular intervals. (Level of Evidence: C)
Class IIb
1. In patients 75 y of age and older at increased risk of
bleeding but without frank contraindications to oral
anticoagulant therapy, and in other patients with
moderate risk factors for thromboembolism who are
unable to safely tolerate anticoagulation at the stan-
dard intensity of INR 2.0 to 3.0, a lower INR target
of 2.0 (range 1.6 to 2.5) may be considered for
primary prevention of ischemic stroke and systemic
embolism. (Level of Evidence: C)
2. When surgical procedures require interruption of
oral anticoagulant therapy for longer than 1 wk in
high-risk patients, unfractionated heparin may be
administered or low-molecular-weight heparin given
by subcutaneous injection, although the efficacy of
these alternatives in this situation is uncertain.
(Level of Evidence: C)
3. Following percutaneous coronary intervention or
revascularization surgery in patients with AF, low-
dose aspirin (less than 100 mg per d) and/or clopi-
dogrel (75 mg per d) may be given concurrently with
anticoagulation to prevent myocardial ischemic
events, but these strategies have not been thoroughly
evaluated and are associated with an increased risk
of bleeding. (Level of Evidence: C)
4. In patients undergoing percutaneous coronary inter-
vention, anticoagulation may be interrupted to prevent
bleeding at the site of peripheral arterial puncture, but
the vitamin K antagonist should be resumed as soon as
possible after the procedure and the dose adjusted to
achieve an INR in the therapeutic range. Aspirin may
be given temporarily during the hiatus, but the main-
tenance regimen should then consist of the combina-
tion of clopidogrel, 75 mg daily, plus warfarin (INR 2.0
to 3.0). Clopidogrel should be given for a minimum of
1 mo after implantation of a bare metal stent, at least
3 mo for a sirolimus-eluting stent, at least 6 mo for a
paclitaxel-eluting stent, and 12 mo or longer in selected
patients, following which warfarin may be continued
as monotherapy in the absence of a subsequent coro-
nary event. When warfarin is given in combination
with clopidogrel or low-dose aspirin, the dose intensity
must be carefully regulated. (Level of Evidence: C)
5. In patients with AF younger than 60 y without heart
disease or risk factors for thromboembolism (lone
AF), the risk of thromboembolism is low without
treatment and the effectiveness of aspirin for pri-
mary prevention of stroke relative to the risk of
bleeding has not been established. (Level of Evi-
dence: C)
6. In patients with AF who sustain ischemic stroke or
systemic embolism during treatment with low-
intensity anticoagulation (INR 2.0 to 3.0), rather
than add an antiplatelet agent, it may be reasonable
to raise the intensity of anticoagulation to a maxi-
mum target INR of 3.0 to 3.5. (Level of Evidence: C)
Class III
Long-term anticoagulation with a vitamin K antagonist
is not recommended for primary prevention of stroke
in patients below the age of 60 y without heart disease
(lone AF) or any risk factors for thromboembolism.
(Level of Evidence: C)
8.1.4.1. Risk Stratification
8.1.4.1.1. EPIDEMIOLOGICAL DATA. In a small, retrospective,
population-based study in Olmsted County, Minnesota, over
3 decades, the 15-y cumulative stroke rate in people with lone
AF (defined as those younger than 60 y with no clinical
history or echocardiographic signs of cardiopulmonary dis-
ease) was 1.3% (11). Conversely, in the Framingham Study,
(28) the age-adjusted stroke rate over a mean follow-up
period of 11 y was 28.2% in those with lone AF, more
liberally defined to include patients with a history of hyper-
tension or cardiomegaly on chest roentgenography, compared
with 6.8% in normal controls (28). In the SPAF study, the
annualized rate of ischemic stroke during aspirin treatment
was similar in those with paroxysmal (3.2%) and permanent
(3.3%) AF (401). Those with prior stroke or TIA have a rate
of subsequent stroke of 10% to 12% per year when treated with
aspirin, and these patients benefit substantially from adjusted-
dose oral anticoagulation (402,403). In addition to prior throm-
boembolism, HF, hypertension, increasing age, and diabetes
mellitus have consistently emerged as independent risk factors
for ischemic stroke associated with nonvalvular AF
(47,261,264,382,405). Other factors, such as female gender,
systolic blood pressure over 160 mm Hg, and LV dysfunction,
have been variably linked to stroke (261,266,406). The relative
risk for ischemic stroke associated with specific clinical features,
derived from a collaborative analysis of participants given no
antithrombotic therapy in the control groups of 5 randomized
trials, is displayed in Table 11.
In patients with nonvalvular AF, prior stroke or TIA is the
strongest independent predictor of stroke, significantly asso-
ciated with stroke in all 6 studies in which it was evaluated,
with incremental relative risk between 1.9 and 3.7 (averaging
approximately 3.0). Attempts to identify patients with prior
stroke or TIA who have relatively low stroke risks by virtue
of the absence of other risk factors did not identify any
reliable predictors (261,407–409). The pathogenic constructs
of stroke in AF are incomplete, but available data indicate
that all patients with prior stroke or TIA are at high risk of
recurrent thromboembolism and require anticoagulation un-
less there are firm contraindications in a given patient. Efforts
TABLE 11. Risk Factors for Ischemic Stroke and Systemic
Embolism in Patients With Nonvalvular Atrial Fibrillation
Risk Factors Relative Risk
Previous stroke or TIA 2.5
Diabetes mellitus 1.7
History of hypertension 1.6
Heart failure 1.4
Advanced age (continuous, per decade) 1.4
Data derived from collaborative analysis of 5 untreated control groups in
primary prevention trials (47). As a group, patients with nonvalvular atrial
fibrillation (AF) carry about a 6-fold increased risk of thromboembolism
compared with patients in sinus rhythm. Relative risk refers to comparison of
patients with AF to patients without these risk factors.
TIA indicates transient ischemic attack.
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to enhance risk stratification should remove such patients
from consideration and focus instead on the predictive value
of pertinent risk factors and absolute stroke rates for primary
prevention. Patient age is a consistent independent predictor
of stroke (Fig. 8). In 7 studies in which the variable was
assessed, hazard ratios averaged 1.5 per decade. Nearly half
of AF-associated strokes occur in patients over 75 y, and AF
is the most frequent cause of disabling stroke in elderly
women (21,405,406). Older people are also at increased risk
for anticoagulant-related bleeding (410) and are less likely to
be treated with oral anticoagulation, even in situations for
which it has been proved efficacious, in part because of
concern about the risk of bleeding (411). Special consider-
ation of these older patients is therefore a critical aspect of
effective stroke prophylaxis (405).
Female gender has emerged as an independent predictor of
stroke in 3 cohort studies of patients with AF but not in
several others (47,268,404). The relative increase was 1.6 in
the largest study of the ATRIA cohort (262). In the SPAF
analyses of aspirin-treated patients, gender interacted with
age such that women over 75 y old were at particularly high
risk, but this interaction was not apparent in the AnTicoagu-
lation and Risk factors In Atrial fibrillation (ATRIA) cohort
(262,412).
Similarly, hypertension is a consistent, powerful predictor of
stroke, with a history of hypertension independently predictive
in 5 studies (median relative risk approximately 2.0) and systolic
blood pressure significant in 2 others (mean relative risk approx-
imately 2.0). A history of hypertension and systolic blood
pressure over 160 mm Hg were independently predictive of
stroke in the SPAF aspirin-treated cohorts.
Diabetes was a significant independent predictor in 4
studies, associated with an average relative risk of 1.8, but not
in 2 other studies. The strength of diabetes as a predictor may
be greater in lower-risk patients with AF, prompting specu-
lation that it may be associated with noncardioembolic
strokes. Diabetes is a less powerful independent predictor
than prior stroke/TIA, hypertension, or age, but analysis of
the type, duration, or control of diabetes has not been
undertaken to refine its predictive value for thromboembo-
lism in patients with AF. The reduction in stroke among
warfarin-treated patients with diabetes was below average in
2 studies (413,414).
In 2 studies, CAD was a univariate predictor of stroke in
otherwise low-risk patients (47,415); it has not been shown to
have independent predictive value for stroke in patients with
AF.
Clinical HF has not been conclusively shown to have
independent predictive value for stroke in any study of AF
patients. In the SPAF I and II studies, (412) recent (within 3
mo) HF or impaired LV systolic function (defined as M-mode
echocardiographic fractional shortening less than 25%) was a
significant independent predictor, as was LV systolic dys-
function by 2-dimensional echocardiography in placebo-
treated patients in some studies (266) but not in others
(261,268). Clinical diagnosis of HF may be difficult in
elderly patients with AF, and misclassification could blunt the
power of association. In short, while it seems logical based on
pathophysiological concepts and echocardiographic corre-
lates that HF should be an independent predictor of stroke in
patients with nonvalvular AF, available data do not provide
strong support.
8.1.4.1.2. ECHOCARDIOGRAPHY AND RISK STRATIFICATION. Echo-
cardiography is valuable to define the origin of AF (e.g.,
detecting rheumatic mitral valve disease or HCM) and may add
information useful in stratifying thromboembolic risk. Among
high-risk AF patients, impaired LV systolic function on trans-
thoracic echocardiography, thrombus, dense SEC or reduced
velocity of blood flow in the LAA, and complex atheromatous
plaque in the thoracic aorta on TEE have been associated with
thromboembolism, and oral anticoagulation effectively lowers
the risk of stroke in AF patients with these features. LA diameter
and fibrocalcific endocardial abnormalities have been less con-
sistently associated with thromboembolism. Whether the ab-
sence of these echocardiographic abnormalities identifies a
low-risk group of patients who could safely avoid anticoagula-
tion has not been established, limiting the value of echocardiog-
raphy as a prime determinant of the need for chronic anticoag-
ulation in patients with AF.
TRANSTHORACIC ECHOCARDIOGRAPHY. Correlations in
placebo-assigned participants in randomized trials of
antithrombotic therapy provide information about the
independent predictive value of transthoracic echocar-
diography for thromboembolic events in patients with
nonvalvular AF (265,416). Meta-analysis of 3 trials
found moderate to severe LV dysfunction to be the only
independent echocardiographic predictor of stroke in
patients with AF after adjustment for clinical features;
the diameter of the LA was less useful (266).
Secondary analyses of aspirin-assigned patients in
multicenter trials yield variable results regarding the
role of transthoracic echocardiography for predicting
thromboembolic risk (54,203). In the SPAF I and II
studies, LV fractional shortening less than 25% (esti-
mated by M-mode echocardiography) was the only
independent echocardiographic predictor of stroke.
Among 2012 aspirin-assigned patients in the SPAF trials
(including 290 in SPAF-III assigned to a relatively
ineffective fixed-dose combination of aspirin plus war-
farin), no transthoracic echocardiographic parameter
Figure 8. Stroke rates in relation to age among patients in
untreated control groups of randomized trials of antithrombotic
therapy. Data are from the Atrial Fibrillation Investigators. Risk
factors for stroke and efficacy of antithrombotic therapy in atrial
fibrillation. Analysis of pooled data from five randomized con-
trolled trials. Arch Intern Med 1994;154:1449–57 (47).
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independently predicted thromboembolism when clini-
cal risk factors were considered. Similarly, no indepen-
dent predictors of thromboembolism were identified by
transthoracic echocardiography and TEE at entry in the
Embolism in the Left Atrial Thrombi (ELAT) study of
409 patients with nonvalvular AF taking aspirin, 160 mg
daily (268).
TRANSESOPHAGEAL ECHOCARDIOGRAPHY. TEE is a sensitive and
specific technique for detection of LA and LAA thrombus, far
surpassing transthoracic echocardiography (203). This modal-
ity also permits superior evaluation for other causes of
cardiogenic embolism (320), as well as a means of measuring
LAA function (319). Several TEE features have been associ-
ated with thromboembolism, including thrombus, reduced
flow velocity, and SEC in the LA or LAA and atheromatous
disease of the aorta (252,417).
Detection of LA/LAA thrombus stands as a contraindica-
tion to elective cardioversion of AF. Unfortunately, the
absence of a detectable thrombus does not preclude stroke
after cardioversion in the absence of anticoagulation therapy
(324,418). A TEE-guided strategy for elective cardioversion
of AF yielded comparable outcomes for thromboembolism
and death compared with conventional anticoagulation for 3
wk before and 4 wk after cardioversion (320).
8.1.4.1.3. THERAPEUTIC IMPLICATIONS. The efficacy and safety
of oral anticoagulation and platelet inhibitor therapy with aspirin
for prevention of stroke in patients with AF have been well
characterized (420). The selection of appropriate antithrombotic
therapy is discussed below in the context of thromboembolic risk
(see Section 8.1.6, Pharmacological Agents to Maintain Sinus
Rhythm, and Section 8.1.7, Out-of-Hospital Initiation of Anti-
arrhythmic Drugs in Patients With Atrial Fibrillation). Patients
with AF who have low rates of stroke when treated with aspirin
may not gain sufficient benefit from anticoagulation to outweigh
the attendant risks and the need for close medical monitoring
(421,422). Estimating the risk of stroke for individual AF
patients is crucial for the decision to provide anticoagulation
therapy to individual patients with AF, (54) but the threshold risk
that warrants anticoagulation is controversial. Patients with a
stroke risk of 2% per year or less do not benefit substantially
from oral anticoagulation, which would require treating 100 or
more patients for 1 y to prevent a single stroke (420). For
high-risk AF patients with stroke rates of 6% per year or greater,
the comparable number needed-to-treat is 25 or fewer, strongly
favoring anticoagulation. Opinion remains divided about routine
anticoagulation for patients at intermediate stroke risk (annual
rate 3% to 5%).
To stratify the risk of ischemic stroke in patients with AF,
several clinical schemes have been proposed based on anal-
yses of prospectively monitored cohorts of participants in
clinical trials in which antithrombotic therapy was controlled
(391,421,423). One set of criteria (Atrial Fibrillation Inves-
tigators [AFI]) is based on multivariate pooled analysis of
1593 participants assigned to the control or placebo groups of
5 randomized primary prevention trials in which 106 ische-
mic strokes occurred over a mean follow-up of 1.4 y (47).
Patients were divided into 2 strata, distinguishing low-risk
patients from those at intermediate or high risk. Although
echocardiographic features were not considered initially, a
subsequent analysis of 3 of the trials identified abnormal LV
systolic function as an independent predictor of stroke (421).
The SPAF study criteria were based on multivariate analysis
of 854 patients assigned to aspirin and followed for a mean of
2.3 y, during which 68 ischemic strokes were observed. These
criteria were subsequently used to select a low-risk cohort for
treatment with aspirin in the SPAF III study. Over a mean
follow-up of 2 y, the rate of ischemic stroke was 2.0% per
year (95% CI 1.5% to 2.8%) and the rate of disabling
ischemic stroke was 0.8% per year (95% CI 0.5% to 1.3%).
Patients with a history of hypertension had a higher rate of
thromboembolism (3.6% per year) than those without hyper-
tension (1.1% per year; p less than 0.001). Other criteria have
been developed by expert consensus (423,424) based on
consideration of the foregoing schemes to classify patients
into low-, intermediate-, and high-risk groups. Still others
have employed recursive partitioning and other techniques to
identify low-risk patients.
Nine schemes that included more than 30 stroke events have
been promulgated based on multivariate analysis of clinical
and/or echocardiographic predictors. Three were derived from
overlapping patient cohorts, while 6 were derived from entirely
independent cohorts (47,261,266,412,415). Of the 6 studies with
distinct patient cohorts, 2 involved participants in randomized
trials, 2 were based on clinical case series, one was a population-
based epidemiological study, and the other was a hospital-based
case-control study. The largest study (262) was limited to
analysis of female gender as an independent predictor.
A multivariate analysis from the Framingham Heart Study
examined risk factors for stroke among 705 patients with
recently detected AF, excluding those who had sustained ische-
mic stroke, TIA, or death within 30 d of diagnosis (425). The
only significant predictors of ischemic stroke were age
(RR 1.3 per decade), female gender (RR 1.9), prior stroke
or TIA (RR 1.9), and diabetes mellitus (RR 1.8), consistent
with earlier studies. Systolic blood pressure became a significant
predictor of stroke when warfarin was included in a time-
dependent Cox proportional hazards model. With a scoring
system based on age, gender, systolic hypertension, diabetes,
and prior stroke or TIA, the proportion of patients classified as
low risk varied from 14.3% to 30.6% depending upon whether
stroke rate thresholds were less than 1.5% per year or less than
2% per year. Observed stroke rates were 1.1% to 1.5% per year
based on 88 validated events. In the future, it may be possible to
consider other characteristics that may contribute to stroke risk,
including genetic abnormalities of hemostatic factors and endo-
thelial dysfunction, but none have yet been identified that have
sufficient predictive value for clinical use in risk stratification
(230,413).
Another stroke risk classification scheme, known as
CHADS2 (Cardiac Failure, Hypertension, Age, Diabetes,
Stroke [Doubled]) integrates elements from several of the
foregoing schemes. The CHADS2 risk index is based on a point
system in which 2 points are assigned for a history of stroke
or TIA and 1 point each is assigned for age over 75 y, a
history of hypertension, diabetes, or recent HF (Table 12)
(415,426). The predictive value of this scoring system was
evaluated in 1733 Medicare beneficiaries with nonvalvular
AF between the ages of 65 and 95 y who were not given
warfarin at hospital discharge. Although high scores were
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associated with an increased stroke rate in this elderly cohort,
few patients had a score of 5 or more or a score of 0. In the
same cohort, the modified AFI scheme had high-risk (prior
stroke or TIA, hypertension, or diabetes) and moderate-risk
(age greater than 65 y without other high-risk features)
categories, corresponding to stroke rates of 5.4% per year
(95% CI 4.2% to 6.5% per year) for high-risk and 2.2% per
year (95% CI 1.1% to 3.5% per year) for moderate-risk
patients. Patients with high-risk features according to the
SPAF criteria (prior stroke or TIA, women older than 75 y, or
recent HF) had a stroke rate of 5.7% per year (95% CI 4.4%
to 7.0% per year); moderate-risk patients (history of hyper-
tension with no other high-risk features) had a rate of 3.3%
per year (95% CI 1.7% to 5.2% per year); and low-risk
patients (without risk factors) had a stroke rate of 1.5% per
year (95% CI 0.5% to 2.8% per year).
Although the schemes for stratification of stroke risk
identify patients who benefit most and least from anticoagu-
lation, the threshold for use of anticoagulation is controver-
sial. Opinion is particularly divided about anticoagulation for
those at intermediate risk (stroke rate 3% to 5% per year).
Some advocate the routine use of anticoagulation for those
with stroke rates in this range, (427) whereas others favor
selective anticoagulation of patients at intermediate risk, with
weight given to individual bleeding risks and patient prefer-
ences (54,428). The threshold of benefit at which AF patients
choose anticoagulation varies; some at intermediate risk elect
anticoagulation, whereas others do not (429). Our recommen-
dations for antithrombotic therapy in patients with AF are
summarized in Table 13.
Atrial flutter is uncommon as a chronic arrhythmia, and the
risk of thromboembolism is not as well established as it is for
AF but is generally estimated as higher than that for patients
with sinus rhythm and less than that for those with persistent
or permanent AF. On the basis of multivariate analysis, Wood
et al (430) reported hypertension as the only significant
correlate of previous thromboembolism for patients with
chronic atrial flutter. From a review of 8 y of retrospective
data from 749 988 hospitalized older patients, including
17 413 with atrial flutter and 337 428 with AF, 3 of 4 patients
with atrial flutter also had or developed AF. The overall
stroke risk ratio for patients with atrial flutter was 1.406, and
for those with AF, it was 1.642 compared with the control
group. Coexisting HF, rheumatic heart disease, and hyperten-
sion predicted an episode of AF in patients with atrial flutter.
Risk ratios for patients with these comorbid conditions were
1.243, 1.464, and 1.333, respectively (431).
Although the overall thromboembolic risk associated with
atrial flutter may be somewhat lower than with AF, it seems
prudent to estimate risk by the use of similar stratification
TABLE 12. Stroke Risk in Patients With Nonvalvular AF Not
Treated With Anticoagulation According to the CHADS2 Index
CHADS2 Risk Criteria Score
Prior stroke or TIA 2
Age 75 y 1
Hypertension 1
Diabetes mellitus 1
Heart failure 1
Patients
(N1733)
Adjusted Stroke
Rate (%/y)*
(95% CI) CHADS2 Score
120 1.9 (1.2 to 3.0) 0
463 2.8 (2.0 to 3.8) 1
523 4.0 (3.1 to 5.1) 2
337 5.9 (4.6 to 7.3) 3
220 8.5 (6.3 to 11.1) 4
65 12.5 (8.2 to 17.5) 5
5 18.2 (10.5 to 27.4) 6
*The adjusted stroke rate was derived from multivariate analysis assuming
no aspirin usage. Data are from van Walraven WC, Hart RG, Wells GA, et al. A
clinical prediction rule to identify patients with atrial fibrillation and a low risk
for stroke while taking aspirin. Arch Intern Med 2003;163:936–43 (415); and
Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification
schemes for predicting stroke: results from the National Registry of Atrial
Fibrillation. JAMA 2001;285:2864–70 (426).
AF indicates atrial fibrillation; CHADS2, Cardiac Failure, Hypertension, Age,
Diabetes, and Stroke (Doubled); CI, confidence interval; and TIA, transient
ischemic attack.
TABLE 13. Antithrombotic Therapy for Patients With Atrial Fibrillation
Risk Category Recommended Therapy
No risk factors Aspirin, 81 to 325 mg daily
One moderate-risk factor Aspirin, 81 to 325 mg daily, or warfarin (INR 2.0
to 3.0, target 2.5)
Any high-risk factor or more than 1
moderate-risk factor
Warfarin (INR 2.0 to 3.0, target 2.5)*
Less Validated or Weaker
Risk Factors Moderate-Risk Factors High-Risk Factors
Female gender Age greater than or equal to 75 y Previous stroke, TIA or embolism
Age 65 to 74 y Hypertension Mitral stenosis
Coronary artery disease Heart failure Prosthetic heart valve*
Thyrotoxicosis LV ejection fraction 35% or less
Diabetes mellitus
*If mechanical valve, target international normalized ratio (INR) greater than 2.5.
INR indicates international normalized ratio; LV, left ventricular; and TIA, transient ischemic attack.
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criteria for both arrhythmias until more robust data become
available (Tables 13 and 14).
8.1.4.2. Antithrombotic Strategies for Prevention of
Ischemic Stroke and Systemic Embolism
Before 1990, antithrombotic therapy for prevention of ische-
mic stroke and systemic embolism in patients with AF was
limited mainly to those with rheumatic heart disease or
prosthetic heart valves (21). Anticoagulation was also ac-
cepted therapy for patients who had sustained ischemic stroke
to prevent recurrence but was often delayed to avoid hemor-
rhagic transformation. Some advocated anticoagulation of
patients with thyrotoxicosis or other conditions associated
with cardiomyopathy. Since then, 24 randomized trials in-
volving patients with nonvalvular AF have been published,
including 20 012 participants with an average follow-up of
1.6 y, a total exposure of about 32 800 patient-y (Table 15).
In these studies, patient age averaged 71 y; 36% were women.
Most trials originated in Europe (14 trials, 7273 participants)
or North America (7 trials, 8349 participants). Most studied
oral vitamin K inhibitors or aspirin in varying dosages/
intensities, but other anticoagulants (low-molecular-weight
heparin, ximelagatran) and other antiplatelet agents (dipyri-
damole, indobufen, trifulsal) have also been tested. Nine trials
had double-blind designs for antiplatelet (57,403,432–435) or
anticoagulation (436–438) comparisons.
8.1.4.2.1. ANTICOAGULATION WITH VITAMIN K ANTAGONIST
AGENTS. Five large randomized trials published between 1989
and 1992 evaluated oral anticoagulation mainly for primary
prevention of thromboembolism in patients with nonvalvular AF
(57,428,432,436,437) (Fig. 9, Table 15). A sixth trial focused on
secondary prevention among patients who had survived nondis-
abling stroke or TIA (403). Meta-analysis according to the
principle of intention to treat showed that adjusted-dose oral
anticoagulation is highly efficacious for prevention of all stroke
(both ischemic and hemorrhagic), with a risk reduction of 62%
(95% CI 48% to 72%) versus placebo (420) (Fig. 9). This
reduction was similar for both primary and secondary prevention
and for both disabling and nondisabling strokes. By on-treatment
analysis (excluding patients not undergoing oral anticoagulation
at the time of stroke), the preventive efficacy of oral anticoag-
ulation exceeded 80%. Four of these trials were placebo con-
trolled; of the 2 that were double blinded with regard to
anticoagulation (437), one was stopped early because of external
evidence that oral anticoagulation was superior to placebo, and
the other included no female subjects. In 3 of the trials, oral
anticoagulant dosing was regulated according to the prothrom-
bin time ratio; 2 used INR target ranges of 2.5 to 4.0 and 2.0 to
3.0. These trials are summarized in Table 15. The duration of
follow-up was generally between 1 and 2 y; the longest was
2.2 y, whereas in clinical practice, the need for antithrombotic
therapy in patients with AF typically extends over much longer
periods.
All reported trials excluded patients considered at high risk
of bleeding. Patient age and the intensity of anticoagulation
are the most powerful predictors of major bleeding (449–
454). Trial participants, at an average age of 69 y, were
carefully selected and managed, however, and it is unclear
whether the relatively low observed rates of major hemor-
rhage also apply to patients with AF in clinical practice, who
have a mean age of about 75 y and less closely regulated
anticoagulation therapy (19,431,455).
The target intensity of anticoagulation involves a balance
between prevention of ischemic stroke and avoidance of
TABLE 14. Risk-Based Approach to Antithrombotic Therapy in Patients With Atrial Fibrillation
Patient Features Antithrombotic Therapy
Class of
Recommendation
Age less than 60 y, no heart disease (lone AF) Aspirin (81 to 325 mg per day) or no therapy I
Age less than 60 y, heart disease but no risk
factors*
Aspirin (81 to 325 mg per day) I
Age 60 to 74 y, no risk factors* Aspirin (81 to 325 mg per day) I
Age 65 to 74 y with diabetes mellitus or CAD Oral anticoagulation (INR 2.0 to 3.0) I
Age 75 y or older, women Oral anticoagulation (INR 2.0 to 3.0) I
Age 75 y or older, men, no other risk factors Oral anticoagulation (INR 2.0 to 3.0) or aspirin
(81 to 325 mg per day)
I
Age 65 or older, heart failure Oral anticoagulation (INR 2.0 to 3.0) I
LV ejection fraction less than 35% or
fractional shortening less than 25%, and
hypertension
Oral anticoagulation (INR 2.0 to 3.0) I
Rheumatic heart disease (mitral stenosis) Oral anticoagulation
(INR 2.0 to 3.0)
I
Prosthetic heart valves Oral anticoagulation
(INR 2.0 to 3.0 or higher)
I
Prior thromboembolism Oral anticoagulation (INR 2.0 to 3.0 or higher) I
Persistent atrial thrombus on TEE Oral anticoagulation (INR 2.0 to 3.0 or higher) IIa
*Risk factors for thromboembolism include heart failure (HF), left ventricular (LV) ejection fraction less than 35%, and history of
hypertension.
AF indicates atrial fibrillation; CAD, coronary artery disease; INR, international normalized ratio; and TEE, transesophageal
echocardiography.
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hemorrhagic complications (Fig. 10). Targeting the lowest
adequate intensity of anticoagulation to minimize the risk of
bleeding is particularly important for elderly AF patients.
Maximum protection against ischemic stroke in AF is prob-
ably achieved at an INR range of 2.0 to 3.0 (456), whereas an
INR range of 1.6 to 2.5 is associated with incomplete
efficacy, estimated at approximately 80% of that achieved
with higher-intensity anticoagulation (432,449). Two ran-
domized trials with a target INR of 1.4 to 2.8 (estimated mean
achieved INR 2.0 to 2.1) found the largest relative risk
reductions for ischemic stroke. A trial in which AF patients
with prior stroke or TIA were randomly assigned to target
INR ranges of 2.2 to 3.5 versus 1.5 to 2.1 found a greater rate
of major hemorrhage with the higher intensity (450). For
patients with nonvalvular AF, an INR of 1.6 to 3.0 is
efficacious and relatively safe. For primary prevention in
most AF patients under age 75 y and for secondary preven-
tion, an INR of 2.5 (target range 2.0 to 3.0) is recommended.
A target INR of 2.0 (target range 1.6 to 2.5) seems reasonable
for primary prevention in patients older than 75 y who are
considered at high risk of bleeding. In clinical trials, INRs
achieved during follow-up were more often below than above
the target range. Low-intensity anticoagulation requires spe-
cial efforts to minimize time spent below the target range,
during which stroke protection is sharply reduced. The major
bleeding rate for 5 randomized clinical trials was 1.2% per
year (202) (Fig. 11).
Despite anticoagulation of more elderly patients with AF,
rates of intracerebral hemorrhage are considerably lower than
in the past, typically between 0.1% and 0.6% in contemporary
reports. This may reflect lower anticoagulation intensity,
more careful dose regulation, or better control of hyperten-
sion (438,457). In 2 time-dependent INR analyses of antico-
agulation in elderly AF cohorts, intracranial bleeding in-
TABLE 15. Randomized Trials of Antithrombotic Therapy in Patients With Nonvalvular AF
Trials Reference Year Published No. of Patients Interventions
Large published trials
Copenhagen Atrial Fibrillation, Aspirin,
Anticoagulation I (AFASAK I)
432 1989 1007 VKA, ASA, placebo
Copenhagen Atrial Fibrillation, Aspirin,
Anticoagulation II (AFASAK II)
439 1998 677 VKA, ASA, LDA  ASA, LDA
Stroke Prevention in Atrial Fibrillation I (SPAF I) 57 1991 1330 VKA, ASA, placebo
Stroke Prevention in Atrial Fibrillation II (SPAF II) 440 1994 1100 VKA, ASA
Stroke Prevention in Atrial Fibrillation III (SPAF III) 402 1996 1044 VKA, LDA  ASA
Boston Area Anticoagulation Trial for Atrial
Fibrillation (BAATAF)
428 1990 420 VKA, control
Canadian Atrial Fibrillation Anticoagulation (CAFA) 436 1991 378 VKA, placebo
Stroke Prevention in Nonrheumatic Atrial
Fibrillation (SPINAF)
437 1992 571 VKA, placebo
European Atrial Fibrillation Trial (EAFT) 403 1993 1007 VKA, ASA, placebo
Studio Italiano Fibrillazione Atriale (SIFA) 441 1997 916 VKA, indobufen
Minidose Warfarin in Nonrheumatic Atrial
Fibrillation
442 1998 303 VKA, LDA*
Prevention of Arterial Thromboembolism in Atrial
Fibrillation (PATAF)
443 1999 729 VKA, LDA,* ASA
Stroke Prevention using an Oral Direct Thrombin
Inhibitor In Patients with Atrial Fibrillation
(SPORTIF-III)
477 2003 3407 DTI, VKA
Stroke Prevention using an Oral Direct Thrombin
Inhibitor In Patients With Atrial Fibrillation
(SPORTIF-V)
438 2005 3922 DTI, VKA
National Study for Prevention of Embolism in
Atrial Fibrillation (NASPEAF)
445 2004 1209 VKA, triflusal, VKA  triflusal
Small or pilot trials
Harenberg et al. 446 1993 75 LMW heparin, control
Low-dose Aspirin, Stroke, Atrial Fibrillation
(LASAF)
447 1996 285 ASA, placebo
Subgroups with AF in other trials
European Stroke Prevention Study II (ESPS II) 404 1997 429 ASA, dipyridamole, placebo
Adapted with permission from Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation:
a meta-analysis. Ann Intern Med 1999;131:492–501 (420).
AF, atrial fibrillation; ASA, aspirin; DTI, direct thrombin inhibitor; LDA, low-dose aspirin; LMW, low-molecular-weight; and VKA, vitamin K antagonist.
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creased with INR values over 3.5 to 4.0, and there was no
increment with values between 2.0 and 3.0 compared with
lower INR levels (454,456). Pooled results of randomized
trials and a large cohort comparison, however, suggest a
doubling of intracranial hemorrhages with mean INR values
between 2.0 and 2.5 (458). Other than dose intensity, ad-
vanced age, and hypertension, factors associated with higher
rates of intracerebral hemorrhage during anticoagulant ther-
apy include associated cerebrovascular disease and possibly
concomitant antiplatelet therapy, tobacco or alcohol con-
sumption, ethnicity, genotype, and certain vascular abnormal-
ities detected by brain imaging, such as amyloid angiopathy,
leukoaraiosis, or microbleeds (457). No stratification scheme
for prediction of intracerebral hemorrhage during anticoagu-
lant therapy has been prospectively evaluated.
8.1.4.2.2. ASPIRIN FOR ANTITHROMBOTIC THERAPY IN PATIENTS WITH
ATRIAL FIBRILLATION. Aspirin offers only modest protection against
stroke for patients with AF (46,57,403,432,439,440,443,447,
448) (Fig. 12). Meta-analysis of 5 randomized trials showed a
stroke reduction of 19% (95% CI 2% to 34%) (420). The effect
of aspirin on stroke in these trials was less consistent than that of
oral anticoagulation, (420,459) but differences in patient features
may have influenced aspirin efficacy. For example, aspirin
reduced stroke occurrence by 33% in primary prevention studies
(in which the stroke rate with placebo averaged 5% per year)
versus 11% for secondary prevention trials (in which the stroke
rate with placebo averaged 14% per year) (420). Aspirin may be
more efficacious for AF patients with hypertension or diabetes
(459) and for reduction of noncardioembolic versus cardioem-
bolic ischemic strokes in AF patients (200). Cardioembolic
strokes are, on average, more disabling than noncardioembolic
strokes (250). Aspirin appears to prevent nondisabling strokes
more than disabling strokes (420). Thus, the greater the risk of
disabling cardioembolic stroke in a population of patients with
AF, the less protection is afforded by aspirin (250).
Additional information about event rates on aspirin or no
antithrombotic therapy can be extracted from contemporary
databases such as the ATRIA cohort of 13 428 ambulatory
patients with AF enrolled in the Kaiser Permanente Medical
Care Program in North Carolina during the period 1996
through 1999 (262,456,458,461). In the 11 526 patients
without apparent contraindications to anticoagulation, (458)
6320 patients were treated with warfarin. Among the 5089
patients not treated with warfarin, the absolute rate of
thromboembolism was 2.0% per year (461). There was a
history of stroke or TIA in only 4% of the patients not treated
with anticoagulation, making this mainly a primary preven-
tion cohort (458). During a mean follow-up of 2.2 y (median
2.35 y), 249 thromboembolic events (231 ischemic strokes
and 18 systemic embolic events outside the central nervous
system) occurred among the patients who were not anticoag-
ulated (2.0% per year [95% CI 1.8% to 2.3%]). From a nested
case-control study of 294 patients, it was estimated that about
45% were using aspirin. When those from the larger cohort
with contraindications to warfarin (who were older and more
often had prior stroke or TIA) were included, the rate of
thromboembolism was 2.5% per year.
While the use of administrative and claims-based data from
a managed care organization may have been prone to under-
detection of stroke events, these rates were not very different
from those in other reported populations. By comparison,
among 1853 patients without prior thromboembolic events
assigned to aspirin in the SPAF I, II, and III trials, the rate of
ischemic stroke was 2.7% per year (261). In the AFI cohort of
2732 patients from 6 randomized trials (about half from the
SPAF trials), without prior stroke or TIA, the rate of ischemic
stroke was 2.1% per year with aspirin therapy. Among 210
patients in the population-based Cardiovascular Health Study
(mean age 74 y) followed without anticoagulation, the stroke
rate was 2.6% per year (462). When stratified according to the
Figure 9. Effects on all stroke (ischemic and hemorrhagic) of ther-
apies for patients with atrial fibrillation. Adjusted-dose warfarin
compared with placebo (six random trials. Adapted with permis-
sion from Hart RG, Benavente O, McBride R, et al. Antithrombotic
therapy to prevent stroke in patients with atrial fibrillation: a meta-
analysis. Ann Intern Med 1999;131:492–501 (420). AFASAK indi-
cates Copenhagen Atrial Fibrillation, Aspirin, Anticoagulation;
BAATAF, Boston Area Anticoagulation Trial for Atrial Fibrillation;
CAFA, Canadian Atrial Fibrillation Anticoagulation; CI, confidence
interval; EAFT, European Atrial Fibrillation Trial; SPAF, Stroke Pre-
vention in Atrial Fibrillation; and SPINAF, Stroke Prevention in Non-
rheumatic Atrial Fibrillation.
Figure 10. Adjusted odds ratios for ischemic stroke and intracra-
nial bleeding in relation to intensity of anticoagulation. Modified
with permission from Hylek EM, Singer DE. Risk factors for intra-
cranial hemorrhage in outpatients taking warfarin. Ann Intern Med
1994;120:897–902 (451). Data from Odén A, Fahlén M and Hart
RG. Optimal INR for prevention of stroke and death in atrial fibrilla-
tion: a critical appraisal. Thromb Res 2006;117:493–9 (452).
e186 Fuster et al. JACC Vol. 48, No. 4, 2006
ACC/AHA/ESC Practice Guidelines August 15, 2006:e149–246
CHADS2 stroke risk scheme, (426) patients in the ATRIA
cohort with a single stroke risk factor (32% of the cohort)
who were not anticoagulated had a rate of stroke and systemic
embolism of 1.5% per year (95% CI 1.2% to 1.9%) (458). Of
670 patients treated with aspirin in 6 clinical trials, the stroke
rate was 2.2% per year for those with a CHADS2 score of 1
(95% CI 1.6% to 3.1% per year) (463).
In summary, adjusted-dose oral anticoagulation is more
efficacious than aspirin for prevention of stroke in patients
with AF, as suggested by indirect comparisons and by a 33%
risk reduction (95% CI 13% to 49%) in a meta-analysis of 5
trials (420). Randomized trials involving high-risk AF pa-
tients (stroke rates greater than 6% per year) show larger
relative risk reductions by adjusted-dose oral anticoagulation
relative to aspirin (Fig. 12), whereas the relative risk reduc-
tions are consistently smaller in trials of AF patients with
lower stroke rates. Accordingly, oral anticoagulation may be
most beneficial for AF patients at higher intrinsic thrombo-
embolic risk, offering only modest reductions over aspirin in
both the relative risk and absolute rates of stroke for patients
at low risk. Individual risk varies over time, so the need for
anticoagulation must be reevaluated periodically in all pa-
tients with AF.
8.1.4.2.3. OTHER ANTIPLATELET AGENTS FOR ANTITHROMBOTIC
THERAPY IN PATIENTS WITH ATRIAL FIBRILLATION. Anticoag-
ulation with oral vitamin K antagonists has been compared
with platelet cyclooxygenase inhibitors other than aspirin in 2
trials involving 1395 participants. In the Italian Studio Ital-
iano Fibrillazione Atriale (SIFA) study, (441) indobufen, 100
Figure 11. Annual rates of major hemorrhage during anticoagulation in primary prevention trials involving patients with nonvalvular atrial
fibrillation. The mean age of participants was 69 years. Major hemorrhage was variously defined but typically involved bleeding severe
enough to require hospitalization, transfusion or surgical intervention, involved a critical anatomical site, or was permanently disabling
or fatal. Data adapted from Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial
fibrillation: a meta-analysis. Ann Intern Med 1999;131:492–501 (420). AFASAK indicates Copenhagen Atrial Fibrillation, Aspirin, Antico-
agulation; BAATAF, Boston Area Anticoagulation Trial for Atrial Fibrillation; CAFA, Canadian Atrial Fibrillation Anticoagulation; SPAF,
Stroke Prevention in Atrial Fibrillation; and SPINAF, Stroke Prevention in Nonrheumatic Atrial Fibrillation.
Figure 12. Effects on all stroke (ischemic and hemorrhagic) of therapies for patients with atrial fibrillation: warfarin compared with aspi-
rin and aspirin compared with placebo. Modified with permission from Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic
therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492–501 (420). AFASAK indicates
Copenhagen Atrial Fibrillation, Aspirin, Anticoagulation; CI, confidence interval; EAFT, European Atrial Fibrillation Trial; ESPS, European
Stroke Prevention Study; LASAF, Low-dose Aspirin, Stroke, Atrial Fibrillation; UK-TIA, The United Kingdom transient ischaemic attack
aspirin trial; PATAF, Prevention of Arterial Thromboembolism in Atrial Fibrillation; SPAF, Stroke Prevention in Atrial Fibrillation; and
SPINAF, Stroke Prevention in Nonrheumatic Atrial Fibrillation.
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to 200 mg twice daily, was compared with warfarin (INR 2.0
to 3.5) in 916 patients with recent cerebral ischemic events.
Incidences of the combined endpoint of nonfatal stroke,
intracerebral bleeding, pulmonary or systemic embolism, MI,
and vascular death were not significantly different between
treatment groups, but more ischemic strokes occurred in the
indobufen group (18) than in the warfarin group (10). In the
primary prevention cohort of the Spanish National Study for
Prevention of Embolism in Atrial Fibrillation (NASPEAF)
trial, (445) the rate of the composite of thromboembolism
plus cardiovascular death was lower with acenocoumarol
than with triflusal. There was no significant difference in
rates of ischemic stroke and systemic embolism. Neither in-
dobufen nor trifusal is widely available; these agents have not
been compared with aspirin for efficacy and safety, nor do they
offer advantages over anticoagulation with a vitamin K antago-
nist in patients with AF at high risk of thromboembolism.
In the Atrial Fibrillation Clopidogrel Trial with Irbesartan
for Prevention of Vascular Events (ACTIVE-W), which was
stopped on the recommendation of the Data Safety and
Monitoring Board before planned follow-up was completed,
the combination of the thienopyridine antiplatelet agent
clopidogrel (75 mg daily) plus aspirin (75 to 100 mg daily)
proved inferior to warfarin (target INR 2.0 to 3.0) in patients
with an average of 2 stroke risk factors in addition to AF
(464). Additional studies are ongoing to assess the impact of
this therapy for patients unable or unwilling to take warfarin.
8.1.4.2.4. COMBINING ANTICOAGULANT AND PLATELET-INHIBI-
TOR THERAPY. Combinations of oral anticoagulants plus
antiplatelet agents to reduce the risk of hemorrhage by
allowing lower intensities of anticoagulation or to augment
efficacy for selected patients at particularly high risk of
thromboembolism, such as those with prior stroke, have been
evaluated in several trials. Such a strategy has been successful
in reducing the risk of thromboembolism in patients with
mechanical heart valves (465). Still another objective of
combination therapy is to enhance protection against ische-
mic cardiac events in patients with AF who have established
coronary atherosclerosis or diabetes. In 2 trials, SPAF III and
Copenhagen Atrial FIbrillation, Aspirin, and Anticoagulation
(AFASAK) 2, the combination of low-dose oral anticoagula-
tion (INR less than 1.5) with aspirin added little protection
against stroke compared with aspirin alone in patients with
AF (402,439).
In 2 other trials, substantially higher intensities of antico-
agulation combined with platelet inhibitor agents were eval-
uated in patients with AF. The French Fluindione-Aspirin
Combination in High Risk Patients With AF (FFAACS)
study compared the oral anticoagulant fluindione (target INR
2.0 to 2.6) plus placebo or in combination with aspirin, 100
mg daily, versus fluindione alone in patients at high risk of
stroke. The trial was stopped with only 157 patients enrolled
(mean follow-up 0.84 y) because of excessive hemorrhage in
the group receiving the combination therapy (433).
In the larger Spanish National Study for Primary Preven-
tion of Embolism in Nonrheumatic Atrial Fibrillation (NAS-
PEAF) study, patients were stratified into a high-risk group
(n  495) with AF and rheumatic mitral stenosis or AF and a
history of stroke, TIA, or systemic embolism, and a lower-
risk group (n  714) with AF and age greater than 60 y,
hypertension, or HF (445). The higher-risk patients were
randomized to anticoagulation with acenocoumrarol (target
INR 2.0 to 3.0) or to acenocoumarol (INR 1.4 to 2.4)
combined with the platelet cyclooxygenase inhibitor triflusal
(600 mg daily). The lower-risk patients were randomized to
triflusal alone, acenocoumarol alone (INR 2.0 to 3.0), or the
combination of triflusal plus acenocoumarol (INR 1.25 to
2.0). The achieved anticoagulation intensities in the antico-
agulation and combination therapy arms were closer to one
another than intended, however (mean INR 2.5 with aceno-
coumarol alone in both risk strata versus 1.96 and 2.18 for the
combination arms in the lower- and higher-risk groups during
median follow-up of 2.6 and 2.9 y, respectively). The primary
outcome was a composite of thromboembolism plus cardio-
vascular death (sudden death or death due to thromboembo-
lism, stroke, bleeding, or HF but not MI). Patients in both risk
categories had a lower risk of primary events with the
combination therapy than with acenocoumarol alone. These
observations suggest that a combination of platelet inhibitor
and anticoagulant therapy might be effective and relatively
protective if targeted INR levels are closer to the standard
range, but the superiority of combination therapy over mono-
therapy with a vitamin K antagonist for prevention of
ischemic stroke and MI has not been convincingly
established.
Combining aspirin with an oral anticoagulant at higher
intensities may accentuate intracranial hemorrhage, particu-
larly in elderly AF patients (466). In a retrospective analysis
of 10 093 patients with AF after hospital discharge (mean age
77 y), platelet inhibitor medication was associated with a
higher rate of intracerebral hemorrhage (relative risk 3.0,
95% CI 1.6% to 5.5%) (467), but 2 case-control studies
yielded conflicting results (454,468).
The superior efficacy of anticoagulation over aspirin for
prevention of recurrent stroke in patients with AF was
demonstrated in the European Atrial Fibrillation Trial (403).
Therefore, unless a clear contraindication exists, AF patients
with a recent stroke or TIA should be treated with long-term
anticoagulation rather than antiplatelet therapy. There is no
evidence that combining anticoagulation with an antiplatelet
agent reduces the risk of stroke compared with anticoagulant
therapy alone. Hence, pending further data for AF patients
who sustain cardioembolic events while receiving low-
intensity anticoagulation, anticoagulation intensity should be
increased to a maximum target INR of 3.0 to 3.5 rather than
routinely adding antiplatelet agents.
Several studies have evaluated anticoagulation in combi-
nation with aspirin for prevention of ischemic cardiac events
in patients with CAD. From these it may be possible to draw
inferences regarding management of antithrombotic therapy
in patients who have both CAD and AF. A meta-analysis of
31 randomized trials of oral anticoagulant therapy published
between 1960 and 1999 involving patients with CAD treated
for at least 3 mo and stratified by the intensities of anticoag-
ulation and aspirin therapy came to the following conclusions
(469). High-intensity (INR 2.8 to 4.8) and moderate-intensity
(INR 2.0 to 3.0) oral anticoagulation regimens reduced rates
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of MI and stroke but increased the risk of bleeding 6.0- to
7.7-fold. Combining aspirin with low-intensity anticoagula-
tion (INR less than 2.0) was not superior to aspirin alone.
While the combination of moderate- to high-intensity oral
anticoagulation plus aspirin appeared promising compared
with aspirin alone, the combination was associated with
increased bleeding.
From the results of more contemporary trials involving
long-term treatment of patients with acute myocardial ische-
mia (470–473) and the Combined Hemotherapy and Mortal-
ity Prevention Study (CHAMP), (474) it appears that high-
intensity oral anticoagulation (INR 3.0 to 4.0) is more
effective than aspirin but increases the risk of bleeding. The
combination of aspirin and moderate-intensity warfarin (INR
2.0 to 3.0) is more effective than aspirin alone but is
associated with a greater risk of bleeding. The combination of
aspirin and moderate-intensity warfarin (INR 2.0 to 3.0) is as
effective as high-intensity warfarin and associated with a
similar risk of bleeding. The contemporary trials, however,
have not addressed the effectiveness of moderate-intensity
warfarin (INR 2.0 to 3.0) alone. In the absence of direct
evidence, it cannot be assumed that moderate-intensity war-
farin is superior to aspirin in preventing death or reinfarction.
The choice for long-term management of patients with CAD
and AF therefore involves aspirin alone, aspirin plus
moderate-intensity warfarin (INR 2.0 to 3.0), or warfarin
alone (INR 2.0 to 3.0). For those with risk factors for stroke,
the latter 2 regimens are more effective than aspirin alone but
are associated with more bleeding and inconvenience. Fur-
ther, without close INR control, the combination regimen
may be associated with a greater risk of bleeding. For most
patients with AF who have stable CAD, warfarin anticoagu-
lation alone (target INR 2.0 to 3.0) should provide satisfac-
tory antithrombotic prophylaxis against both cerebral and
myocardial ischemic events.
The importance of platelet-inhibitor drugs for prevention
of recurrent myocardial ischemia is enhanced in patients
undergoing percutaneous coronary intervention, but no ade-
quate studies have been published that specifically address
this issue in patients who also require chronic anticoagulation
because of AF. It is the consensus of the authors of these
guidelines that the most important agent for the maintenance
of coronary and stent patency is the thienopyridine derivative
clopidogrel and that the addition of aspirin to the chronic
anticoagulant regimen contributes more risk than benefit.
Although it is usually necessary to interrupt or reduce
anticoagulation to prevent bleeding at the site of peripheral
arterial puncture, the vitamin K antagonist should be resumed
as soon as possible after the procedure and the dose adjusted
to achieve an INR in the therapeutic range. Aspirin may be
given temporarily during the hiatus, but the maintenance
regimen should then consist of the combination of clopi-
dogrel, 75 mg daily, plus warfarin (INR 2.0 to 3.0) for 9 to 12
mo, following which warfarin may be continued as mono-
therapy in the absence of a subsequent coronary event.
8.1.4.2.5. EMERGING AND INVESTIGATIONAL ANTITHROMBOTIC
AGENTS. While clearly efficacious against stroke in patients
with AF, warfarin carries a substantial risk of hemorrhage, a
narrow therapeutic margin necessitating frequent monitoring
of the INR level, and interactions with numerous drugs and
foods that may cause a need for dose adjustments. These
limitations result in undertreatment of a considerable propor-
tion of the AF population at risk, particularly the elderly, for
whom numerous concomitant medications are typically pre-
scribed (455,475), engendering a quest for safer, more con-
venient alternatives.
Because of its central role in thrombogenesis, thrombin
(factor IIa) represents an attractive target for specific inhibi-
tion. Direct thrombin inhibitors bind to the active site of
thrombin and prevent it from cleaving fibrinogen to form
fibrin. These compounds also suppress thrombin-mediated
activation of platelets and coagulation factors V, VIII, XI, and
XIII. Ximelagatran is administered orally and converted after
absorption to the active direct thrombin inhibitor melagatran.
The compound appears to have stable pharmacokinetics
independent of the hepatic P450 enzyme system and a low
potential for food or drug interactions (476). Two long-term
phase III studies compared ximelagatran with warfarin in
patients with AF, SPORTIF (Stroke Prevention using an Oral
Thrombin Inhibitor in patients with atrial Fibrillation) -III and
-V, with a combined population of more than 7000 (444). In
these trials, ximelagatran was administered without dose
titration or coagulation monitoring and was compared with
warfarin (INR 2.0 to 3.0) for the primary endpoint of all
stroke (ischemic and hemorrhagic) and systemic embolism.
SPORTIF-III involved an open-label design (444) and
careful regulation of dosing among patients assigned to
warfarin, with INR values within the therapeutic range for
66% of the duration of exposure. The relative risk reduction
of 29% and absolute risk reduction of 0.7% per year accord-
ing to intention-to-treat confirmed the noninferiority of
ximelagatran to warfarin. By on-treatment analysis, the rela-
tive risk reduction with ximelagatran was 41% (p  0.018.
There was no significant difference between treatments in
rates of hemorrhagic stroke, fatal bleeding, or other major
bleeding, but when minor hemorrhages are considered as
well, ximelagatran caused significantly less bleeding (25.5%
vs. 29.5% per year, p  0.007).
The results of the SPORTIF-V trial, in which treatment was
administered in a double-blind manner, were similar to those of
SPORTIF-III (438). The primary event rates were 1.6% per year
with ximelagatran and 1.2% per year with warfarin (absolute
difference 0.45% per year, 95% CI 0.13% to 1.03% per year, p
less than 0.001 for the noninferiority hypothesis), and there was
no difference between treatment groups in rates of major
bleeding, but as in the SPORTIF-III study, total bleeding (major
plus minor) was lower with ximelagatran.
In both the SPORTIF-III and V trials, serum alanine
aminotransferase levels rose to greater than 3 times the upper
limit of normal in about 6% of patients treated with ximel-
agatran. Hence, despite evidence of efficacy comparable to
carefully adjusted warfarin and some advantage in terms of
bleeding risk, ximelagatran will not be marketed for clinical
use as an anticoagulant, mainly because of concerns about
hepatic toxicity (478). Trials of a variety of investigational
oral anticoagulant compounds that directly inhibit thrombin,
antagonize factor Xa, or inactivate prothrombin are ongoing
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or planned, but there are no currently available alternatives to
vitamin K antagonists.
8.1.4.2.6. INTERRUPTION OF ANTICOAGULATION FOR DIAGNOS-
TIC OR THERAPEUTIC PROCEDURES. From time to time, it may
be necessary to interrupt oral anticoagulant therapy in prep-
aration for elective surgical procedures. In patients with
mechanical prosthetic heart valves, it is generally appropriate
to substitute unfractionated or low-molecular-weight heparin
to prevent thrombosis (479,480). In patients with AF who do
not have mechanical valves, however, based on extrapolation
from the annual rate of thromboembolism in patients with
nonvalvular AF, it is the consensus of the Writing Committee
that anticoagulation may be interrupted for a period of up to
1 wk for surgical or diagnostic procedures that carry a risk of
bleeding without substituting heparin. In high-risk patients
(particularly those with prior stroke, TIA, or systemic embo-
lism) or when a series of procedures requires interruption of
oral anticoagulant therapy for longer periods, unfractionated
or low-molecular-weight heparin may be administered intra-
venously or subcutaneously.
The use of low-molecular-weight heparin instead of un-
fractionated heparin in patients with AF is based largely on
extrapolation from venous thromboembolic disease states and
from limited observational studies (481). In general, low-
molecular-weight heparins have several pharmacological ad-
vantages over unfractionated heparin. These include a longer
half-life, more predictable bioavailability (greater than 90%
after subcutaneous injection), predictable clearance (enabling
once- or twice-daily subcutaneous administration), and a
predictable antithrombotic response based on body weight,
which permits fixed-dose treatment without laboratory mon-
itoring except under special circumstances such as obesity,
renal insufficiency, or pregnancy (482). Treatment with
low-molecular-weight heparin is associated with a lower risk
of heparin-induced thrombocytopenia than unfractionated
heparin (483). The favorable properties of low-molecular-
weight heparins may simplify the treatment of AF in acute
situations and shorten or eliminate the need for hospitaliza-
tion to initiate anticoagulation. Self-administration of low-
molecular-weight heparins out of hospital by patients with
AF undergoing elective cardioversion is a promising ap-
proach that may result in cost savings (484).
8.1.4.3. Nonpharmacological Approaches to Prevention
of Thromboembolism
An emerging option for patients with AF who cannot
safely undergo anticoagulation, which is not yet suffi-
ciently investigated to allow general clinical application, is
obliteration of the LAA to remove a principal nidus of
thrombus formation (485,486). In addition to direct surgi-
cal amputation or truncation of appendage, several meth-
ods are under development to achieve this with intravas-
cular catheters or transpericardial approaches (487). The
efficacy of these techniques is presumably related to the
completeness and permanence of elimination of blood flow
into and out of the LAA. This has been demonstrated by
TEE at the time of intervention, but the durability of the
effect has not been confirmed by subsequent examinations
over several years. Whether mechanical measures intended
to prevent embolism from thrombotic material in the LAA
will prove to be comparably effective and safer than
anticoagulation for some patients remains to be established
(488). These must presently be considered investigational,
and indications for this type of intervention have not been
convincingly established.
8.1.5. Cardioversion of Atrial Fibrillation
RECOMMENDATIONS
Recommendations for Pharmacological Cardioversion of
Atrial Fibrillation
Class I
Administration of flecainide, dofetilide, propafenone,
or ibutilide is recommended for pharmacological car-
dioversion of AF. (Level of Evidence: A)
Class IIa
1. Administration of amiodarone is a reasonable option
for pharmacological cardioversion of AF. (Level of
Evidence: A)
2. A single oral bolus dose of propafenone or flecainide
(“pill-in-the-pocket”) can be administered to termi-
nate persistent AF outside the hospital once treat-
ment has proved safe in hospital for selected patients
without sinus or AV node dysfunction, bundle-
branch block, QT-interval prolongation, the Bru-
gada syndrome, or structural heart disease. Before
antiarrhythmic medication is initiated, a beta
blocker or nondihydropyridine calcium channel an-
tagonist should be given to prevent rapid AV con-
duction in the event atrial flutter occurs. (Level of
Evidence: C)
3. Administration of amiodarone can be beneficial on
an outpatient basis in patients with paroxysmal or
persistent AF when rapid restoration of sinus rhythm
is not deemed necessary. (Level of Evidence: C)
Class IIb
Administration of quinidine or procainamide might be
considered for pharmacological cardioversion of AF,
but the usefulness of these agents is not well established.
(Level of Evidence: C)
Class III
1. Digoxin and sotalol may be harmful when used for
pharmacological cardioversion of AF and are not
recommended. (Level of Evidence: A)
2. Quinidine, procainamide, disopyramide, and dofeti-
lide should not be started out of hospital for conver-
sion of AF to sinus rhythm. (Level of Evidence: B)
8.1.5.1. Basis for Cardioversion of Atrial Fibrillation
Cardioversion may be performed electively to restore sinus
rhythm in patients with persistent AF. The need for cardio-
version may be immediate when the arrhythmia is the main
factor responsible for acute HF, hypotension, or worsening of
angina pectoris in a patient with CAD. Nevertheless, cardio-
version carries a risk of thromboembolism unless anticoagu-
lation prophylaxis is initiated before the procedure, and this
risk is greatest when the arrhythmia has been present for
longer than 48 h.
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8.1.5.2. Methods of Cardioversion
Cardioversion may be achieved by means of drugs or elec-
trical shocks. Drugs were commonly used before direct-
current cardioversion became a standard procedure. The
development of new drugs has increased the popularity of
pharmacological cardioversion, but the disadvantages include
the risk of drug-induced torsades de pointes or other serious
arrhythmias. Moreover, pharmacological cardioversion is less
effective than direct-current cardioversion when biphasic
shocks are used. The disadvantage of electrical cardioversion
is that it requires conscious sedation or anesthesia, which
pharmacological cardioversion does not.
There is no evidence that the risk of thromboembolism or
stroke differs between pharmacological and electrical meth-
ods of cardioversion. The recommendations for anticoagula-
tion are therefore the same for both methods, as outlined in
Section 8.1.4 (Preventing Thromboembolism. Cardioversion
in patients with AF following recent heart surgery or MI is
addressed later (see Section 8.4, Special Considerations).
8.1.5.3. Pharmacological Cardioversion
The quality of evidence available to gauge the effectiveness
of pharmacological cardioversion is limited by small samples,
lack of standard inclusion criteria (many studies include both
patients with AF and those with atrial flutter), variable
intervals from drug administration to assessment of outcome,
and arbitrary dose selection. Although pharmacological and
direct-current cardioversion have not been compared directly,
pharmacological approaches appear simpler but are less
efficacious. The major risk is related to the toxicity of
antiarrhythmic drugs. In developing these guidelines,
placebo-controlled trials of pharmacological cardioversion in
which drugs were administered over short periods of time
specifically to restore sinus rhythm have been emphasized.
Trials in which the control group was given another antiar-
rhythmic drug have, however, been considered as well.
Pharmacological cardioversion seems most effective when
initiated within 7 d after the onset of an episode of AF
(489 – 492). A majority of these patients have a first-
documented episode of AF or an unknown pattern of AF at
the time of treatment. (See Section 3, Classification.) A large
proportion of patients with recent-onset AF experience spon-
taneous cardioversion within 24 to 48 h (493–495). Sponta-
neous conversion is less frequent in patients with AF of
longer than 7-d duration, and the efficacy of pharmacological
cardioversion is markedly reduced in these patients as well.
Pharmacological cardioversion may accelerate restoration of
sinus rhythm in patients with recent-onset AF, but the
advantage over placebo is modest after 24 to 48 h, and drug
therapy is much less effective in patients with persistent AF.
Some drugs have a delayed onset of action, and conversion
may not occur for several days after initiation of treatment
(496). Drug treatment abbreviated the interval to cardiover-
sion compared with placebo in some studies without affecting
the proportion of patients who remained in sinus rhythm after
24 h (494). A potential interaction of antiarrhythmic drugs
with vitamin K antagonist oral anticoagulants, increasing or
decreasing the anticoagulant effect, is an issue whenever
these drugs are added or withdrawn from the treatment
regimen. The problem is amplified when anticoagulation is
initiated in preparation for elective cardioversion. Addition of
an antiarrhythmic drug to enhance the likelihood that sinus
rhythm will be restored and maintained may perturb the
intensity of anticoagulation beyond the intended therapeutic
range, raising the risk of bleeding or thromboembolic
complications.
A summary of recommendations concerning the use of
pharmacological agents and recommended doses is presented
in Tables 16, 17, and 18. Algorithms for pharmacological
management of AF are given in Figures 13, 14, 15, and 16.
Throughout this document, reference is made to the Vaughan
Williams classification of antiarrhythmic drugs (497), modified
to include drugs that became available after the original classi-
fication was developed (Table 19). Considerations specific to
individual agents are summarized below. Within each category,
drugs are listed alphabetically. The antiarrhythmic drugs listed
have been approved by federal regulatory agencies in the United
TABLE 16. Recommendations for Pharmacological Cardioversion of Atrial Fibrillation of Up to 7-d Duration
Drug* Route of Administration
Class of
Recommendation
Level of
Evidence References
Agents with proven efficacy
Dofetilide Oral I A 498–503
Flecainide Oral or intravenous I A 489–491, 493, 504–509
Ibutilide Intravenous I A 510–515
Propafenone Oral or intravenous I A 491, 494, 495, 505, 509, 516–526, 557
Amiodarone Oral or intravenous IIa A 496, 504, 516, 527–534
Less effective or incompletely studied agents
Disopyramide Intravenous IIb B 544
Procainamide Intravenous IIb B 510, 512, 536
Quinidine Oral IIb B 489, 494, 524, 529, 537–539, 698
Should not be administered
Digoxin Oral or intravenous III A 375, 494, 505, 526, 530, 542
Sotalol Oral or intravenous III A 513, 538–540, 543
*The doses of medications used in these studies may not be the same as those recommended by the manufacturers. Drugs are listed alphabetically within each
category of recommendation and level of evidence.
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States and/or Europe for clinical use, but their use for the
treatment of AF has not been approved in all cases. Furthermore,
not all agents are approved for use in all countries. The
recommendations given in this document are based on published
data and do not necessarily adhere to the regulations and labeling
requirements of government agencies.
8.1.5.4. Agents With Proven Efficacy for Cardioversion of
Atrial Fibrillation
8.1.5.4.1. AMIODARONE. Data on amiodarone are confusing
because the drug may be given intravenously or orally and the
effects vary with the route of administration. Five meta-anal-
yses of trials compared amiodarone to placebo or other drugs
for conversion of recent-onset AF (546–549). One concluded
that intravenous amiodarone was no more effective than
placebo (550), while another found amiodarone effective but
associated with adverse reactions (546). Another meta-anal-
ysis found amiodarone more effective than placebo after 6 to
8 h and at 24 h but not at 1 to 2 h (547). Amiodarone was
inferior to type IC drugs for up to 8 h, but there was no
difference at 24 h, indicating delayed conversion with ami-
odarone. In another meta-analysis of 21 trials involving
heterogeneous populations, the relative likelihood of achiev-
ing sinus rhythm over a 4-wk period with oral/intravenous
amiodarone was 4.33 in patients with AF of longer than 48-h
duration and 1.40 in those with AF of less than 48-h duration
(548). In a meta-analysis of 18 trials, the efficacy of amiod-
arone ranged from 34% to 69% with bolus (3 to 7 mg/kg body
weight) regimens and 55% to 95% when the bolus was
followed by a continuous infusion (900 to 3000 mg daily)
(550). Predictors of successful conversion were shorter dura-
tion of AF, smaller LA size, and higher amiodarone dose.
Amiodarone was not superior to other antiarrhythmic drugs
for conversion of recent-onset AF but was relatively safe in
patients with structural heart disease, including those with LV
dysfunction for whom administration of class IC drugs is
contraindicated. In addition, limited information suggests that
amiodarone is equally effective for conversion of AF or atrial
flutter. Because safety data are limited, randomized trials are
needed to determine the benefit of amiodarone for conversion
of recent-onset AF in specific patient populations.
In the SAFE-T trial involving 665 patients with persistent AF,
conversion occurred in 27% of patients after 28 d of treatment
with amiodarone, compared with 24% with sotalol and 0.8%
with placebo (292). Although the speed of response may differ
during sustained oral therapy, amiodarone, propafenone, and
sotalol seemed equally effective in converting persistent AF to
sinus rhythm. Apart from intravenous drug therapy for conver-
sion early after onset of AF (within 24 h), antiarrhythmic drug
agents may also be given over a longer period of time in an effort
to achieve cardioversion after a longer period of AF. Under these
circumstances, administration of oral amiodarone is associated
with a conversion rate between 15% and 40% over 28 d
(292,529,533,551). In a comparative study, amiodarone and
propafenone were associated with similar rates (40%) of con-
verting persistent AF averaging 5 mo in duration (551). Remark-
ably, all cases in which conversion followed administration of
amiodarone occurred after 7 d, with responses continuing to
28 d, whereas conversion occurred more rapidly with
propafenone (between 1 and 14 d).
Adverse effects of amiodarone include bradycardia, hypo-
tension, visual disturbances, thyroid abnormalities, nausea,
and constipation after oral administration and phlebitis after
peripheral intravenous administration. Serious toxicity has
been reported, including death due to bradycardia ending in
cardiac arrest (496,504,516,527–534,537,551).
8.1.5.4.2. DOFETILIDE. Oral dofetilide is more effective than
placebo for cardioversion of AF that has persisted longer than 1
wk, but available studies have not further stratified patients on
the basis of the duration of the arrhythmia. Dofetilide appears
more effective for cardioversion of atrial flutter than of AF. A
response may take days or weeks when the drug is given orally.
The intravenous form is investigational (498–502).
8.1.5.4.3. FLECAINIDE. Flecainide administered orally or intra-
venously was effective for cardioversion of recent-onset AF
TABLE 17. Recommendations for Pharmacological Cardioversion of Atrial Fibrillation Present for More Than 7 d
Drug* Route of Administration
Recommendation
Class
Level of
Evidence References
Agents with proven efficacy
Dofetilide Oral I A 498–503
Amiodarone Oral or intravenous IIa A 496, 504, 516, 527–534
Ibutilide Intravenous IIa A 510–515
Less effective or incompletely studied agents
Disopyramide Intravenous IIb B 544
Flecainide Oral IIb B 489–491, 493, 504–509
Procainamide Intravenous IIb C 510, 512, 536, 557
Propafenone Oral or intravenous IIb B 494, 495, 505, 509, 516–526
Quinidine Oral IIb B 489, 494, 524, 529, 537–539, 698
Should not be administered
Digoxin Oral or intravenous III B 375, 494, 505, 526, 530, 542
Sotalol Oral or intravenous III B 513, 538–540, 543
*The doses of medications used in these studies may not be the same as those recommended by the manufacturers. Drugs are listed alphabetically within each
category by class and level of evidence.
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TABLE 18. Recommended Doses of Drugs Proven Effective for Pharmacological Cardioversion of Atrial Fibrillation
Drug* Route of Administration Dosage† Potential Adverse Effects References
Amiodarone Oral Inpatient: 1.2 to 1.8 g per day in
divided dose until 10 g total, then
200 to 400 mg per day
maintenance or 30 mg/kg as single
dose
Outpatient: 600 to 800 mg per day
divided dose until 10 g total, then
200 to 400 mg per day
maintenance
Hypotension, bradycardia, QT prolongation,
torsades de pointes (rare), GI upset,
constipation, phlebitis (IV)
496, 504, 516, 527–534, 537, 545
Intravenous/oral 5 to 7 mg/kg over 30 to 60 min,
then 1.2 to 1.8 g per day continuous
IV or in divided oral doses until 10 g
total, then 200 to 400 mg per day
maintenance
Dofetilide Oral Creatinine
Clearance Dose
(mL/min) (mcg BID)
More than 60
40 to 60
20 to 40
Less than 20
500
250
125
Contraindicated
QT prolongation, torsades de pointes; adjust
dose for renal function, body size, and age
498–503
Flecainide Oral 200 to 300 mg‡ Hypotension, atrial flutter with high ventricular
rate
489–491, 493, 504, 505, 507–509
Intravenous 1.5 to 3.0 mg/kg over 10 to 20
min‡
Ibutilide Intravenous 1 mg over 10 min; repeat 1 mg
when necessary
QT prolongation, torsades de pointes 510–515
Propafenone Oral 600 mg Hypotension, atrial flutter with high ventricular
rate
491, 494, 495, 505, 506, 509,
516–526, 557Intravenous 1.5 to 2.0 mg/kg over 10 to 20
min‡
Quinidine§ Oral 0.75 to 1.5 g in divided doses over
6 to 12 h, usually with a
rate-slowing drug
QT prolongation, torsades de pointes, GI upset,
hypotension
489, 494, 524, 529, 537–539
*Drugs are listed alphabetically.
†Dosages given in the table may differ from those recommended by the manufacturers.
‡Insufficient data are available on which to base specific recommendations for the use of one loading regimen over another for patients with ischemic heart disease
or impaired left ventricular function, and these drugs should be used cautiously or not at all in such patients.
§The use of quinidine loading to achieve pharmacological conversion of atrial fibrillation is controversial, and safer methods are available with the alternative agents
listed in the table. Quinidine should be used with caution.
AF indicates atrial fibrillation; BID, twice a day; GI, gastrointestinal; and IV, intravenous.
Figure 13. Pharmacological management of
patients with newly discovered atrial fibrillation (AF.
*See Figure 15. HF indicates heart failure.
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in placebo-controlled trials. In 7 studies, the success of a
single oral loading dose (300 mg) for cardioversion of
recent-onset AF ranged from 57% to 68% at 2 to 4 h and 75%
to 91% at 8 h after drug administration (552). Single oral
loading and intravenous loading regimens of flecainide were
equally efficacious, but a response usually occurs within 3 h
after oral administration and 1 h after intravenous adminis-
tration. Arrhythmias, including atrial flutter with rapid ven-
tricular rates and bradycardia after conversion, are relatively
frequent adverse effects. Transient hypotension and mild
neurological side effects may also occur. Overall, adverse
reactions are slightly more frequent with flecainide than with
propafenone, and these drugs should be avoided in patients
with underlying organic heart disease involving abnormal
ventricular function (489–491,493,504,505,507–509).
8.1.5.4.4. IBUTILIDE. In placebo-controlled trials, intravenous
ibutilide has proved effective for cardioversion within a few
weeks after onset of AF. Available data are insufficient to
establish its efficacy for conversion of persistent AF of longer
duration. Ibutilide may be used in patients who fail to convert
following treatment with propafenone (553) or in those in whom
the arrhythmia recurs during treatment with propafenone or
flecainide (554). The risk of torsades de pointes was about 1% in
these studies, lower than the approximate 4% incidence ob-
served during ibutilide monotherapy (555). Presumably, this is
related to the protective effect of sodium channel blockade with
type IC drugs (554). Ibutilide is more effective for conversion of
atrial flutter than of AF. An effect may be expected within 1 h
after administration. In clinical practice, there is a 4% risk of
torsades de pointes ventricular tachycardia and appropriate
resuscitation equipment must therefore be immediately avail-
able. Women are more susceptible than men to this complication
(5.6% vs. 3% in a meta-analysis) (555). Ibutilide should be
avoided in patients with very low ejection fractions or HF
because of the higher risk of ventricular proarrhythmia (556).
Serum concentrations of potassium and magnesium should be
measured before administration of ibutilide, and patients should
be monitored for at least 4 h afterward. Hypotension is an
infrequent adverse response (510–515).
8.1.5.4.5. PROPAFENONE. Placebo-controlled trials have veri-
fied that propafenone, given orally or intravenously, is
effective for pharmacological cardioversion of recent-onset
AF. The effect occurs between 2 and 6 h after oral adminis-
tration and earlier after intravenous injection, so that when
compared with the intravenous regimen, oral propafenone
Figure 14. Pharmacological management of patients with recur-
rent paroxysmal atrial fibrillation (AF). *See Figure 15. AAD indi-
cates antiarrhythmic drug.
Figure 15. Antiarrhythmic drug therapy to maintain sinus rhythm in patients with recurrent paroxysmal or persistent atrial fibrillation.
Within each box, drugs are listed alphabetically and not in order of suggested use. The vertical flow indicates order of preference under
each condition. The seriousness of heart disease proceeds from left to right, and selection of therapy in patients with multiple condi-
tions depends on the most serious condition present. See Section 8.3.3.3 for details. LVH indicates left ventricular hypertrophy.
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resulted in fewer conversions in the first 2 h. In 12 placebo-
controlled trials, the success rate of oral propafenone (600
mg) for cardioversion of recent-onset AF ranged from 56% to
83% (557). Oral propafenone was as efficacious as flecainide
but superior to oral amiodarone and quinidine plus digoxin
(494,558). Limited data suggest reduced efficacy in patients
with persistent AF, in conversion of atrial flutter, and in
patients with structural heart disease. Adverse effects are
uncommon but include rapid atrial flutter, ventricular
tachycardia, intraventricular conduction disturbances, hypo-
tension, and bradycardia at conversion. Available data on the
use of various regimens of propafenone loading in patients
with organic heart disease are scant. This agent should be
used cautiously or not at all for conversion of AF in such
cases and should be avoided in patients with HF or severe
obstructive lung disease (491,495,505,506,509,516–526,557).
8.1.5.5. Less Effective or Incompletely Studied Agents for
Cardioversion of Atrial Fibrillation
8.1.5.5.1. QUINIDINE. Quinidine is used less frequently than other
pharmacological agents, due to the perception that it is less
efficacious and has more frequent side effects, although direct
comparative studies are lacking. Quinidine is usually adminis-
tered after digoxin or verapamil has been given to control the
ventricular response rate. Potential adverse effects include QT-
interval prolongation that may precede torsades de pointes,
nausea, diarrhea, fever, hepatic dysfunction, thrombocytopenia,
and hemolytic anemia. During the initiation of quinidine ther-
apy, hypotension and acceleration of the ventricular response to
AF may occur on a vagolytic basis. A clinical response may be
expected 2 to 6 h after administration (489,491,494,524,529,
537–539,545).
8.1.5.5.2. PROCAINAMIDE. Intravenous procainamide has been
used extensively for conversion within 24 h of onset of AF,
and several studies suggest that it may be superior to placebo
Figure 16. Pharmacological management of patients with recurrent persistent or permanent atrial fibrillation (AF). Initiate drug therapy
before cardioversion to reduce the likelihood of early recurrence of AF. *See Figure 15. AAD indicates antiarrhythmic drug.
TABLE 19. Vaughan Williams Classification of
Antiarrhythmic Drugs
Type IA
Disopyramide
Procainamide
Quinidine
Type IB
Lidocaine
Mexiletine
Type IC
Flecainide
Propafenone
Type II
Beta blockers (e.g., propranolol)
Type III
Amiodarone
Bretylium
Dofetilide
Ibutilide
Sotalol
Type IV
Nondihydropyridine calcium channel antagonists (verapamil and diltiazem)
Table includes compounds introduced after publication of the original classification.
Modified with permission from Vaughan Williams EM. A classification of
antiarrhythmic actions reassessed after a decade of new drugs. J Clin
Pharmacol 1984;24:129-47 (497). © 1984 by Sage Publications Inc.
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(510,512,536). Procainamide appears less useful than some
other drugs and has not been tested adequately in patients
with persistent AF. Hypotension is the major adverse effect
after intravenous administration.
8.1.5.5.3. BETA BLOCKERS. When given intravenously, the
short-acting beta blocker esmolol may have modest efficacy for
pharmacological cardioversion of recent-onset AF, but this has
not been established by comparison with placebo. Conversion is
probably mediated through slowing of the ventricular rate. It is
not useful in patients with persistent AF, and there are no data
comparing its relative efficacy for atrial flutter and AF. A
response may be expected within 1 h after initiation of intrave-
nous infusion. Hypotension and bronchospasm are the major
adverse effects of esmolol and other beta blockers (492,559).
8.1.5.5.4. NONDIHYDROPYRIDINE CALCIUM CHANNEL ANTAGO-
NISTS (VERAPAMIL AND DILTIAZEM). The nondihydropyridine
calcium channel antagonists verapamil and diltiazem have
not been found effective for pharmacological cardioversion
of recent-onset or persistent AF, but they act rapidly to
control the rate of ventricular response (373,491,492,532).
The negative inotropic effects of nondihydropine calcium
channel blockers might result in hypotension; caution should
be used in patients with HF.
8.1.5.5.5. DIGOXIN. Digitalis glycosides are generally not
more effective than placebo for conversion of recent-onset
AF to sinus rhythm. Digoxin may prolong the duration of
episodes of paroxysmal AF in some patients, (375) and it
has not been evaluated adequately in patients with persis-
tent AF except to achieve rate control. Digoxin has few
adverse effects after acute administration in therapeutic
doses, aside from AV block and increased ventricular
ectopy, but all manifestations of digitalis toxicity are dose
related (375,378,494,505,526,530,540,542).
8.1.5.5.6. DISOPYRAMIDE. Disopyramide has not been tested
adequately for conversion of AF but may be effective when
administered intravenously. Adverse effects include dryness
of mucous membranes, especially in the mouth, constipation,
urinary retention, and depression of LV contractility. The last
reaction makes it a relatively unattractive option for pharma-
cological conversion of AF.
8.1.5.5.7. SOTALOL. In contrast to its relative efficacy for
maintenance of sinus rhythm, sotalol has no proved efficacy for
pharmacological cardioversion of recent-onset or persistent AF
when given either orally or intravenously. It does, however,
control the heart rate (513,538–540,543). In patients who toler-
ate AF relatively well, a wait-and-see approach using oral sotalol
is an appropriate option. Side effects consist mainly of QT
prolongation associated with torsades de pointes.
8.1.6. Pharmacological Agents to Maintain Sinus Rhythm
8.1.6.1. Agents With Proven Efficacy to Maintain
Sinus Rhythm
Thirty-six controlled trials evaluating 7 antiarrhythmic drugs for
the maintenance of sinus rhythm in patients with paroxysmal or
persistent AF, 14 controlled trials of drug prophylaxis involving
patients with paroxysmal AF, and 22 trials of drug prophylaxis
for maintenance of sinus rhythm in patients with persistent AF
were identified. Comparative data are not sufficient to permit
subclassification by drug or etiology. Individual drugs, listed
alphabetically, are described below, and doses for maintenance
of sinus rhythm are given in Table 20. It should be noted that any
membrane-active agent may cause proarrhythmia.
8.1.6.1.1. AMIODARONE. Available evidence suggests that
amiodarone is more effective than either class I drugs, sotalol,
or placebo in the long-term maintenance of sinus rhythm in
patients with paroxysmal or persistent AF refractory to other
drugs (560–574). However, amiodarone is associated with a
relatively high incidence of potentially severe extracardiac
toxic effects, making it a second-line or last-resort agent in
many cases. The use of low-dose amiodarone (200 mg daily
or less) may be effective and associated with fewer side
effects (537,561,565,566) than higher-dose regimens. In pa-
tients with LVH, HF, CAD, and/or previous MI, amiodarone
is associated with a low risk of proarrhythmia, making it an
appropriate initial choice to prevent recurrent AF in these
situations. Use of amiodarone for AF is associated with the
added benefit of effective rate control, frequently eliminating
the need for other drugs to control the ventricular rate.
A majority of the 403 patients in the CTAF study (561) had
first-time paroxysmal (46%) or persistent (54%) AF of less
than 6-mo duration. AF was considered persistent when more
than half the previous episodes had required cardioversion,
TABLE 20. Typical Doses of Drugs Used to Maintain Sinus Rhythm in Patients With Atrial Fibrillation*
Drug† Daily Dosage Potential Adverse Effects
Amiodarone‡ 100 to 400 mg Photosensitivity, pulmonary toxicity, polyneuropathy, GI upset, bradycardia, torsades de pointes
(rare), hepatic toxicity, thyroid dysfunction, eye complications
Disopyramide 400 to 750 mg Torsades de pointes, HF, glaucoma, urinary retention, dry mouth
Dofetilide§ 500 to 1000 mcg Torsades de pointes
Flecainide 200 to 300 mg Ventricular tachycardia, HF, conversion to atrial flutter with rapid conduction through the AV node
Propafenone 450 to 900 mg Ventricular tachycardia, HF, conversion to atrial flutter with rapid conduction through the AV node
Sotalol§ 160 to 320 mg Torsades de pointes, HF, bradycardia, exacerbation of chronic obstructive or bronchospastic lung
disease
*Drugs and doses given here have been determined by consensus on the basis of published studies.
†Drugs are listed alphabetically.
‡A loading dose of 600 mg per day is usually given for one month or 1000 mg per day for 1 week.
§Dose should be adjusted for renal function and QT-interval response during in-hospital initiation phase.
AF indicates atrial fibrillation; AV, atrioventricular; GI, gastrointestinal; and HF, heart failure.
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implying that many of the cases designated as persistent AF
actually had spontaneously terminating paroxysmal AF. Amiod-
arone maintained sinus rhythm more successfully than
propafenone or sotalol (69% vs. 39%) over a 16-mo follow-up
period. The reduced recurrence of AF was associated with
improved quality of life, fewer AF-related procedures, and lower
cost (347). Nevertheless, 18% of patients stopped amiodarone
because of side effects after a mean of 468 d, compared with
11% of patients assigned to sotalol or propafenone.
Of 222 patients randomized to either amiodarone or class I
agents in the AFFIRM study, 62% treated with amiodarone
remained in sinus rhythm at 1 y compared with 23% on class
I agents. In 256 patients randomized between amiodarone and
sotalol, 60% versus 38% sustained sinus rhythm (570). In
patients with paroxysmal AF, amiodarone was more effective
than propafenone (575) and sotalol, (562) but this advantage
was offset by a higher incidence of side effects (562). In
patients who develop recurrent AF during long-term therapy
with oral amiodarone, intravenous amiodarone exerted an
additional therapeutic effect to terminate recurrences (576).
Amiodarone increases the success rate of electric cardio-
version and prevents relapses by suppressing atrial ectopy in
patients with persistent AF (577–579).
Experimentally, amiodarone, but not dofetilide or flecain-
ide, reverses pacing-induced atrial remodeling and inhibits
the inducibility and stability of AF (580). To date, only a few
randomized studies have been performed with amiodarone
after cardioversion in patients with persistent AF. Amiod-
arone was tested as a first-line agent in a study of patients
postcardioversion (537) stratified according to age, duration
of AF, mitral valve disease, and cardiac surgery. After 6 mo,
amiodarone was more effective (83% of patients remaining in
sinus rhythm) than quinidine (43%). Amiodarone was asso-
ciated with fewer side effects than quinidine over 6 mo, but
side effects often occur after more prolonged treatment with
amiodarone. In a crossover study of 32 patients who had
persistent AF for more than 3 wk randomized to amiodarone or
quinidine (537) when pharmacological conversion did not occur
with quinidine (direct-current cardioversion was not used),
amiodarone was better tolerated and far more effective in
achieving restoration and long-term maintenance of sinus
rhythm. After 9 mo, 18 of 27 (67%) amiodarone-treated patients
were in sinus rhythm versus 2 of 17 (12%) taking quinidine.
The double-blind, placebo-controlled SAFE-T trial (292)
involved 665 patients with persistent AF, of whom 267
received amiodarone, 261 received sotalol, and 137 received
placebo. After a run-in period of 28 d allowing for a full
antiarrhythmic effect, spontaneous conversion occurred in
27% of those given amiodarone, 24% on sotalol, and 0.8% on
placebo. Among patients who did not experience conversion
pharmacologically, direct-current shocks subsequently failed
in 28%, 26.5%, and 32% of patients in the 3 treatment groups,
respectively. This indicates that sotalol and amiodarone,
when given on a chronic basis, are equally effective in
converting persistent AF to sinus rhythm (see Section 8.1.5.4,
Agents With Proven Efficacy for Cardioversion of Atrial
Fibrillation). The median times to recurrence of AF were
significantly longer with amiodarone (487 d) than with
sotalol (74 d) or placebo (6 d). In patients with ischemic heart
disease, the median time to AF recurrence did not differ
between amiodarone (569 d) and sotalol (428 d). There were
no significant differences in major adverse events, but the
duration of amiodarone therapy may have been insufficient to
expose toxicity. Although amiodarone is more effective than
sotalol, sotalol was equally effective in patients with CAD,
for whom it is preferred because of lower toxicity.
One uncontrolled study involved 89 patients with persistent
AF in whom previous treatments had failed; actuarially, 53%
were in sinus rhythm after 3 y of amiodarone therapy (566). In
another study (563) of 110 patients with refractory AF (57 with
paroxysmal AF) or atrial flutter in whom a median of 2 class I
agents had failed, amiodarone (268 plus or minus 100 mg daily)
was associated with recurrence in 9% of patients with persistent
AF and 40% of those with paroxysmal AF over 5 y. Several
other uncontrolled studies also support the use of amiodarone as
an agent of last resort (564,568,581,582). In one, a dose of 200
mg daily appeared effective in patients for whom cardioversion
had failed; 52% underwent repeated cardioversion with success
for 12 mo (531).
8.1.6.1.2. BETA BLOCKERS. Beta blockers are generally not
considered primary therapy for maintenance of sinus rhythm in
patients with AF and structural heart disease. Various beta
blockers have shown moderate but consistent efficacy to prevent
AF recurrence or reduce the frequency of paroxysmal AF,
comparable to conventional antiarrhythmic drugs (583–586).
One placebo-controlled study (583) of 394 patients with persis-
tent AF found a lower risk of early recurrence after cardiover-
sion and slower ventricular response with sustained-release
metoprolol than placebo (583). Two studies found atenolol (587)
and bisoprolol (584) as effective as sotalol and better than
placebo in reducing the frequency and duration of paroxysmal
AF and in reducing the probability of relapse after cardioversion,
but proarrhythmic events occurred more often during treatment
with sotalol. In patients with persistent AF, carvedilol and
bisoprolol initiated after cardioversion produced similar reduc-
tions in relapse over the course of 1 y (585). These results
confirm a previous observational study in which beta blockers
reduced the risk of developing AF during an average follow-up
of 3.2 y (25). Beta blockers have the advantage of controlling the
ventricular rate when AF recurs and reduce or abolish associated
symptoms, but unawareness of recurrent AF may have disad-
vantages. These agents may be effective in postoperative pa-
tients but potentially aggravate vagally mediated AF.
8.1.6.1.3. DOFETILIDE. Two large-scale, double-blind, ran-
domized studies support the efficacy of dofetilide for preven-
tion of AF or atrial flutter (503). Results from the Symptom-
atic Atrial Fibrillation Investigative Research on Dofetilide
(SAFIRE-D) study found dofetilide associated with conver-
sion to sinus rhythm, (503) most (87%) within 30 h after
treatment was initiated. In SAFIRE-D, (503) dofetilide (500
mcg daily) exhibited 58% efficacy in maintaining sinus
rhythm 1 y after cardioversion compared with only 25% in
the placebo group. In the Distensibility Improvement And
Remodeling in Diastolic Heart Failure (DIAMOND) (588)
study of patients with compromised LV function, sinus
rhythm was maintained in 79% of the dofetilide group
compared with 42% of the placebo group. The incidence of
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torsades de pointes was 0.8%. Four of 5 such events occurred
in the first 3 d. To reduce the risk of early proarrhythmia,
dofetilide must be initiated in the hospital at a dose titrated to
renal function and the QT interval.
8.1.6.1.4. DISOPYRAMIDE. Several small, randomized studies
support the efficacy of disopyramide to prevent recurrent AF
after direct-current cardioversion. One study comparing
propafenone and disopyramide showed equal efficacy, but
propafenone was better tolerated (589). Treatment with diso-
pyramide for more than 3 mo after cardioversion was asso-
ciated with an excellent long-term outcome in an uncon-
trolled study: 98 of 106 patients were free of recurrent AF,
and 67% remained in sinus rhythm after a mean of 6.7 y.
Although the duration of AF was more than 12 mo in most
patients, few had significant underlying cardiac disease other
than previously treated thyrotoxicosis. It is not clear, there-
fore, whether disopyramide was the critical factor in sup-
pressing AF (544). Disopyramide has negative inotropic and
negative dromotropic effects that may cause HF or AV block
(544,589–592). Disopyramide may be considered first-line
therapy in vagally induced AF, and its negative inotropic
effects may be desirable in patients with HCM associated
with dynamic outflow tract obstruction (593).
8.1.6.1.5. FLECAINIDE. Two placebo-controlled studies
(594,595) found flecainide effective in postponing the first
recurrence of AF and the overall time spent in AF; and in
other randomized studies (596,597) efficacy was comparable
to quinidine with fewer side effects. Several uncontrolled
studies (598–600) found that flecainide delayed recurrence.
Severe ventricular proarrhythmia or sudden death was not
observed at a mean dose of 199 mg daily among patients with
little or no structural heart disease. Side effects in 5 patients
(9%) were predominantly related to negative dromotropism,
with or without syncope. Flecainide (200 mg daily) was
superior to long-acting quinidine (1100 mg daily) in prevent-
ing recurrent AF after cardioversion and associated with
fewer side effects, but one patient died a month after entry,
presumably due to proarrhythmia (600).
8.1.6.1.6. PROPAFENONE. The United Kingdom Paroxysmal
Supraventricular Tachycardia (UK PSVT) study was a large,
randomized, placebo-controlled trial of propafenone in which
transtelephonic monitoring was used to detect relapses to AF
(601). The primary endpoint was time to first recurrence or
adverse event. A dose of 300 mg twice daily was effective
and 300 mg 3 times daily even more effective, but the higher
dose was associated with more frequent side effects. In a
small, placebo-controlled study, (602) propafenone, com-
pared with placebo, reduced days in AF from 51% to 27%.
Propafenone was more effective than quinidine in another
randomized comparison (603). In an open-label randomized
study involving 100 patients with AF (with balanced propor-
tions of paroxysmal and persistent AF), propafenone and
sotalol were equally effective in maintaining sinus rhythm
(30% vs. 37% of patients in sinus rhythm at 12 mo,
respectively) (604). The pattern of AF (paroxysmal or per-
sistent), LA size, and previous response to drug therapy did
not predict efficacy, but statistical power for this secondary
analysis was limited. Other uncontrolled studies, usually
involving selected patients refractory to other antiarrhythmic
drugs, also support the efficacy of propafenone (605–609).
In a randomized study, propafenone and disopyramide
appeared equally effective in preventing postcardioversion
AF, but propafenone was better tolerated (589). A few
observational studies involving mixed cohorts of patients
with paroxysmal and persistent AF found propafenone effec-
tive in terms of maintenance of sinus rhythm and reduction of
arrhythmia-related complaints (608).
In 2 placebo-controlled studies on patients with symptom-
atic AF (610,611), a sustained-release formulation of
propafenone (225, 325, and 425 mg twice daily) delayed the
first symptomatic recurrence and reduced the ventricular rate
at the time of relapse.
Like other highly effective class IC drugs, propafenone
should not be used in patients with ischemic heart disease or
LV dysfunction due to the high risk for proarrhythmic effects.
Close follow-up is necessary to avoid adverse effects due to
the development of ischemia or HF.
8.1.6.1.7. SOTALOL. Sotalol is not effective for conversion of AF
to sinus rhythm, but it may be used to prevent AF. Two
placebo-controlled studies (612,613) involving patients in sinus
rhythm and at least one documented prior episode of AF found
sotalol safe and effective at doses ranging from 80 to 160 mg
twice daily. Patients considered at risk of proarrhythmia, HF, or
AV conduction disturbances were excluded; whether any of the
participants had undergone previous direct-current cardioversion
was not reported (561,612). The effects of the reverse use
dependence of sotalol and proarrhythmic risk may be greater
after conversion to slower rates in sinus rhythm than during AF
with a rapid ventricular response.
In another study, (604) sotalol and propafenone seemed
equally effective for maintenance of sinus rhythm in patients
with AF. In the CTAF study, sotalol and propafenone (given
separately) were less effective than amiodarone as assessed
by the number of patients without documented recurrence of
AF. The difference between outcomes with these drugs was
less marked when the number of patients continuing treat-
ment without side effects was considered. In an uncontrolled
study of a stepped-care approach beginning with propafenone
and, after failure, then sotalol, paroxysmal AF occurred in
nearly 50% of patients, but only 27% of those with persistent
AF converted to sinus rhythm at 6 mo (609).
Sotalol was as effective as and better tolerated than slow-
release quinidine sulfate for preventing recurrent AF in a
multicenter study (614). Moreover, sotalol was more effective in
suppressing symptoms in patients who relapsed into AF, prob-
ably because it induced a slower ventricular rate. In patients with
recurrent AF, propafenone was as effective as sotalol in main-
taining sinus rhythm 1 y after cardioversion. Recurrences oc-
curred later and were less symptomatic with either drug than
with placebo (615). Several studies found sotalol and the
combination of quinidine and verapamil equally effective after
cardioversion of AF, although ventricular arrhythmias (includ-
ing torsades de pointes) were more frequent with quinidine
(538,615). Sotalol should be avoided in patients with asthma,
HF, renal insufficiency, or QT interval prolongation.
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8.1.6.2. Drugs With Unproven Efficacy or No
Longer Recommended
8.1.6.2.1. DIGOXIN. Available evidence does not support a
role for digitalis in suppressing recurrent AF in most patients.
The lack of an AV blocking effect during sympathetic
stimulation results in poor rate control with digoxin, and
hence it does not usually reduce symptoms associated with
recurrent paroxysmal AF (30).
8.1.6.2.2. PROCAINAMIDE. No adequate studies of procainamide
are available. Long-term treatment is frequently associated with
development of antinuclear antibodies and is occasionally asso-
ciated with arthralgia or agranulocytosis.
8.1.6.2.3. QUINIDINE. Quinidine has not been evaluated exten-
sively in patients with paroxysmal AF but appears approxi-
mately as effective as class IC drugs (596,597,616). In one
study (603), quinidine was less effective than propafenone
(22% of patients free from AF with quinidine vs. 50% with
propafenone). Side effects are more prominent than with
other antiarrhythmic drugs, and proarrhythmia is a particular
concern. A meta-analysis of 6 trials found quinidine superior
to no treatment to maintain sinus rhythm after cardioversion
of AF (50% vs. 25% of patients, respectively, over 1 y).
However, total mortality was significantly higher among
patients given quinidine (12 of 413 patients; 2.9%) than
among those not given quinidine (3 of 387 patients; 0.8%)
(609). In a registry analysis (616), 6 of 570 patients less than
65 y old died shortly after restoration of sinus rhythm while
taking quinidine. Up to 30% of patients taking quinidine
experience intolerable side effects, most commonly diarrhea.
Other investigators (614) found sotalol and quinidine equally
effective for maintaining sinus rhythm after direct-current
cardioversion of AF. Sotalol, but not quinidine, reduced heart
rate in patients with recurrent AF, and there were fewer
symptoms with sotalol (535,592,614,617–624).
In 2 European multicenter studies, the combination of
quinidine plus verapamil was as effective as or superior to
sotalol in preventing recurrences of paroxysmal and persis-
tent AF. In the Suppression Of Paroxysmal Atrial
Tachyarrhythmias (SOPAT) trial (625), 1033 patients (mean
age 60 y, 62% male) with frequent episodes of symptomatic
paroxysmal AF either received high-dose quinidine (480 mg
per day) plus verapamil (240 mg per day; 263 patients),
low-dose quinidine (320 mg per day) plus verapamil (160 mg
per day; 255 patients), sotalol (320 mg per day; 264 patients),
or placebo (251 patients). Each of the active treatments was
statistically superior to placebo and not different from one
another with respect to time to first recurrence or drug
discontinuation. The symptomatic AF burden also improved
(3.4%, 4.5%, 2.9%, and 6.1% of days for each treatment
group, respectively). Four deaths, 13 episodes of syncope,
and 1 episode of ventricular tachycardia were documented,
with 1 death and occurrence of VT related to quinidine plus
verapamil. Sotalol and the quinidine-verapamil combination
were associated with more severe side effects.
The Prevention of Atrial Fibrillation After Cardioversion
(PAFAC) trial (287) compared the efficacy and safety of the
combination of quinidine plus verapamil (377 patients), sotalol
(383 patients), and placebo (88 patients) in patients with persis-
tent AF or following direct-current cardioversion, with daily
transtelephonic monitoring for detection of recurrent AF. AF
recurrence or death occurred in 572 patients (67%), and AF
recurrence became persistent in 348 (41%). Over 1 y, recurrence
rates were 83% with placebo, 67% with sotalol, and 65% with
the combination of quinidine plus verapamil, the last mentioned
statistically superior to placebo but not different from sotalol.
Persistent AF occurred in 77%, 49%, and 38%, respectively,
with the quinidine-verapamil combination superior to placebo
and to sotalol. About 70% of AF recurrences were asymptom-
atic. Adverse events were comparable on sotalol and quinidine/
verapamil, except that torsades de pointes was confined to the
sotalol group. Therefore, the combination of quinidine plus
verapamil appeared useful to prevent recurrent AF after cardio-
version of persistent AF.
8.1.6.2.4. VERAPAMIL AND DILTIAZEM. There is no evidence to
support the antiarrhythmic efficacy of calcium channel an-
tagonist drugs in patients with paroxysmal AF, but they
reduce heart rate during an attack such that symptoms may
disappear despite recurrent AF. In one study, diltiazem
reduced the number of AF episodes occurring in a 3-mo
period by approximately 50% (626).
8.1.7. Out-of-Hospital Initiation of Antiarrhythmic Drugs
in Patients With Atrial Fibrillation
A frequent issue related to pharmacological cardioversion of
AF is whether to initiate antiarrhythmic drug therapy in
hospital or on an outpatient basis. The major concern is the
potential for serious adverse effects, including torsades de
pointes (Table 21). With the exception of those involving
low-dose oral amiodarone (533), virtually all studies of
pharmacological cardioversion have involved hospitalized
patients. However, one study (627) provided a clinically
useful approach with out-of-hospital patient-controlled con-
version using class IC drugs (see Tables 6, 7, and 8).
The “pill-in-the-pocket” strategy consists of the self-
administration of a single oral dose of drug shortly after the onset
of symptomatic AF to improve quality of life, decrease hospital
admission, and reduce cost (628). Recommendations for out-of-
hospital initiation or intermittent use of antiarrhythmic drugs
differ for patients with paroxysmal and persistent AF. In patients
with paroxysmal AF, the aims are to terminate an episode or to
prevent recurrence. In patients with persistent AF, the aims are to
achieve pharmacological cardioversion of AF, obviating the
need for direct-current cardioversion, or to enhance the success
of direct-current cardioversion by lowering the defibrillation
threshold and prevent early recurrence of AF.
In patients with lone AF without structural heart disease,
class IC drugs may be initiated on an outpatient basis. For
other selected patients without sinus or AV node dysfunction,
bundle-branch block, QT-interval prolongation, the Brugada
syndrome, or structural heart disease, “pill-in-the-pocket”
administration of propafenone and flecainide outside the
hospital becomes an option once treatment has proved safe in
hospital given the relative safety (lack of organ toxicity and
low estimated incidence of proarrhythmia) (181,557,629–
631). Before these agents are initiated, however, a beta
blocker or nondihydropyridine calcium channel antagonist is
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generally recommended to prevent rapid AV conduction in
the event of atrial flutter (632–636). Unless AV node
conduction is impaired, a short-acting beta blocker or nondi-
hydropyridine calcium channel antagonist should be given at
least 30 min before administration of a type IC antiarrhythmic
agent to terminate an acute episode of AF, or the AV nodal
blocking agents should be prescribed as continuous back-
ground therapy. Sudden death related to idiopathic ventricular
fibrillation may occur in patients with the Brugada syndrome
following administration of class I antiarrhythmic drugs even
in patients with structurally normal hearts (637,638). Because
termination of paroxysmal AF may be associated with bra-
dycardia due to sinus node or AV node dysfunction, an initial
conversion trial should be undertaken in hospital before a
patient is declared fit for outpatient “pill-in-the-pocket” use
of flecainide or propafenone for conversion of subsequent
recurrences of AF. Table 22 lists other factors associated with
proarrhythmic toxicity, including proarrhythmic effects,
which vary according to the electrophysiological properties
of the various drugs. For class IC agents, risk factors for
proarrhythmia include female gender.
Few prospective data are available on the relative safety
of initiating antiarrhythmic drug therapy in the outpatient
versus inpatient setting, and the decision to initiate therapy
out of hospital should be carefully individualized. The
efficacy and safety of self-administered oral loading of
flecainide and propafenone in terminating recent-onset AF
outside of hospital were analyzed in 268 patients with
minimal heart disease with hemodynamically well-
tolerated recent-onset AF (627). Fifty-eight patients (22%)
were excluded because of treatment failure or side effects.
Using resolution of palpitations within 6 h after drug
ingestion as the criterion of efficacy, treatment was suc-
cessful in 534 episodes (94%), during 15-mo follow-up,
with conversion occurring over a mean of 2 h. Compared
with conventional care, the numbers of emergency depart-
ment visits and hospitalizations were significantly re-
duced. Among patients with recurrences, treatment was
effective in 84%, and adverse effects were reported by 7%
of patients. Despite efficacy, 5% of patients dropped out of
the study because of multiple recurrences, side effects
(mostly nausea), or anxiety. Thus, the “pill-in-the-pocket”
approach appears feasible and safe for selected patients
with AF, but the safety of this approach without previous
inpatient evaluation remains uncertain.
As long as the baseline uncorrected QT interval is less than
450 ms, serum electrolytes are normal, and risk factors
associated with class III drug–related proarrhythmia are
considered (Table 23), sotalol may be initiated in outpatients
with little or no heart disease. It is safest to start sotalol when
the patient is in sinus rhythm. Amiodarone can also usually be
given safely on an outpatient basis, even in patients with
persistent AF, because it causes minimal depression of
myocardial function and has low proarrhythmic potential,
(566) but in-hospital loading may be necessary for earlier
restoration of sinus rhythm in patients with HF or other forms
of hemodynamic compromise related to AF. Loading regi-
mens typically call for administration of 600 mg daily for 4
wk (566) or 1 g daily for 1 wk, (531) followed by lower
maintenance doses. Amiodarone, class IA or IC agents, or
sotalol can be associated with bradycardia requiring perma-
nent pacemaker implantation (639); this is more frequent with
amiodarone, and amiodarone-associated bradycardia is more
common in women than in men. Quinidine, procainamide,
and disopyramide should not be started out of hospital.
Currently, out-of-hospital initiation of dofetilide is not per-
mitted. Transtelephonic monitoring or other methods of ECG
surveillance may be used to monitor cardiac rhythm and
conduction as pharmacological antiarrhythmic therapy is
initiated in patients with AF. Specifically, the PR interval
(when flecainide, propafenone, sotalol, or amiodarone are
used), QRS duration (with flecainide or propafenone), and
QT interval (with dofetilide, sotalol, or amiodarone) should
be measured. As a general rule, antiarrhythmic drugs should
be started at a relatively low dose and titrated based on
response, and the ECG should be reassessed after each dose
change. The heart rate should be monitored at approximately
weekly intervals by checking the pulse rate, using an event
recorder, or reading ECG tracings obtained at the office. The
dose of other medication for rate control should be reduced
when the rate slows after initiation of amiodarone and
stopped if the rate slows excessively. Concomitant drug
therapies (see Table 19) should be monitored closely, and
both the patient and the physician should be alert to possible
deleterious interactions. The doses of digoxin and warfarin, in
particular, should usually be reduced upon initiation of
amiodarone in anticipation of the rises in serum digoxin
levels and INR that typically occur.
TABLE 21. Types of Proarrhythmia During Treatment With
Various Antiarrhythmic Drugs for AF or Atrial Flutter According
to the Vaughan Williams Classification
Ventricular proarrhythmia
Torsades de pointes (VW types IA and III drugs*)
Sustained monomorphic ventricular tachycardia (usually VW type IC drugs)
Sustained polymorphic ventricular tachycardia/VF without long QT (VW
types IA, IC, and III drugs)
Atrial proarrhythmia
Provocation of recurrence (probably VW types IA, IC, and III drugs)
Conversion of AF to flutter (usually VW type IC drugs)
Increase of defibrillation threshold (a potential problem with VW type IC
drugs)
Abnormalities of conduction or impulse formation
Acceleration of ventricular rate during AF (VW types IA and IC drugs)
Accelerated conduction over accessory pathway (digoxin, intravenous
verapamil, or diltiazem†)
Sinus node dysfunction, atrioventricular block (almost all drugs)
Vaughan Williams (VW) classification of antiarrhythmic drugs from Vaughan
Williams EM. A classification of antiarrhythmic actions reassessed after a
decade of new drugs. J Clin Pharmacol 1984;24:129–47.
*This complication is rare with amiodarone.
†Although the potential for beta blockers to potentiate conduction across the
accessory pathway is controversial, caution should also be exercised for the
use of these agents in patients with AF associated with preexcitation.
AF indicates atrial fibrillation; VF, ventricular fibrillation.
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8.1.8. Drugs Under Development
To overcome the limited efficacy and considerable toxicity of
available drugs for maintaining sinus rhythm, selective blockers of
atrial ion channels and nonselective ion channel blockers are under
development. Use of nonantiarrhythmic drugs, such as inhibitors of
the renin-angiotensin system, n-3 polyunsaturated fatty acids, and
statins, which might modify the underlying atrial remodeling, have
not been extensively investigated for this purpose (640–645).
TABLE 22. Factors Predisposing to Drug-Induced Ventricular Proarrhythmia
VW Types IA and III Agents VW Type IC Agents
Long QT interval (QTc greater than or equal to 460 ms) Wide QRS duration (more than 120 ms)
Long QT interval syndrome Concomitant VT
Structural heart disease, substantial LVH Structural heart disease
Depressed LV function* Depressed LV function*
Hypokalemia/hypomagnesemia*
Female gender
Renal dysfunction*
Bradycardia* Rapid ventricular response rate*
1. (Drug-induced) sinus node disease or AV block 1. During exercise
2. (Drug-induced) conversion of AF to sinus rhythm 2. During rapid AV conduction
3. Ectopy producing short-long R-R sequences
Rapid dose increase Rapid dose increase
High dose (sotalol, dofetilide), drug accumulation* High dose, drug accumulation*
Addition of drugs* Addition of drugs*
1. Diuretics 1. Negative inotropic drugs
2. Other QT-prolonging antiarrhythmic drugs
3. Nonantiarrhythmic drugs listed in http://www.torsades.org/
Previous proarrhythmia
After initiation of drug
Excessive QT lengthening Excessive (more than 150%) QRS widening
*Some of these factors may develop later after initiation of drug treatment. See Section 8.3.3.3 in the full-text guidelines
for details. Vaughan Williams (VW) classification of antiarrhythmic drugs from Vaughan Williams EM. A classification of
antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1984;24:129–47 (497).
AF indicates atrial fibrillation; AV, atrioventricular; LV, left ventricular; LVH, left ventricular hypertrophy; QTc,
indicates corrected QT interval; and VT, ventricular tachycardia.
Efficacy
Enhance Conversion
by DC Shock and
Prevent IRAF*
Recommendation
Class
Level of
Evidence
Known Amiodarone I B
Flecainide
Ibutilide
Propafenone
Sotalol
Uncertain/unknown Beta blockers IIb C
Diltiazem
Disopyramide
Dofetilide
Procainamide
Verapamil
All drugs (except beta blockers and amiodarone) should be initiated in the hospital.
*Drugs are listed alphabetically within each class of recommendation.
AF indicates atrial fibrillation; DC, direct-current; IRAF, immediate recurrence of atrial fibrillation; and SRAF,
subacute recurrence of atrial fibrillation.
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Suppress SRAF and
Maintenance Therapy Class
All drugs in recommendation class I
(except ibutilide) plus beta blockers
Diltiazem
Dofetilide
Verapamil
I a
TABLE 23.    Pharmacological Treatment Before Cardioversion in Patients With Persistent AF:
Effects of Various Antiarrhythmic Drugs on Immediate Recurrence, Outcome of Transthoracic 
Direct-Current Shock, or Both
8.1.8.1. Atrioselective Agents
The finding that the ultra-rapid delayed rectifier (IKur) exists in
atrial but not ventricular tissue opened the possibility that
atrioselective drugs without ventricular proarrhythmic toxic-
ity could be developed for treatment of patients with AF
(643,646). IKur blockers (NIP-142, RSD1235, AVE0118)
prolong atrial refractoriness (left more than right) with no
effect on ventricular repolarization and show strong atrial
antiarrhythmic efficacy (642,644,645,647). AVE0118 is an
IKur and Ito blocker that, unlike dofetilide, increases refracto-
riness in electrically remodeled atria, prolongs atrial wave-
length, and converts persistent AF to sinus rhythm without
disturbing intra-atrial conduction velocity or prolonging the
QT interval (648).
8.1.8.2. Nonselective Ion Channel–Blocking Drugs
Azimilide and dronedarone block multiple potassium, so-
dium, and calcium currents and prolong the cardiac action
potential without reverse use-dependence (641–643,645).
Azimilide has a long elimination half-life (114 h),
allowing for once-daily administration. In patients with
paroxysmal SVT enrolled in 4 clinical trials, azimilide at
doses of 100 and 125 mg daily prolonged time to recur-
rence of AF and atrial flutter (647,649) and reduced
symptoms associated with recurrence (650). Patients with
ischemic heart disease and HF displayed greater efficacy
than those without structural heart disease. In a placebo-
controlled trial involving 3717 survivors of MI with LV
systolic dysfunction, (651) azimilide, 100 mg daily, was
associated with a 1-y mortality rate similar to placebo.
Fewer patients in the azimilide group developed AF or new
or worsening HF than those given placebo, (651) and more
patients in the azimilide group converted from AF to sinus
rhythm (652). The major adverse effects of azimilide were
severe neutropenia (less than 500 cells per microliter) in
0.9% and torsades de pointes in 0.5% of treated patients
(651).
Dronedarone is a noniodinated amiodarone derivative
(653,654). In a randomized, placebo-controlled study in-
volving 204 patients undergoing cardioversion of persis-
tent AF (655), dronedarone (800 mg daily) delayed first
recurrence from 5.3 to 60 d. Higher doses (1200 and 1600
mg daily) were no more effective and associated with
gastrointestinal side effects (diarrhea, nausea, and vomit-
ing. To date, neither organ toxicity nor proarrhythmia has
been reported. In 2 placebo-controlled trials, European
Trial in Atrial Fibrillation or Flutter Patients Receiving
Dronedarone for Maintenance of Sinus Rhythm
(EURIDIS) (656) and American-Australian Trial with
Dronedarone in Atrial Fibrillation or Flutter Patients for
Maintenance of Sinus Rhythm (ADONIS) (657), droneda-
rone prolonged the time to first documented AF/atrial
flutter recurrence and helped control the ventricular rate.
Tedisamil, an antianginal agent, blocks several potassium
channels and causes a reverse rate-dependent QT-interval
prolongation. Tedisamil (0.4 and 0.6 mg/kg) was superior to
placebo for rapid conversion (within 35 min) of recent-onset
AF or atrial flutter (658). The main side effects were pain at
the injection site and ventricular tachycardia.
8.2. Direct-Current Cardioversion of Atrial
Fibrillation and Flutter
RECOMMENDATIONS
Class I
1. When a rapid ventricular response does not respond
promptly to pharmacological measures for patients
with AF with ongoing myocardial ischemia, symp-
tomatic hypotension, angina, or HF, immediate
R-wave synchronized direct-current cardioversion is
recommended. (Level of Evidence: C)
2. Immediate direct-current cardioversion is recom-
mended for patients with AF involving preexcitation
when very rapid tachycardia or hemodynamic insta-
bility occurs. (Level of Evidence: B)
3. Cardioversion is recommended in patients without
hemodynamic instability when symptoms of AF are
unacceptable to the patient. In case of early relapse
of AF after cardioversion, repeated direct-current
cardioversion attempts may be made following ad-
ministration of antiarrhythmic medication. (Level of
Evidence: C)
Class IIa
1. Direct-current cardioversion can be useful to restore
sinus rhythm as part of a long-term management
strategy for patients with AF. (Level of Evidence: B)
2. Patient preference is a reasonable consideration in
the selection of infrequently repeated cardioversions
for the management of symptomatic or recurrent
AF. (Level of Evidence: C)
Class III
1. Frequent repetition of direct-current cardioversion
is not recommended for patients who have relatively
short periods of sinus rhythm between relapses of
AF after multiple cardioversion procedures despite
prophylactic antiarrhythmic drug therapy. (Level of
Evidence: C)
2. Electrical cardioversion is contraindicated in pa-
tients with digitalis toxicity or hypokalemia. (Level
of Evidence: C)
8.2.1. Terminology
Direct-current cardioversion involves delivery of an electrical
shock synchronized with the intrinsic activity of the heart by
sensing the R wave of the ECG to ensure that electrical
stimulation does not occur during the vulnerable phase of the
cardiac cycle (659). Direct-current cardioversion is used to
normalize all abnormal cardiac rhythms except ventricular
fibrillation. The term defibrillation implies an asynchronous
discharge, which is appropriate for correction of ventricular
fibrillation because R-wave synchronization is not feasible,
but not for AF.
8.2.2. Technical Aspects
Successful cardioversion of AF depends on the underlying
heart disease and the current density delivered to the atrial
myocardium. Current may be delivered through external
chest wall electrodes or through an internal cardiac electrode.
Although the latter technique has been considered superior to
external countershocks in obese patients and in patients with
obstructive lung disease, it has not been widely applied. The
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frequency of recurrent AF does not differ between the 2
methods (355,660–664).
The current density delivered to the heart by transthoracic
electrodes depends on the defibrillator capacitor voltage,
output waveform, size and position of the electrode paddles,
and thoracic impedance. For a given paddle surface area,
current density decreases with increasing impedance, related
to the thickness and composition of the paddles, contact
medium between electrodes and skin, distance between pad-
dles, body size, respiratory phase, number of shocks, and
interval between shocks (665).
Use of electrolyte-impregnated pads can minimize the
electrical resistance between electrode and skin. Pulmonary
tissue between paddles and the heart inhibits conduction, so
shocks delivered during expiration or chest compression
deliver higher energy to the heart. Large paddles lower
impedance but may make current density in cardiac tissue
insufficient; conversely, undersized paddles may cause injury
due to excess current density. Animal experiments have
shown that the optimum diameter approximates the cross-
sectional area of the heart. There are no firm data regarding
the best paddle size for cardioversion of AF, but a diameter of
8 to 12 cm (665) is generally recommended.
Because the combination of high impedance and low
energy reduces the success of cardioversion, measurement of
impedance has been proposed to shorten the procedure and
improve outcomes (666,667). Kerber et al (668) reported
better efficacy by automatically increasing energy delivery
when the impedance exceeded 70 ohms.
The output waveform also influences energy delivery during
direct-current cardioversion. In a randomized trial, 77 patients
treated with sinusoidal monophasic shocks had a cumulative
success rate of 79% compared with 94% in 88 subjects cardio-
verted with rectilinear biphasic shocks, and the latter required
less energy. In addition to rectilinear biphasic shocks, indepen-
dent correlates of successful conversion were thoracic imped-
ance and the duration of AF (669). For cardioversion of AF, a
biphasic shock waveform has greater efficacy, requires fewer
shocks and lower delivered energy, and results in less dermal
injury than a monophasic shock waveform, and represents the
present standard for cardioversion of AF (670).
In their original description of cardioversion, Lown et al
(659,671) recommended an anterior-posterior electrode config-
uration over anterior-anterior positioning, but others disagree
(665,672,673). Anterior-posterior positioning allows current to
reach a sufficient mass of atrial myocardium to achieve cardio-
version of AF when the pathology involves both atria (as in
patients with atrial septal defects or cardiomyopathy). A draw-
back of this configuration is the amount of pulmonary tissue
separating the anterior paddle and the heart, particularly in
patients with emphysema. Placing the anterior electrode to the
left of the sternum reduces electrode separation. The paddles
should be placed directly against the chest wall, under rather
than over the breast tissue. Other paddle positions result in less
current flow through crucial parts of the heart (665). In a
randomized study involving 301 subjects undergoing elective
external cardioversion, the energy required was lower and the
overall success (adding the outcome of low-energy shocks to
that of high-energy shocks) was greater with the anterior-
posterior configuration (87%) than with the anterior-lateral
alignment (76%) (674). Animal experiments show a wide
margin of safety between the energy required for cardioversion
of AF and that associated with myocardial depression (675,676).
Even without apparent myocardial damage, transient ST-
segment elevation may appear on the ECG after cardioversion
(677,678) and blood levels of creatine kinase may rise. Serum
troponin-T and troponin-I levels did not rise significantly in a
study of 72 cardioversion attempts with average energy over
400 J (range 50 to 1280 J) (679). In 10% of the patients, creatine
kinase-MB levels rose beyond levels attributable to skeletal
muscle trauma, and this was related to energy delivered. Micro-
scopic myocardial damage related to direct-current cardiover-
sion has not been confirmed and is probably clinically
insignificant.
8.2.3. Procedural Aspects
Cardioversion should be performed with the patient under
adequate general anesthesia in a fasting state. Short-acting
anesthetic drugs or agents that produce conscious sedation are
preferred to enable rapid recovery after the procedure; over-
night hospitalization is seldom required (680). The electric
shock should be synchronized with the QRS complex, trig-
gered by monitoring the R wave with an appropriately
selected ECG lead that also clearly displays atrial activation
to facilitate assessment of outcome. The initial energy may be
low for cardioversion of atrial flutter, but higher energy is
required for AF. The energy output has traditionally been
increased successively in increments of 100 J to a maximum
of 400 J, but some physicians begin with higher energies to
reduce the number of shocks and thus the total energy
delivered. To avoid myocardial damage, some have sug-
gested that the interval between consecutive shocks should be
at least 1 min (681). In 64 patients randomly assigned to
initial monophasic waveform energies of 100, 200, or 360 J,
high initial energy was significantly more effective than low
levels (immediate success rates 14% with 100 J, 39% with
200 J, and 95% with 360 J, respectively), resulting in fewer
shocks and less cumulative energy when 360 J was delivered
initially (682). These data indicate that an initial shock of
100 J with monophasic waveform is often too low for
direct-current cardioversion of AF; hence, an initial energy of
200 J or greater is recommended. A similar recommendation
to start with 200 J applies to biphasic waveforms, particularly
when cardioverting patients with AF of long duration (683).
External cardioversion of AF with a rectilinear biphasic
waveform (99.1% of 1877 procedures in 1361 patients) was
more effective than a monophasic sinusoidal waveform
(92.4% of 2818 procedures in 2025 patients; p less than
0.001), but comparable for patients with atrial flutter (99.2%
and 99.8%, respectively). The median successful energy level
was 100 J with the biphasic waveform compared with 200 J
with the monophasic waveform (684).
8.2.4. Direct-Current Cardioversion in Patients With
Implanted Pacemakers and Defibrillators
When appropriate precautions are taken, cardioversion of AF
is safe in patients with implanted pacemaker or defibrillator
devices. Pacemaker generators and defibrillators are designed
with circuits protected against sudden external electrical
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discharges, but programmed data may be altered by current
surges. Electricity conducted along an implanted electrode
may cause endocardial injury and lead to a temporary or
permanent increase in stimulation threshold, resulting in
loss of ventricular capture. To ensure appropriate function,
the implanted device should be interrogated and, if neces-
sary, reprogrammed before and after cardioversion. De-
vices are typically implanted anteriorly, so the paddles
used for external cardioversion should be positioned as
distantly as possible, preferably in the anterior-posterior
configuration. The risk of exit block is greatest when one
paddle is positioned near the impulse generator and the
other over the cardiac apex, and lower with the anterior-
posterior electrode configuration and with bipolar elec-
trode systems (685,686). Low-energy internal cardiover-
sion does not interfere with pacemaker function in patients
with electrodes positioned in the RA, coronary sinus, or
left pulmonary artery (687).
8.2.5. Risks and Complications of Direct-Current
Cardioversion of Atrial Fibrillation
The risks of direct-current cardioversion are mainly related
to thromboembolism and arrhythmias. Thromboembolic
events have been reported in 1% to 7% of patients not
given prophylactic anticoagulation before cardioversion of
AF (688,689). Prophylactic antithrombotic therapy is dis-
cussed below. (See Section 8.2.7, Prevention of Thrombo-
embolism in Patients With Atrial Fibrillation Undergoing
Cardioversion.)
Various benign arrhythmias, especially ventricular and
supraventricular premature beats, bradycardia, and short
periods of sinus arrest, may arise after cardioversion and
commonly subside spontaneously (690). More dangerous
arrhythmias, such as ventricular tachycardia and fibrilla-
tion, may arise in the face of hypokalemia, digitalis
intoxication, or improper synchronization (691,692). Se-
rum potassium levels should be in the normal range for
safe, effective cardioversion. Magnesium supplementation
does not enhance cardioversion (693). Cardioversion is
contraindicated in cases of digitalis toxicity because re-
sulting ventricular tachyarrhythmia may be difficult to
terminate. A serum digitalis level in the therapeutic range
does not exclude clinical toxicity but is not generally
associated with malignant ventricular arrhythmias during
cardioversion (694), so it is not routinely necessary to
interrupt digoxin before elective cardioversion of AF. It is
important, however, to exclude clinical and ECG signs of
digitalis excess and delay cardioversion until a toxic state
has been corrected, which usually requires withdrawal of
digoxin for longer than 24 h.
In patients with long-standing AF, cardioversion commonly
unmasks underlying sinus node dysfunction. A slow ventricular
response to AF in the absence of drugs that slow conduction
across the AV node may indicate an intrinsic conduction defect.
The patient should be evaluated before cardioversion with this in
mind so a transvenous or transcutaneous pacemaker can be used
prophylactically (695).
8.2.6. Pharmacological Enhancement of Direct-Current
Cardioversion
RECOMMENDATIONS
Class IIa
1. Pretreatment with amiodarone, flecainide, ibutilide,
propafenone, or sotalol can be useful to enhance the
success of direct-current cardioversion and prevent
recurrent atrial fibrillation. (Level of Evidence: B)
2. In patients who relapse to AF after successful car-
dioversion, it can be useful to repeat the procedure
following prophylactic administration of antiar-
rhythmic medication. (Level of Evidence: C)
Class IIb
1. For patients with persistent AF, administration of beta
blockers, disopyramide, diltiazem, dofetilide, procain-
amide, or verapamil may be considered, although the
efficacy of these agents to enhance the success of
direct-current cardioversion or to prevent early recur-
rence of AF is uncertain. (Level of Evidence: C)
2. Out-of-hospital initiation of antiarrhythmic medica-
tions may be considered in patients without heart
disease to enhance the success of cardioversion of
AF. (Level of Evidence: C)
3. Out-of-hospital administration of antiarrhythmic med-
ications may be considered to enhance the success of
cardioversion of AF in patients with certain forms of
heart disease once the safety of the drug has been
verified for the patient. (Level of Evidence: C)
Although most recurrences of AF occur within the first month
after direct-current cardioversion, research with internal atrial
cardioversion (696) and postconversion studies using trans-
thoracic shocks (697) have established several patterns of AF
recurrence (Fig. 17). In some cases, direct-current counter-
Figure 17. Hypothetical illustration of cardioversion failure.
Three types of recurrences after electrical cardioversion of per-
sistent atrial fibrillation (AF) are shown. The efficacy of drugs
varies in enhancement of shock conversion and suppression of
recurrences. Modified with permission from van Gelder IC,
Tuinenburg AE, Schoonderwoerd BS, et al. Pharmacologic ver-
sus direct-current electrical cardioversion of atrial flutter and
fibrillation. Am J Cardiol 1999;84:147R–51R, with permission
from Excerpta Medica Inc (704). ECV indicates external cardio-
version; IRAF, immediate recurrence of AF defined as the first
recurrence of AF after cardioversion; and SR, sinus rhythm.
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shock fails to elicit even a single isolated sinus or ectopic
atrial beat, tantamount to a high atrial defibrillation threshold.
In others, AF recurs within a few minutes after a period of
sinus rhythm, (698,699) and recurrence after cardioversion is
sometimes delayed for days or weeks (697). Complete shock
failure and immediate recurrence occur in approximately
25% of patients undergoing direct-current cardioversion of
AF, and subacute recurrences occur within 2 wk in almost an
equal proportion (698).
Restoration and maintenance of sinus rhythm are less
likely when AF has been present for longer than 1 y than in
patients with AF of shorter duration. The variation in imme-
diate success rates for direct-current cardioversion from 70%
to 99% in the literature (617,682,684,700,701) is partly
explained by differences in patient characteristics and the
waveform used but also depends upon the definition of
success, because the interval at which the result is evaluated
ranges from moments to several days. Over time, the propor-
tion of AF caused by rheumatic heart disease has declined,
the average age of the AF population has increased, (700–
702) and the incidences of lone AF have remained constant,
making it difficult to compare the outcome of cardioversion
across various studies.
In a large consecutive series of patients undergoing car-
dioversion of AF published in 1991, 24% were classified as
having ischemic heart disease, 24% with rheumatic valvular
disease, 15% with lone AF, 11% with hypertension, 10% with
cardiomyopathy, 8% with nonrheumatic valvular disease, 6%
with congenital heart disease, and 2% with hyperthyroidism
(700). Seventy percent were in sinus rhythm 24 h after
cardioversion. Multivariate analysis found a short duration of
AF, atrial flutter, and younger age to be independent predic-
tors of success, whereas LA enlargement, underlying organic
heart disease, and cardiomegaly were associated with HF. A
decade later, a study of 166 consecutive patients followed
after first direct-current cardioversion found that short dura-
tion of AF, smaller LA size, and treatment with beta blockers,
verapamil, or diltiazem were clinical predictors of both initial
success and maintenance of sinus rhythm (703). In another
series of 100 patients, the primary success rate assessed 3 d
after cardioversion was 86% (701), increasing to 94% when
the procedure was repeated during treatment with quinidine
or disopyramide. Only 23% of patients remained in sinus
rhythm after 1 y, however, and 16% remained after 2 y. In
those who relapsed to AF, repeated cardioversion after
administration of antiarrhythmic medication resulted in sinus
rhythm in 40% and 33% after 1 and 2 y, respectively. For
patients who relapsed again, a third cardioversion resulted in
sinus rhythm in 54% after 1 y and 41% after 2 y. Thus, sinus
rhythm can be restored in a substantial proportion of patients
by direct-current cardioversion, but the rate of relapse is
high without concomitant antiarrhythmic drug therapy (704)
(Fig. 17).
When given in conjunction with direct-current cardiover-
sion, the primary aims of antiarrhythmic medication therapy
are to increase the likelihood of success (e.g., by lowering the
cardioversion threshold) and to prevent recurrent AF. En-
hanced efficacy may involve multiple mechanisms, such as
decreasing the energy required to achieve cardioversion,
prolonging atrial refractory periods, and suppressing atrial
ectopy that may cause early recurrence of AF (580,705).
Antiarrhythmic medications may be initiated out of hospital
or in hospital immediately prior to direct-current cardiover-
sion. (See Section 8.1.7, Out-of-Hospital Initiation of Anti-
arrhythmic Drugs in Patients With Atrial Fibrillation.) The
risks of pharmacological treatment include the possibility of
paradoxically increasing the defibrillation threshold, as de-
scribed with flecainide (600), accelerating the ventricular rate
when class IA or IC drugs are given without an AV nodal
blocking agent, (632–636,706) and inducing ventricular ar-
rhythmias (see Table 21).
Prophylactic drug therapy to prevent early recurrence of
AF should be considered individually for each patient.
Patients with lone AF of relatively short duration are less
prone to early recurrence of AF than are those with heart
disease and longer AF duration, who therefore stand to gain
more from prophylactic administration of antiarrhythmic
medication. Pretreatment with pharmacological agents is
most appropriate in patients who fail to respond to direct-
current cardioversion and in those who develop immediate or
subacute recurrence of AF. In patients with late recurrence
and those undergoing initial cardioversion of persistent AF,
pretreatment is optional. Antiarrhythmic drug therapy is
recommended in conjunction with a second cardioversion
attempt, particularly when early relapse has occurred. Addi-
tional cardioversion, beyond a second attempt, is of limited
value and should be reserved for carefully selected patients.
Infrequently repeated cardioversions may be acceptable in
patients who are highly symptomatic upon relapse to AF.
Specific Pharmacological Agents for Prevention
of Recurrent AF in Patients Undergoing
Electrical Cardioversion
8.2.6.1. Amiodarone
In patients with persistent AF, treatment with amiodarone for 6
wk before and after cardioversion increased the conversion rate
and the likelihood of maintaining sinus rhythm and reduced
supraventricular ectopic activity that may trigger recurrent AF
(579). Prophylactic treatment with amiodarone was also effec-
tive when an initial attempt at direct-current cardioversion had
failed (531,569). In patients with persistent AF randomly as-
signed to treatment with carvedilol, amiodarone, or placebo for
4 wk before direct-current cardioversion, the 2 drugs yielded
similar cardioversion rates, but amiodarone proved superior at
maintaining sinus rhythm after conversion (707).
8.2.6.2. Beta-Adrenergic Antagonists
Although beta blockers are unlikely to enhance the success of
cardioversion or to suppress immediate or late recurrence of
AF, they may reduce subacute recurrences (583).
8.2.6.3. Nondihydropyridine Calcium Channel Antagonists
Therapy with calcium-channel antagonists prior to electrical
cardioversion of AF has yielded contradictory results. Several
studies found that verapamil (708,709) reduced immediate or
early recurrences of AF. On the other hand, verapamil and
diltiazem may increase AF duration, shorten refractoriness,
and increase the spatial dispersion of refractoriness leading to
more sustained AF (710,711). In patients with persistent AF,
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the addition of verapamil to class I or class II drugs can
prevent immediate recurrence after cardioversion (712), and
prophylaxis against subacute recurrence was enhanced when
this combination was given for 3 d before and after cardio-
version (713,714). Verapamil also reduced AF recurrence
when a second cardioversion was performed after early
recurrence of AF (714). In a comparative study (715),
amiodarone and diltiazem were more effective than digoxin
for prevention of early recurrence, whereas at 1 mo the
recurrence rate was lower with amiodarone (28%) than with
diltiazem (56%) or digoxin (78%). In patients with persistent
AF, treatment with verapamil 1 mo before and after direct-
current cardioversion did not improve the outcome of cardio-
version (716).
8.2.6.4. Quinidine
A loading dose of quinidine (1200 mg orally 24 h before
direct-current cardioversion) significantly reduced the num-
ber of shocks and the energy required in patients with
persistent AF. Quinidine prevented immediate recurrence in
25 cases, whereas recurrence developed in 7 of 25 controls
(698). When quinidine (600 to 800 mg 3 times daily for 2 d)
failed to convert the rhythm, there was no difference in
defibrillation threshold between patients randomized to con-
tinue or withdraw the drug (617).
8.2.6.5. Type IC Antiarrhythmic Agents
In-hospital treatment with oral propafenone started 2 d
before direct-current cardioversion decreases early recur-
rence of AF after shock, thus allowing more patients to be
discharged from the hospital with sinus rhythm. Compared
with placebo, propafenone did not influence either the
mean defibrillation threshold or the rate of conversion
(shock efficacy 84% vs. 82%, respectively) but suppressed
immediate recurrences (within 10 min), and 74% versus
53% of patients were in sinus rhythm after 2 d (522). In
patients with persistent AF, pretreatment with intravenous
flecainide had no significant effect on the success of
direct-current cardioversion (717).
8.2.6.6. Type III Antiarrhythmic Agents
Controlled studies are needed to determine the most
effective treatment of immediate and subacute recurrences
of AF. Type III antiarrhythmic drugs may suppress sub-
acute recurrences less effectively than late recurrences of
AF (Table 23). Available data suggest that starting phar-
macological therapy and establishing therapeutic plasma
drug concentrations before direct-current cardioversion
enhance immediate success and suppress early recur-
rences. After cardioversion to sinus rhythm, patients re-
ceiving drugs that prolong the QT interval should be
monitored in the hospital for 24 to 48 h to evaluate the
effects of heart rate slowing and allow for prompt inter-
vention in the event torsades de pointes develops.
In randomized studies of direct-current cardioversion, pa-
tients pretreated with ibutilide were more often converted to
sinus rhythm than untreated controls, and those in whom
cardioversion initially failed could more often be converted
when the procedure was repeated after treatment with ibuti-
lide (556,718). Ibutilide was more effective than verapamil in
preventing immediate recurrence of AF (705).
8.2.7. Prevention of Thromboembolism in Patients With
Atrial Fibrillation Undergoing Cardioversion
RECOMMENDATIONS
Class I
1. For patients with AF of 48-h duration or longer, or
when the duration of AF is unknown, anticoagula-
tion (INR 2.0 to 3.0) is recommended for at least 3
wk prior to and 4 wk after cardioversion, regardless
of the method (electrical or pharmacological) used to
restore sinus rhythm. (Level of Evidence: B)
2. For patients with AF of more than 48-h duration
requiring immediate cardioversion because of hemo-
dynamic instability, heparin should be administered
concurrently (unless contraindicated) by an initial
intravenous bolus injection followed by a continuous
infusion in a dose adjusted to prolong the activated
partial thromboplastin time to 1.5 to 2 times the
reference control value. Thereafter, oral anticoagu-
lation (INR 2.0 to 3.0) should be provided for at least
4 wk, as for patients undergoing elective cardiover-
sion. Limited data support subcutaneous adminis-
tration of low-molecular-weight heparin in this indi-
cation. (Level of Evidence: C)
3. For patients with AF of less than 48-h duration
associated with hemodynamic instability (angina
pectoris, MI, shock, or pulmonary edema), cardio-
version should be performed immediately without
delay for prior initiation of anticoagulation. (Level of
Evidence: C)
Class IIa
1. During the first 48 h after onset of AF, the need for
anticoagulation before and after cardioversion may
be based on the patient’s risk of thromboembolism.
(Level of Evidence: C)
2. As an alternative to anticoagulation prior to cardio-
version of AF, it is reasonable to perform TEE in
search of thrombus in the LA or LAA. (Level of
Evidence: B)
2a. For patients with no identifiable thrombus, car-
dioversion is reasonable immediately after anti-
coagulation with unfractionated heparin (e.g.,
initiate by intravenous bolus injection and an
infusion continued at a dose adjusted to prolong
the activated partial thromboplastin time to 1.5
to 2 times the control value until oral anticoag-
ulation has been established with a vitamin K
antagonist (e.g., warfarin), as evidenced by an
INR equal to or greater than 2.0.). (Level of
Evidence: B)
Thereafter, oral anticoagulation (INR 2.0 to
3.0) is reasonable for a total anticoagulation
period of at least 4 wk, as for patients undergo-
ing elective cardioversion. (Level of Evidence: B)
Limited data are available to support the
subcutaneous administration of a low-
molecular-weight heparin in this indication.
(Level of Evidence: C)
2b. For patients in whom thrombus is identified by
TEE, oral anticoagulation (INR 2.0 to 3.0) is
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reasonable for at least 3 wk prior to and 4 wk
after restoration of sinus rhythm, and a longer
period of anticoagulation may be appropriate
even after apparently successful cardioversion,
because the risk of thromboembolism often re-
mains elevated in such cases. (Level of Evidence: C)
3. For patients with atrial flutter undergoing cardio-
version, anticoagulation can be beneficial accord-
ing to the recommendations as for patients with
AF. (Level of Evidence: C)
Randomized studies of antithrombotic therapy are lacking for
patients undergoing cardioversion of AF or atrial flutter, but in
case-control series, the risk of thromboembolism was between
1% and 5% (689,719). The risk was near the low end of this
spectrum when anticoagulation (INR 2.0 to 3.0) was given for 3
to 4 wk before and after conversion (54,181,695). It is now
common practice to administer anticoagulant drugs when pre-
paring patients with AF of more than 2-d duration for cardio-
version. Manning et al (304) suggested that TEE might be used
to identify patients without LAA thrombus who do not require
anticoagulation, but a subsequent investigation (324) and meta-
analysis found this approach to be unreliable (720).
If most AF-associated strokes result from embolism of
stasis-induced thrombus from the LAA, then restoration and
maintenance of atrial contraction should logically reduce
thromboembolic risk. LV function can also improve after
cardioversion (721), potentially lowering embolic risk and
improving cerebral hemodynamics (722). There is no evi-
dence, however, that cardioversion followed by prolonged
maintenance of sinus rhythm effectively reduces thromboem-
bolism in AF patients. Conversion of AF to sinus rhythm
results in transient mechanical dysfunction of the LA and
LAA (417) known as “stunning,” which can occur after
spontaneous, pharmacological (723,724), or electrical (724–
726) conversion of AF or after radiofrequency catheter
ablation of atrial flutter (226) and which may be associated
with SEC (417). Recovery of mechanical function may be
delayed for several weeks, depending in part on the duration
of AF before conversion (191,727,728). This could explain
why some patients without demonstrable LA thrombus on
TEE before cardioversion subsequently experience thrombo-
embolic events (324). Presumably, thrombus forms during
the period of stunning and is expelled after the return of
mechanical function, explaining the clustering of thrombo-
embolic events during the first 10 d after cardioversion (212).
Patients with AF or atrial flutter in whom LAA thrombus
is identified by TEE are at high risk of thromboembolism and
should be anticoagulated for at least 3 wk prior to and 4 wk
after pharmacological or direct-current cardioversion. In a
multicenter study, 1222 patients with either AF persisting
longer than 2 d or atrial flutter and previous AF (729) were
randomized to a TEE-guided or conventional strategy. In the
group undergoing TEE, cardioversion was postponed when
thrombus was identified, and warfarin was administered for 3
wk before TEE was repeated to confirm resolution of throm-
bus. Anticoagulation with heparin was used briefly before
cardioversion and with warfarin for 4 wk after cardioversion.
The other group received anticoagulation for 3 wk before and
4 wk after cardioversion without intercurrent TEE. Both
approaches were associated with comparably low risks of
stroke (0.81% with the TEE approach and 0.50% with the
conventional approach) after 8 wk, there were no differences
in the proportion of patients achieving successful cardiover-
sion, and the risk of major bleeding did not differ signifi-
cantly. The clinical benefit of the TEE-guided approach was
limited to saving time before cardioversion.
Anticoagulation is recommended for 3 wk prior to and 4
wk after cardioversion for patients with AF of unknown
duration or with AF for more than 48 h. Although LA
thrombus and systemic embolism have been documented in
patients with AF of shorter duration, the need for anticoagu-
lation is less clear. When acute AF produces hemodynamic
instability in the form of angina pectoris, MI, shock, or
pulmonary edema, immediate cardioversion should not be
delayed to deliver therapeutic anticoagulation, but intrave-
nous unfractionated heparin or subcutaneous injection of a
low-molecular-weight heparin should be initiated before car-
dioversion by direct-current countershock or intravenous
antiarrhythmic medication.
Protection against late embolism may require continuation of
anticoagulation for a more extended period after the procedure,
and the duration of anticoagulation after cardioversion depends
both on the likelihood that AF will recur in an individual patient
with or without symptoms and on the intrinsic risk of thrombo-
embolism. Late events are probably due to both the development
of thrombus as a consequence of atrial stunning and the delayed
recovery of atrial contraction after cardioversion. Pooled data
from 32 studies of cardioversion of AF or atrial flutter suggest
that 98% of clinical thromboembolic events occur within 10 d
(212). These data, not yet verified by prospective studies,
support administration of an anticoagulant for at least 4 wk after
cardioversion, and continuation of anticoagulation for a consid-
erably longer period may be warranted even after apparently
successful cardioversion.
Stroke or systemic embolism has been reported in patients
with atrial flutter undergoing cardioversion, (730–732) and
anticoagulation should be considered with either the conven-
tional or TEE-guided strategy. TEE-guided cardioversion of
atrial flutter has been performed with a low rate of systemic
embolism, particularly when patients are stratified for other risk
factors on the basis of clinical and/or TEE features (600,733).
8.3. Maintenance of Sinus Rhythm
RECOMMENDATIONS
Class I
Before initiating antiarrhythmic drug therapy, treat-
ment of precipitating or reversible causes of AF is
recommended. (Level of Evidence: C)
Class IIa
1. Pharmacological therapy can be useful in patients
with AF to maintain sinus rhythm and prevent
tachycardia-induced cardiomyopathy. (Level of Evi-
dence: C)
2. Infrequent, well-tolerated recurrence of AF is rea-
sonable as a successful outcome of antiarrhythmic
drug therapy. (Level of Evidence: C)
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3. Outpatient initiation of antiarrhythmic drug ther-
apy is reasonable in patients with AF who have no
associated heart disease when the agent is well
tolerated. (Level of Evidence: C)
4. In patients with lone AF without structural heart
disease, initiation of propafenone or flecainide can
be beneficial on an outpatient basis in patients with
paroxysmal AF who are in sinus rhythm at the time
of drug initiation. (Level of Evidence: B)
5. Sotalol can be beneficial in outpatients in sinus
rhythm with little or no heart disease, prone to
paroxysmal AF, if the baseline uncorrected QT
interval is less than 460 ms, serum electrolytes are
normal, and risk factors associated with class III
drug–related proarrhythmia are not present. (Level
of Evidence: C)
6. Catheter ablation is a reasonable alternative to
pharmacological therapy to prevent recurrent AF in
symptomatic patients with little or no LA enlarge-
ment. (Level of Evidence: C)
Class III
1. Antiarrhythmic therapy with a particular drug is
not recommended for maintenance of sinus rhythm
in patients with AF who have well-defined risk
factors for proarrhythmia with that agent. (Level of
Evidence: A)
2. Pharmacological therapy is not recommended for
maintenance of sinus rhythm in patients with ad-
vanced sinus node disease or AV node dysfunction
unless they have a functioning electronic cardiac
pacemaker. (Level of Evidence: C)
8.3.1. Pharmacological Therapy
8.3.1.1. Goals of Treatment
Whether paroxysmal or persistent, AF is a chronic disorder,
and recurrence at some point is likely in most patients
(704,734,735) (see Fig. 13). Many patients eventually need
prophylactic antiarrhythmic drug therapy to maintain sinus
rhythm, suppress symptoms, improve exercise capacity and
hemodynamic function, and prevent tachycardia-induced car-
diomyopathy due to AF. Because factors that predispose to
recurrent AF (advanced age, HF, hypertension, LA enlarge-
ment, and LV dysfunction) are risk factors for thromboem-
bolism, the risk of stroke may not be reduced by correction of
the rhythm disturbance. It is not known whether maintenance
of sinus rhythm prevents thromboembolism, HF, or death in
patients with a history of AF (736,737). Trials in which rate-
versus rhythm-control strategies were compared in patients
with persistent and paroxysmal AF (293,294,296,343,344)
found no reduction in death, disabling stroke, hospitaliza-
tions, new arrhythmias, or thromboembolic complications in
the rhythm-control group (296). Pharmacological mainte-
nance of sinus rhythm may reduce morbidity in patients with
HF (501,738), but one observational study demonstrated that
serial cardioversion in those with persistent AF did not avoid
complications (739). Pharmacological therapy to maintain
sinus rhythm is indicated in patients who have troublesome
symptoms related to paroxysmal AF or recurrent AF after
cardioversion who can tolerate antiarrhythmic drugs and have
a good chance of remaining in sinus rhythm over an extended
period (e.g., young patients without organic heart disease or
hypertension, a short duration of AF, and normal LA size)
(293,740). When antiarrhythmic medication does not result in
symptomatic improvement or causes adverse effects, how-
ever, it should be abandoned.
8.3.1.2. Endpoints in Antiarrhythmic Drug Studies
Various antiarrhythmic drugs have been investigated for
maintenance of sinus rhythm in patients with AF. The number
and quality of studies with each drug are limited; endpoints
vary, and few studies meet current standards of good clinical
practice. The arrhythmia burden and quality of life have not
been assessed consistently. In studies of patients with parox-
ysmal AF, the time to first recurrence, number of recurrences
over a specified interval, proportion of patients without
recurrence during follow-up, and combinations of these data
have been reported. The proportion of patients in sinus
rhythm during follow-up is a less useful endpoint in studies of
paroxysmal rather than persistent AF. Most studies of persis-
tent AF involved antiarrhythmic drug therapy administered
before or after direct-current cardioversion. Because of clus-
tering of recurrences in the first few weeks after cardioversion
(697,713), the median time to first recurrence detected by
transtelephonic monitoring may not differ between 2 treat-
ment strategies. Furthermore, because recurrent AF tends to
persist, neither the interval between recurrences nor the
number of episodes in a given period represents a suitable
endpoint unless a serial cardioversion strategy is employed.
Given these factors, the appropriate endpoints for evaluation
of treatment efficacy in patients with paroxysmal and persis-
tent AF have little in common. This hampers comparative
evaluation of treatments aimed at maintenance of sinus
rhythm in cohorts containing patients with both patterns of
AF, and studies of mixed cohorts therefore do not contribute
heavily to these guidelines. The duration of follow-up varied
considerably among studies and was generally insufficient to
permit meaningful extrapolation to years of treatment in what
is often a lifelong cardiac rhythm disorder.
Recurrence of AF is not equivalent to treatment failure. In
several studies (594,598), patients with recurrent AF often
chose to continue antiarrhythmic treatment, perhaps because
episodes of AF became less frequent, briefer, or less symp-
tomatic. A reduction in arrhythmia burden may therefore
constitute therapeutic success for some patients, while to
others any recurrence of AF may seem intolerable. Assess-
ment based upon time to recurrence in patients with parox-
ysmal AF or upon the number of patients with persistent AF
who sustain sinus rhythm after cardioversion may overlook
potentially valuable treatment strategies. Available studies
are heterogeneous in other respects as well. The efficacy of
treatment for atrial flutter and AF is usually not reported
separately. Underlying heart disease or extracardiac disease is
present in 80% of patients with persistent AF, but this is not
always described in detail. It is often not clear when patients
first experienced AF or whether AF was persistent, and the
frequencies of previous AF episodes and cardioversions are
not uniformly described. Most controlled trials of antiarrhyth-
mic drugs included few patients at risk of drug-induced HF,
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proarrhythmia, or conduction disturbances, and this should be
kept in mind in applying the recommendations below.
The AFFIRM substudy investigators found that with AF
recurrence, if one is willing to cardiovert the rhythm and keep
the patient on the same antiarrhythmic drug, or cardiovert the
rhythm and treat the patient with a different antiarrhythmic
drug, about 80% of all patients will be in sinus rhythm by the
end of 1 y (570).
8.3.1.3. Predictors of Recurrent AF
Most patients with AF, except those with postoperative or
self-limited AF secondary to transient or acute illness, even-
tually experience recurrence. Risk factors for frequent recur-
rence of paroxysmal AF (more than 1 episode per month)
include female gender and underlying heart disease (741). In
one study of patients with persistent AF, the 4-y arrhythmia-
free survival rate was less than 10% after single-shock
direct-current cardioversion without prophylactic drug ther-
apy (735). Predictors of recurrences within that interval
included hypertension, age over 55 y, and AF duration longer
than 3 mo. Serial cardioversions and prophylactic drug
therapy resulted in freedom from recurrent AF in approxi-
mately 30% of patients (735), and with this approach predic-
tors of recurrence included age over 70 y, AF duration
beyond 3 mo, and HF (735). Other risk factors for recurrent
AF include LA enlargement and rheumatic heart disease.
8.3.2. General Approach to Antiarrhythmic Drug Therapy
Before administering any antiarrhythmic agent, reversible
precipitants of AF should be identified and corrected. Most
are related to coronary or valvular heart disease, hyperten-
sion, or HF. Patients who develop HF in association with
alcohol intake should abstain from alcohol consumption.
Indefinite antiarrhythmic treatment is seldom prescribed after
a first episode, although a period of several weeks may help
stabilize sinus rhythm after cardioversion. Similarly, patients
experiencing breakthrough arrhythmias may not require a
change in antiarrhythmic drug therapy when recurrences are
infrequent and mild. Beta-adrenergic antagonist medication
may be effective in patients who develop AF only during
exercise, but a single, specific inciting cause rarely accounts
for all episodes of AF, and the majority of patients do not
sustain sinus rhythm without antiarrhythmic therapy. Selec-
tion of an appropriate agent is based first on safety, tailored to
whatever underlying heart disease may be present, consider-
ing the number and pattern of prior episodes of AF (742).
In patients with lone AF, a beta blocker may be tried first,
but flecainide, propafenone, and sotalol are particularly ef-
fective. Amiodarone and dofetilide are recommended as
alternative therapies. Quinidine, procainamide, and disopyr-
amide are not favored unless amiodarone fails or is contra-
indicated. For patients with vagally induced AF, however, the
anticholinergic activity of long-acting disopyramide makes it
a relatively attractive theoretical choice. In that situation,
flecainide and amiodarone represent secondary and tertiary
treatment options, respectively, whereas propafenone is not
recommended because its (weak) intrinsic beta-blocking ac-
tivity may aggravate vagally mediated paroxysmal AF. In
patients with adrenergically mediated AF, beta blockers
represent first-line treatment, followed by sotalol and amiod-
arone. In patients with adrenergically mediated lone AF,
amiodarone represents a less appealing selection. Vagally
induced AF can occur by itself, but more typically it is part of
the overall patient profile. In patients with nocturnal AF, the
possibility of sleep apnea should be considered (see Fig. 15).
When treatment with a single antiarrhythmic drug fails,
combinations may be tried. Useful combinations include a
beta blocker, sotalol, or amiodarone with a class IC agent.
The combination of a calcium channel blocker, such as
diltiazem, with a class IC agent, such as flecainide or
propafenone, is advantageous in some patients. A drug that is
initially safe may become proarrhythmic if coronary disease
or HF develops or if the patient begins other medication that
exerts a proarrhythmic interaction. Thus, the patient should
be alerted to the potential significance of such symptoms as
syncope, angina, or dyspnea and warned about the use of
noncardiac drugs that might prolong the QT interval. A useful
source of information on this topic is the Internet site
http://www.torsades.org.
The optimum method for monitoring antiarrhythmic drug
treatment varies with the agent involved as well as with
patient factors. Prospectively acquired data on upper limits of
drug-induced prolongation of QRS duration or QT interval
are not available. Given recommendations represent the
consensus of the writing committee. With class IC drugs,
prolongation of the QRS interval should not exceed 50%.
Exercise testing may help detect QRS widening that occurs
only at rapid heart rates (use-dependent conduction slowing).
For class IA or class III drugs, with the possible exception of
amiodarone, the corrected QT interval in sinus rhythm should
be kept below 520 ms. During follow-up, plasma potassium
and magnesium levels and renal function should be checked
periodically because renal insufficiency leads to drug accu-
mulation and predisposes to proarrhythmia. In individual
patients, serial noninvasive assessment of LV function is
indicated, especially when clinical HF develops during treat-
ment of AF.
8.3.3. Selection of Antiarrhythmic Agents in Patients With
Cardiac Diseases
Pharmacological management algorithms to maintain sinus
rhythm in patients with AF (see Figs. 13, 14, 15, and 16) and
applications in specific cardiac disease states are based on
available evidence and extrapolated from experience with
these agents in other situations.
8.3.3.1. Heart Failure
Patients with HF are particularly prone to the ventricular
proarrhythmic effects of antiarrhythmic drugs because of
myocardial vulnerability and electrolyte imbalance. Random-
ized trials have demonstrated the safety of amiodarone and
dofetilide (given separately) in patients with HF (501,743),
and these are the recommended drugs for maintenance of
sinus rhythm in patients with AF in the presence of HF.
In a subgroup analysis of data from the Congestive Heart
Failure Survival Trial of Antiarrhythmic Therapy (CHF-
STAT) study (738), amiodarone reduced the incidence of AF
over 4 y in patients with HF to 4% compared with 8% with
placebo. Conversion to sinus rhythm occurred in 31% of
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patients on amiodarone versus 8% with placebo and was
associated with significantly better survival.
The Danish Investigations of Arrhythmias and Mortality
on Dofetilide in Heart Failure (DIAMOND-CHF) trial ran-
domized 1518 patients with symptomatic HF. In a substudy
of 506 patients with HF and AF or atrial flutter (501,588),
dofetilide (0.5 mg twice daily initiated in hospital) increased
the probability of sinus rhythm after 1 y to 79% compared
with 42% with placebo. In the dofetilide group, 44% of
patients with AF converted to sinus rhythm compared with
39% in the placebo group. Dofetilide had no effect on
mortality, but the combined endpoint of all-cause mortality
and HF hospitalization was lower in the treated group than
with placebo (501,588). Torsades de pointes developed in 25
patients treated with dofetilide (3.3%), and three-quarters of
these events occurred within the first 3 d of treatment.
Patients with LV dysfunction and persistent AF should be
treated with beta blockers and ACE inhibitors and/or angiotensin
II receptor antagonists, because these agents help control the
heart rate, improve ventricular function, and prolong survival
(744–747). In patients with HF or LV dysfunction post-MI,
ACE inhibitor therapy reduced the incidence of AF
(36,748,749). In a retrospective analysis of patients with LV
dysfunction in the SOLVD trials (38), enalapril reduced the
incidence of AF by 78% relative to placebo. In the CHARM and
Val-HeFT studies, angiotensin II receptor antagonists given in
combination with ACE inhibitors were superior to ACE inhib-
itors alone for prevention of AF. A post hoc analysis of the
Cardiac Insufficiency Bisoprolol Study (CIBIS II), however,
found no impact of bisoprolol on survival or hospitalization for
HF in patients with AF (750). In the Carvedilol Post-Infarct
Survival Control in Left Ventricular Dysfunction (CAPRI-
CORN) (751) and Carvedilol Prospective Randomized Cumu-
lative Survival (COPERNICUS) trials (752), AF and atrial
flutter were more common in the placebo groups than in patients
treated with carvedilol. Retrospective analysis of patients in the
U.S. Carvedilol Heart Failure Trial program with AF compli-
cating HF (753) suggested that carvedilol improved LV ejection
fraction. In a study by Khand et al (754), the combination of
carvedilol and digoxin reduced symptoms, improved ventricular
function, and improved ventricular rate control compared with
either agent alone.
8.3.3.2. Coronary Artery Disease
In stable patients with CAD, beta blockers may be considered
first, although their use is supported by only 2 studies
(583,587) and data on efficacy for maintenance of sinus
rhythm in patients with persistent AF after cardioversion are
not convincing (583). When antiarrhythmic therapy beyond
beta blockers is needed for control of AF in survivors of acute
MI, several randomized trials have demonstrated that sotalol,
(755) amiodarone (756,757), dofetilide (758), and azimilide
(651) have neutral effects on survival. Sotalol has substantial
beta-blocking activity and may be the preferred initial anti-
arrhythmic agent in patients with AF who have ischemic
heart disease, because it is associated with less long-term
toxicity than amiodarone. Amiodarone increases the risk of
bradyarrhythmia requiring permanent pacemaker implanta-
tion in elderly patients with AF who have previously sus-
tained MI (759) but may be preferred over sotalol in patients
with HF (755–757). Neither flecainide nor propafenone is
recommended in these situations, but quinidine, procain-
amide, and disopyramide may be considered as third-line
choices in patients with coronary disease. The Danish Inves-
tigations of Arrhythmias and Mortality on Dofetilide in
Myocardial Infarction (DIAMOND-MI) trial (758) involved
selected post-MI patients in whom the antiarrhythmic benefit
of dofetilide balanced the risk of proarrhythmic toxicity,
making this a second-line antiarrhythmic agent. In patients
with coronary disease who have not developed MI or HF,
however, it is uncertain whether the benefit of dofetilide
outweighs risk, and more experience is needed before this
drug can be recommended even as a second-line agent in such
patients.
8.3.3.3. Hypertensive Heart Disease
Hypertension is the most prevalent and potentially modifiable
independent risk factor for the development of AF and its
complications, including thromboembolism (760,761). Blood
pressure control may become an opportune strategy for
prevention of AF. Patients with LVH may face an increased
risk of torsades de pointes related to early ventricular after-
depolarizations (742,762,763). Thus, class IC agents and
amiodarone are preferred over type IA and type III antiar-
rhythmic agents as first-line therapy. In the absence of
ischemia or LVH, propafenone or flecainide is a reasonable
choice. Proarrhythmia with one agent does not predict this
response to another, and patients with LVH who develop
torsades de pointes during treatment with a class III agent
may tolerate a class IC agent. Amiodarone prolongs the QT
interval but carries a very low risk of ventricular proarrhyth-
mia. Its extracardiac toxicity relegates it to second-line
therapy in these individuals, but it becomes a first-line agent
in the face of substantial LVH. When amiodarone and sotalol
either fail or are inappropriate, disopyramide, quinidine, or
procainamide represents a reasonable alternative.
Beta blockers may be the first line of treatment to maintain
sinus rhythm in patients with MI, HF, and hypertension.
Compared with patients with lone AF, those with hyperten-
sion are more likely to maintain sinus rhythm after cardio-
version of persistent AF when treated with a beta blocker
(764). Drugs modulating the renin-angiotensin system reduce
structural cardiac changes (765), and ACE inhibition was
associated with a lower incidence of AF compared with
calcium channel blockade in patients with hypertension
during 4.5 y of follow-up in a retrospective, longitudinal
cohort study from a database of 8 million patients in a
managed care setting (42). In patients at increased risk of
cardiovascular events, therapy with either the ACE inhibitor
ramipril (766–768) or angiotensin receptor antagonist losar-
tan (769,770) lowered the risk of stroke. A similar benefit has
been reported with perindopril in a subset of patients with AF
treated for prevention of recurrent stroke (771). New-onset
AF and stroke were significantly reduced by losartan com-
pared with atenolol in hypertensive patients with ECG-
documented LVH, despite a similar reduction of blood
pressure (41). The benefit of losartan was greater in patients
with AF than those with sinus rhythm for the primary
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composite endpoint (cardiovascular mortality, stroke, and
MI) and for cardiovascular mortality alone (772). Presum-
ably, the beneficial effects of beta blockers and drugs mod-
ulating the renin-angiotensin system are at least partly related
to lower blood pressure.
8.3.4. Nonpharmacological Therapy for Atrial Fibrillation
The inconsistent efficacy and potential toxicity of antiar-
rhythmic drug therapies have stimulated exploration of a
wide spectrum of alternative nonpharmacological therapies
for the prevention and control of AF.
8.3.4.1. Surgical Ablation
Over the past 25 y, surgery has contributed to understanding of
both the anatomy and electrophysiology of commonly encoun-
tered arrhythmias, including the WPW syndrome, AV nodal
reentry, ventricular tachycardia, and atrial tachycardia. A decade
of research in the 1980s demonstrated the critical elements
necessary to cure AF surgically, including techniques that
entirely eliminate macroreentrant circuits in the atria while
preserving sinus node and atrial transport functions. The surgical
approach was based on the hypothesis that reentry is the
predominant mechanism responsible for the development and
maintenance of AF (773), leading to the concept that atrial
incisions at critical locations would create barriers to conduction
and prevent sustained AF. The procedure developed to accom-
plish these goals was based on the concept of a geographical
maze, accounting for the term “maze” procedure used to
describe this type of cardiac operation (774).
Since its introduction, the procedure has gone through 3
iterations (maze I, II, and III) using cut-and-sew techniques that
ensure transmural lesions to isolate the PV, connect these
dividing lines to the mitral valve annulus, and create electrical
barriers in the RA that prevent macroentrant rhythms—atrial
flutter or AF—from becoming sustained (775). Success rates of
around 95% over 15 y of follow-up have been reported in
patients undergoing mitral valve surgery (776). Other studies
suggest success rates around 70% (777). Atrial transport func-
tion is maintained and, when combined with amputation or
obliteration of the LAA, postoperative thromboembolic events
are substantially reduced. Risks include death (less than 1%
when performed as an isolated procedure), the need for perma-
nent pacing (with right-sided lesions), recurrent bleeding requir-
ing reoperation, impaired atrial transport function, delayed atrial
arrhythmias (especially atrial flutter), and atrioesophageal
fistula.
Variations of the maze procedure have been investigated at
several centers to determine the lesion sets necessary for
success. Studies in patients with persistent AF have demon-
strated the importance of complete lesions that extend to the
mitral valve annulus; electrical isolation of the PV alone is
associated with a lower success rate. Bipolar radiofrequency
(778), cryoablation, and microwave energy have been used as
alternatives to the “cut-and-sew” technique. In one study,
maintenance of sinus rhythm following the maze procedure in
patients with AF was associated with improvement in some
aspects of quality of life (348).
Despite its high success rate, the maze operation has not been
widely adopted other than for patients undergoing cardiac
surgery because of the need for cardiopulmonary bypass. A wide
variety of less invasive modifications are under investigation,
including thoracoscopic and catheter-based epicardial tech-
niques (777). If the efficacy of these adaptations approaches that
of the endocardial maze procedure and they can be performed
safely, they may become acceptable alternatives for a larger
proportion of patients with AF.
8.3.4.2. Catheter Ablation
Early radiofrequency catheter ablation techniques emulated
the surgical maze procedure by introducing linear scars in the
atrial endocardium (779). While the success rate was approx-
imately 40% to 50%, a relatively high complication rate
diminished enthusiasm for this approach (105). The observa-
tion that potentials arising in or near the ostia of the PV often
provoked AF, and demonstration that elimination of these
foci abolished AF escalated enthusiasm for catheter-based
ablation (105). Initially, areas of automaticity within the PV
were targeted, and in a series of 45 patients with paroxysmal
AF, 62% became free of symptomatic AF over a mean
follow-up of 8 mo, but 70% required multiple procedures
(105). In another study, the success rate was 86% over a 6-mo
follow-up (780). Subsequent research has demonstrated that
potentials may arise in multiple regions of the RA and LA,
including the LA posterior wall, superior vena cava, vein of
Marshall, crista terminalis, interatrial septum, and coronary
sinus, (109) and modification of the procedures has incorpo-
rated linear LA ablation, mitral isthmus ablation, or both for
selected patients (781).
The technique of ablation has continued to evolve from
early attempts to target individual ectopic foci within the PV
to circumferential electrical isolation of the entire PV mus-
culature. In a series of 70 patients, 73% were free from AF
following PV isolation without antiarrhythmic medications
during a mean follow-up of 4 mo, but 29 patients required a
second procedure to reach this goal. However, postablation
AF may occur transiently in the first 2 mo (782). Advances
involving isolation of the PV at the antrum using a circular
mapping catheter, guided by intracardiac echocardiography,
have reportedly yielded approximately 80% freedom of
recurrent AF or atrial flutter after the first 2 mo in patients
with paroxysmal AF (783), but success rates were lower in
patients with cardiac dysfunction (784). Still another ap-
proach (785,786) uses a nonfluoroscopic guidance system
and radiofrequency energy delivered circumferentially out-
side the ostia of the PV. In a series of 26 patients, 85% were
free of recurrent AF during a mean follow-up of 9 mo,
including 62% taking no antiarrhythmic medications. The
accumulated experience involves nearly 4000 patients (786),
with approximately 90% success in cases of paroxysmal AF
and 80% in cases of persistent AF (784,787,788). Another
anatomic approach to radiofrequency catheter ablation targets
complex fractionated electrograms (789), with 91% efficacy
reported at 1 y. Restoration of sinus rhythm after catheter
ablation for AF significantly improved LV function, exercise
capacity, symptoms, and quality of life (usually within the
first 3 to 6 mo), even in the presence of concurrent heart
disease and when ventricular rate control was adequate before
ablation (790). While that study lacked a control group of
patients with HF, in another study catheter ablation of AF was
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associated with reduced mortality and morbidity due to HF
and thromboembolism (791).
In selected patients, radiofrequency catheter ablation of the
AV node and pacemaker insertion decreased symptoms of AF
and improved quality-of-life scores compared with medication
therapy (363,387,388,792–794). Baseline quality-of-life scores
are generally lower for patients with AF or atrial flutter than for
those undergoing ablation for other arrhythmias (795). A meta-
analysis of 10 studies of patients with AF (389) found improve-
ment in both symptoms and quality-of-life scores after ablation
and pacing. Although these studies involved selected patients
who remained in AF, the consistent improvement suggests that
quality of life was impaired before intervention. Two studies
have described improvement in symptoms and quality of life
after radiofrequency catheter ablation of atrial flutter (796,797).
New studies comparing strict versus lenient rate control are
under way to investigate this issue further.
Despite these advances, the long-term efficacy of catheter
ablation to prevent recurrent AF requires further study. Avail-
able data demonstrate 1 y or more free from recurrent AF in
most (albeit carefully selected) patients (798–800). It is impor-
tant to bear in mind, however, that AF can recur without
symptoms and be unrecognized by the patient or the physician.
Therefore, it remains uncertain whether apparent cures represent
elimination of AF or transformation into an asymptomatic form
of paroxysmal AF. The distinction has important implications
for the duration of anticoagulation therapy in patients with risk
factors for stroke associated with AF. In addition, little informa-
tion is yet available about the late success of ablation in patients
with HF and other advanced structural heart disease, who may
be less likely to enjoy freedom from AF recurrence.
8.3.4.2.1. COMPLICATIONS OF CATHETER-BASED ABLATION.
Complications of catheter ablation include the adverse events
associated with any cardiac catheterization procedure in addition
to those specific to ablation of AF. Major complications have
been reported in about 6% of procedures and include PV
stenosis, thromboembolism, atrioesophageal fistula, and LA
flutter (788). The initial ablation approach targeting PV ectopy
was associated with an unacceptably high rate of PV stenosis
(780,801), but the incidence has dramatically decreased as a
result of changes in technique. Current approaches avoid deliv-
ering radiofrequency energy within the PV and instead target
areas outside the veins to isolate the ostia from the remainder of
the LA conducting tissue. Use of intracardiac echocardiograph-
ically detected microbubble formation to titrate radiofrequency
energy has also been reported to reduce the incidence of PV
stenosis (783).
Embolic stroke is among the most serious complications of
catheter-based ablation procedures in patients with AF. The
incidence varies from 0% to 5%. A higher intensity of
anticoagulation reduces the risk of thrombus formation dur-
ing ablation (802). A comparison of 2 heparin dosing regi-
mens found LA thrombus in 11.2% of patients when the
activated clotting time (ACT) was 250 to 300 s compared
with 2.8% when the ACT was kept greater than 300 s. Based
on these observations, it seems likely that more aggressive
anticoagulation may reduce the incidence of thromboembo-
lism associated with catheter-based ablation of AF.
Atrioesophageal fistula has been reported with both the
circumferential Pappone approach (803,804) and the Hais-
saguerre PV ablation techniques (804) but is relatively rare.
This complication may be more likely to occur when exten-
sive ablative lesions are applied to the posterior LA wall,
increasing the risk of atrial perforation. The typical manifes-
tations include sudden neurological symptoms or endocardi-
tis, and the outcome in most cases is, unfortunately, fatal.
Depending on the ablation approach, LA flutter may
develop during treatment of AF (805), and this is typically
related to scars created during catheter ablation. An incom-
plete line of ablation is an important predictor of postproce-
dural LA flutter, and extending the ablation line to the mitral
annulus may reduce the frequency of this complication. In
most cases, LA flutter is amenable to further ablation (806).
8.3.4.2.2. FUTURE DIRECTIONS IN CATHETER-BASED ABLATION
THERAPY FOR ATRIAL FIBRILLATION. Catheter-directed ablation
of AF represents a substantial achievement that promises
better therapy for a large number of patients presently
resistant to pharmacological or electrical conversion to sinus
rhythm. The limited available studies suggest that catheter-
based ablation offers benefit to selected patients with AF, but
these studies do not provide convincing evidence of optimum
catheter positioning or absolute rates of treatment success.
Identification of patients who might benefit from ablation
must take into account both potential benefits and short- and
long-term risks. Rates of success and complications vary,
sometimes considerably, from one study to another because
of patient factors, patterns of AF, criteria for definition of
success, duration of follow-up, and technical aspects. Regis-
tries of consecutive case series should incorporate clear and
prospectively defined outcome variables. Double-blind stud-
ies are almost impossible to perform, yet there is a need for
randomized trials in which evaluation of outcomes is blinded
as to treatment modality. A comprehensive evaluation of the
favorable and adverse effects of various ablation techniques
should include measures of quality of life and recurrence
rates compared with pharmacological strategies for rhythm
control and, when this is not successful, with such techniques
of rate control as AV node ablation and pacing. Generation of
these comparative data over relatively long periods of obser-
vation would address the array of invasive and conservative
management approaches available for management of pa-
tients with AF and provide a valuable foundation for future
practice guidelines.
8.3.4.3. Suppression of Atrial Fibrillation Through Pacing
Several studies have examined the role of atrial pacing, either
in the RA alone or in more than one atrial location, to prevent
recurrent paroxysmal AF. In patients with symptomatic
bradycardia, the risk of AF is lower with atrial than with
ventricular pacing (807). In patients with sinus node dysfunc-
tion and normal AV conduction, data from several random-
ized trials support atrial or dual-chamber rather than ventric-
ular pacing for prevention of AF (808 – 811). The
mechanisms by which atrial pacing prevents AF in patients
with sinus node dysfunction include prevention of
bradycardia-induced dispersion of repolarization and sup-
pression of atrial premature beats. Atrial or dual-chamber
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pacing also maintains AV synchrony, preventing retrograde
ventriculoatrial conduction that can cause valvular regurgita-
tion and stretch-induced changes in atrial electrophysiology.
When ventricular pacing with dual-chamber devices is un-
avoidable because of concomitant disease of the AV conduc-
tion system, the evidence is less clear that atrial-based pacing
is superior.
While atrial pacing is effective in preventing development
of AF in patients with symptomatic bradycardia, its utility as
a treatment for paroxysmal AF in patients without conven-
tional indications for pacing has not been proved (812). In the
Atrial Pacing Peri-Ablation for the Prevention of AF (PA3)
study, patients under consideration for AV junction ablation
received dual-chamber pacemakers and were randomized to
atrial pacing versus no pacing. There was no difference in
time to first occurrence of AF or total AF burden (812). In a
continuation of this study comparing atrial pacing with AV
synchronous pacing, patients were randomized to DDDR
versus VDD node pacing after ablation of the AV junction.
Once again, there was no difference in time to first recurrence
of AF or AF burden, and 42% of the patients lapsed into
permanent AF by the end of 1 y (813).
It has been suggested that the incidence of AF may be
lower with atrial septal pacing or multisite atrial pacing than
with pacing in the RA appendage (814). Pacing at right
interatrial septal sites results in preferential conduction to the
LA via Bachmann’s bundle. Pacing from this site shortens
P-wave duration and interatrial conduction time. Clinical
trials of pacing in the interatrial septum to prevent episodes of
paroxysmal AF have yielded mixed results (815–817). While
2 small randomized trials found that atrial septal pacing
reduced the number of episodes of paroxysmal AF and the
incidence of persistent AF at 1 y compared with RA append-
age pacing (815,816), a larger trial showed no effect on AF
burden despite reduction in symptomatic AF (817).
Both bi-atrial (RA appendage and either the proximal or
distal coronary sinus) and dual-site (usually RA appendage
and coronary sinus ostium) pacing have been studied as
means of preventing AF. A small trial of biatrial pacing to
prevent recurrent AF found no benefit compared with con-
ventional RA pacing (818), and a larger trial revealed no
benefit from dual-site compared with single-site pacing,
except in certain subgroups (819). The greater complexity
and more extensive apparatus required have limited the
appeal of dual-site pacing.
Several algorithms have been developed to increase the
percentage of atrial pacing time to suppress atrial premature
beats, prevent atrial pauses, and decrease atrial cycle length
variation in the hope of preventing AF. Prospective studies of
devices that incorporate these algorithms have yielded mixed
results. In one large trial, these pacemaker algorithms de-
creased symptomatic AF burden, but the absolute difference
was small, and there was no gain in terms of quality of life,
mean number of AF episodes, hospitalizations, or mean
duration of AF detected by the pacemaker’s automatic mode-
switching algorithm (820). Other trials have failed to show
any benefit of atrial pacing in preventing AF (817,821).
In addition to pacing algorithms to prevent AF, some
devices are also capable of pacing for termination of AF.
While efficacy has been shown for termination of more
organized atrial tachyarrhythmias, there has been little dem-
onstrated effect on total AF burden (821,822).
In summary, atrial-based pacing is associated with a lower
risk of AF and stroke than ventricular-based pacing in
patients requiring pacemakers for bradyarrhythmias, but the
value of pacing as a primary therapy for prevention of
recurrent AF has not been proven.
8.3.4.4. Internal Atrial Defibrillators
In a sheep model of internal cardioversion of AF (354),
delivery of synchronous shocks between the high RA and
coronary sinus effectively terminated episodes of AF. A
clinical trial of a low-energy transvenous atrial cardioverter
that delivered a 3/3-ms biphasic waveform shock synchro-
nized to the R wave established the safety of internal atrial
cardioversion, but the energy required in patients with per-
sistent AF was relatively high (mean 3.5 J) (355). Intense
basic and clinical research to find more tolerable shock
waveforms led to evaluation of an implantable device capable
of both atrial sensing and cardioversion and ventricular
sensing and pacing in 290 patients with mean LV ejection
fraction greater than 50% who had not responded satisfacto-
rily to therapy with 4 antiarrhythmic drugs (355). In total, 614
episodes of AF were treated with 1497 shocks (mean 2.4
shocks per episode), and the rate of conversion to sinus
rhythm was 93%. As spontaneous episodes were treated
quickly, the interval between episodes of AF lengthened.
Several available devices combining both atrial cardiover-
sion and ventricular defibrillation capabilities with dual-
chamber sensing and pacing have been designed to treat both
atrial and ventricular arrhythmias by pacing before delivering
low- or high-energy shocks. A number of other techniques to
terminate AF by pacing are also under investigation, but
indications may be limited to atrial tachycardia and atrial
flutter. Because these units accurately record the occurrence
of AF, however, they provide valuable representation of AF
control.
An important limitation of atrial defibrillators, unrelated to
efficacy, is that most patients find discharge energies over 1 J
uncomfortable without sedation requiring a medical setting,
and the mean cardioversion threshold is approximately 3 J,
making such devices in their current form unacceptable for
wide clinical use. Optimal devices would use atrial pacing to
maintain sinus rhythm after cardioversion, and some patients
require additional therapy to avoid frequent paroxysms of AF.
Candidates for atrial cardioverters with infrequent episodes of
poorly tolerated AF are typically also candidates for catheter
ablation. As a result, implanted devices have limited utility,
except for patients with LV dysfunction who are candidates
for implantable ventricular defibrillators.
8.4. Special Considerations
8.4.1. Postoperative AF
RECOMMENDATIONS
Class I
1. Unless contraindicated, treatment with an oral beta
blocker to prevent postoperative AF is recom-
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mended for patients undergoing cardiac surgery.
(Level of Evidence: A)
2. Administration of AV nodal blocking agents is rec-
ommended to achieve rate control in patients who
develop postoperative AF. (Level of Evidence: B)
Class IIa
1. Preoperative administration of amiodarone reduces
the incidence of AF in patients undergoing cardiac
surgery and represents appropriate prophylactic
therapy for patients at high risk for postoperative
AF. (Level of Evidence: A)
2. It is reasonable to restore sinus rhythm by pharma-
cological cardioversion with ibutilide or direct-
current cardioversion in patients who develop post-
operative AF as advised for nonsurgical patients.
(Level of Evidence: B)
3. It is reasonable to administer antiarrhythmic medi-
cations in an attempt to maintain sinus rhythm in
patients with recurrent or refractory postoperative
AF, as recommended for other patients who develop
AF. (Level of Evidence: B)
4. It is reasonable to administer antithrombotic medi-
cation in patients who develop postoperative AF, as
recommended for nonsurgical patients. (Level of
Evidence: B)
Class IIb
Prophylactic administration of sotalol may be consid-
ered for patients at risk of developing AF following
cardiac surgery. (Level of Evidence: B)
Although AF may occur after noncardiac surgery, the inci-
dence of atrial arrhythmias including AF after open-heart
surgery is between 20% and 50% (823–825), depending on
definitions and methods of detection. The incidence of
postoperative AF is increasing, perhaps more because of the
age of surgical patients than because of technical factors, and
this is associated with increased morbidity and costs.
8.4.1.1. Clinical and Pathophysiological Correlates
Postoperative AF usually occurs within 5 d of open-heart
surgery, with a peak incidence on the second day. A number
of studies have examined the predictors of AF, cost impact,
length of hospital stay, and the effects of various prophylactic
interventions aimed at reducing the incidence of AF
(824,826–830), but many of these reflect earlier models of
patient management. In an observational study of 4657
patients undergoing coronary artery bypass graft (CABG)
surgery at 70 centers between 1996 and 2000, predictors of
AF included age, a history of AF, COPD, valvular heart
disease, atrial enlargement, perioperative HF, and withdrawal
of either beta blocker or ACE inhibitor medications before or
after surgery (831) (Table 24). Many patients have none of
these factors, however, and it is likely that the greater
collagen content of the atria in older patients or other factors
related to the biology of aging are responsible (825) for the
greater propensity of elderly patients to develop AF after
cardiac surgery (832) (Table 24). Other contributing factors
are pericarditis (826) and increased sympathetic tone. In a
review of 8051 consecutive patients without previously doc-
umented AF (mean 64 y, 67% males) undergoing cardiac
surgery (84% involving CABG only) between 1994 and
2004, there was a strong, independent association between
obesity (body mass index over 30.1 kg/m2) and the develop-
ment of postoperative AF. During the index hospitalization,
AF developed in 22.5% of all cases, and 52% of those over
age 85 y, compared with 6.2% of patients younger than 40 y.
Among the extremely obese, the relative risk of postoperative
AF was 2.39. “Off-pump” CABG was associated with 39%
lower likelihood of developing AF than conventional on-
pump surgery, and the risk of AF correlated with the duration
of cardiopulmonary bypass (833). The arrhythmia is usually
self-correcting, and sinus rhythm resumes in more than 90%
of patients by 6 to 8 wk after surgery (832), a rate of
spontaneous resolution higher than for other forms of AF.
Patients with postoperative AF have a higher inpatient mor-
tality than patients without this arrhythmia (4.7% vs. 2.1%)
and longer hospital stay (median difference 2 d) (831). In
another study, postoperative AF was an independent predictor
of long-term mortality (adjusted odds ratio [OR] 1.5, p less
than 0.001 in retrospective cohort, and OR 3.4, p  0.0018 in
a case-control analysis) over 4 to 5 y (834).
8.4.1.2. Prevention of Postoperative AF
A meta-analysis of 13 randomized trials of prophylactic antiar-
rhythmic therapy involving 1783 patients undergoing cardiac
surgery in which effects on hospital length of stay were ad-
dressed found that while these consistently showed decreases in
the incidence of AF, the effects on hospital stay were less
concordant and amounted to a 1.0 plus or minus 0.2 d overall
decrease in length of hospital stay (p less than 0.001) (835). A
systematic Cochrane database review found 58 studies with a
total of 8565 participants in which interventions included ami-
odarone, beta blockers, solatol, and pacing. By meta-analysis,
the effect size for prevention of stroke by prophylactic treatment
for AF was not statistically significant, nor was the effect on
length or cost of hospital stay. Beta blockers had the greatest
magnitude of effect across 28 trials (4074 patients) (836). In a
meta-analysis of 24 trials (825) limited to patients with ejection
fraction greater than 30% undergoing CABG, prophylactic
TABLE 24. Multivariate Predictors of Postoperative Atrial
Arrhythmias in Patients Undergoing Myocardial
Revascularization Surgery
Advanced age
Male gender
Digoxin
Peripheral arterial disease
Chronic lung disease
Valvular heart disease
Left atrial enlargement
Previous cardiac surgery
Discontinuation of beta-blocker medication
Preoperative atrial tachyarrhythmias
Pericarditis
Elevated postoperative adrenergic tone
Adapted with permission from the Society of Thoracic Surgeons (Creswell
LL, Schuessler RB, Rosenbloom M, Cox JL. Hazards of postoperative atrial
arrhythmias. Ann Thorac Surg 1993;56:539–49 (824).
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administration of beta-blocker medication protected against
supraventricular tachycardia (OR 0.28, 95% CI 0.21 to 0.36). In
a meta-analysis of 27 trials including 3840 patients, sotalol (80
or 120 mg twice daily) was more effective in reducing postop-
erative AF than either other beta-blocker medication or placebo
(829), but the results were not confirmed in another study (491),
in which the difference between sotalol and beta-blocker treat-
ment was small.
When the prophylactic value of amiodarone, 600 mg per day,
initiated at least 7 d preoperatively, was evaluated in 124 patients
undergoing cardiac surgery, the incidence of AF was 25% in the
treated group compared with 53% in patients randomized to
placebo (p 0.003) (837). This approach is impractical unless
patients are identified and treatment started at least 1 wk before
surgery. The Amiodarone Reduction in Coronary Heart (ARCH)
trial involving 300 patients found that postoperative intravenous
administration of amiodarone (1 g daily for 2 d) reduced the
incidence of postoperative AF from 47% to 35% compared with
placebo (p 0.01). The higher overall incidence of postopera-
tive AF and less pronounced prophylactic effect than in other
studies may have been partly related to less-frequent use of beta
blockers (838). More convincing evidence of the efficacy of
amiodarone for prevention of AF in patients undergoing cardiac
surgery comes from the Prophylactic Oral Amiodarone for the
Prevention of Arrhythmias that Begin Early after Revasculariza-
tion, Valve Replacement, or Repair (PAPABEAR) trial, in
which a 13-d perioperative course of oral amiodarone (10 mg/kg
daily beginning 6 d before and continuing for 6 d after surgery)
halved the incidence of postoperative atrial tachyarrhythmias,
including AF patients undergoing CABG, valve replacement, or
valve repair surgery with or without CABG surgery (839).
Although efficacy was evident whether or not beta-blocking
medication was given concurrently, rates of beta-blocker therapy
withdrawal were not reported; hence, differential withdrawal of
beta blockers from more patients in the placebo group may have
exaggerated the apparent effect of amiodarone (840).
Pretreatment with either digoxin or verapamil does not
reliably prevent postoperative AF (825,841,842). Results
with procainamide have been inconsistent, and this drug is
not widely used for prevention of postoperative AF (843).
One report suggested that n-3 polyunsaturated fatty acids may
be effective for prevention of AF in patients undergoing
CABG surgery (844).
There is limited evidence that single-chamber and biatrial
overdrive pacing prevents postoperative AF. In a randomized
trial involving 132 patients undergoing CABG, postoperative
biatrial pacing significantly reduced the incidence of AF in the
biatrial pacing group by 12.5% compared with the other 3
groups (36% LA pacing, 33% RA pacing, and 42% without
pacing; p  0.05). The length of hospital stay was also
significantly reduced in the biatrial pacing group (845). A
meta-analysis of 10 randomized trials comparing various types
of atrial pacing to routine care after CABG surgery found that
AF was reduced by RA pacing (OR 0.68, 95% CI 0.39 to 1.19),
LA pacing (OR 0.57, 95% CI 0.28 to 1.16), and biatrial pacing
(OR 0.46, 95% CI 0.30 to 0.71), but the number of enrolled
patients was small and the pacing sites and protocols varied
(846). Available data suggest that biatrial pacing may be
superior to either LA or RA pacing for prevention of postoper-
ative AF, but evidence is insufficient to permit firm conclusions
or recommendations about this prophylactic modality.
8.4.1.3. Treatment of Postoperative AF
Comorbidity including adrenergic stress often makes it diffi-
cult to control the ventricular rate in patients with postoper-
ative AF. Short-acting beta-blocker agents are particularly
useful when hemodynamic instability is a concern. Other AV
nodal blocking agents, such as the nondihydropyridine cal-
cium channel antagonist agents, can be used as alternatives,
but digoxin is less effective when adrenergic tone is high.
Intravenous amiodarone has been associated with improved
hemodynamics in this setting (379).
Given the self-limited course of postoperative AF, direct-
current cardioversion is usually unnecessary except when the
arrhythmia develops in the early hypothermic period. In the
highly symptomatic patient or when rate control is difficult to
achieve, cardioversion may be performed using the same
precautions regarding anticoagulation as in nonsurgical cases.
A variety of pharmacological agents, including amiodarone
(837,838,847), procainamide, (841) ibutilide, and sotalol,
may be effective to convert AF to sinus rhythm. Although a
class III agent (e.g., ibutilide) was more effective than
placebo for treatment of postoperative AF in one study (848),
oral sotalol is appealing in this situation because its beta-
blocking action slows the ventricular rate and proarrhythmic
toxicity is relatively infrequent, but this agent seems less
effective than others for cardioversion of AF.
A number of studies have shown an increased risk of stroke
in post-CABG patients. Accordingly, anticoagulation with
heparin or oral anticoagulation is appropriate when AF
persists longer than 48 h (849,850). This entails special
challenges because of the greater potential for bleeding in
surgical patients. The choice of drug, heparin and/or an oral
anticoagulant, must be based on the individual clinical
situation.
Atrial flutter is less common than AF after cardiac surgery
(851), but pharmacological therapy is similar. Prevention of
postoperative atrial flutter is as difficult as prevention of AF,
but atrial overdrive pacing is generally useful for termination
of atrial flutter when epicardial electrodes are in place.
8.4.2. Acute Myocardial Infarction
RECOMMENDATIONS
Class I
1. Direct-current cardioversion is recommended for pa-
tients with severe hemodynamic compromise or intrac-
table ischemia, or when adequate rate control cannot
be achieved with pharmacological agents in patients
with acute MI and AF. (Level of Evidence: C)
2. Intravenous administration of amiodarone is recom-
mended to slow a rapid ventricular response to AF
and improve LV function in patients with acute MI.
(Level of Evidence: C)
3. Intravenous beta blockers and nondihydropyridine
calcium antagonists are recommended to slow a
rapid ventricular response to AF in patients with
acute MI who do not display clinical LV dysfunction,
bronchospasm, or AV block. (Level of Evidence: C)
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4. For patients with AF and acute MI, administration
of unfractionated heparin by either continuous in-
travenous infusion or intermittent subcutaneous in-
jection is recommended in a dose sufficient to pro-
long the activated partial thromboplastin time to 1.5
to 2.0 times the control value, unless contraindica-
tions to anticoagulation exist. (Level of Evidence: C)
Class IIa
Intravenous administration of digitalis is reasonable to
slow a rapid ventricular response and improve LV func-
tion in patients with acute MI and AF associated with
severe LV dysfunction and HF. (Level of Evidence: C)
Class III
The administration of class IC antiarrhythmic drugs is
not recommended in patients with AF in the setting of
acute MI. (Level of Evidence: C)
Estimates of the incidence of AF in patients with acute MI
vary depending on the population sampled. In the Coopera-
tive Cardiovascular Project, 22% of Medicare beneficiaries
65 y or older hospitalized for acute MI had AF (270). In the
Trandolapril Cardiac Evaluation (TRACE) study of patients
with LV dysfunction associated with acute MI, 21% had AF
(852). Lower rates of AF were observed in patients selected
for other prospective trials, such as the Global Utilization of
Streptokinase and Tissue Plasminogen Activator for Oc-
cluded Coronary Arteries (GUSTO-I) study, in which the
incidence was 10.4% (853), but this may reflect the younger
age of patients presenting with acute MI associated with
ST-segment elevation on the ECG. AF is more commonly
associated with acute MI in older patients and those with
higher Killip class or LV dysfunction.
AF is associated with increased in-hospital mortality in the
setting of acute MI (25.3% with AF vs. 16.0% without AF),
30-d mortality (29.3% vs. 19.1%), and 1-y mortality (48.3%
vs. 32.7%) (270). Patients who developed AF during hospi-
talization had a worse prognosis than those with AF on
admission (270). Stroke rates are also increased in patients
with MI and AF compared with those without AF (853).
Outcomes for patients with AF and acute MI have improved
in the thrombolytic era compared with prior experience, but a
stroke rate of 3.1% (853) emphasizes the importance of this
association in contemporary clinical practice.
Specific recommendations for management of patients
with AF in the setting of acute MI are based primarily on
consensus, because no adequate trials have tested alternative
strategies. The recommendations in this document are in-
tended to comply with the ACC/AHA Guidelines for the
Management of Patients With ST-Elevation Myocardial In-
farction (854). Physicians should apply the guidelines for
management outlined elsewhere in this document with em-
phasis on recognition of AF and risk stratification and
recognize the significance of the arrhythmia as an indepen-
dent predictor of poor long-term outcome in patients with
acute MI (855,856).
Urgent direct-current cardioversion is appropriate in acute
MI patients presenting with AF and intractable ischemia or
hemodynamic instability. Intravenous administration of a
beta blocker is indicated for rate control in patients with acute
MI to reduce myocardial oxygen demands. Digoxin is an
appropriate alternative for patients with acute MI associated
with severe LV dysfunction and HF. Anticoagulants are
indicated in those with large anterior infarcts and in survivors
of acute MI who develop persistent AF. Treatment with ACE
inhibitors appears to reduce the incidence of AF in patients
with LV dysfunction after acute MI (857). In patients with
reduced LV systolic function after MI, the placebo-controlled
CAPRICORN trial demonstrated a significant reduction in
the incidence of AF and/or atrial flutter in patients treated
with carvedilol (5.4% vs. 2.3%) (858).
8.4.3. Wolff-Parkinson-White (WPW)
Preexcitation Syndromes
RECOMMENDATIONS
Class I
1. Catheter ablation of the accessory pathway is recom-
mended in symptomatic patients with AF who have
WPW syndrome, particularly those with syncope due
to rapid heart rate or those with a short bypass tract
refractory period. (Level of Evidence: B)
2. Immediate direct-current cardioversion is recom-
mended to prevent ventricular fibrillation in pa-
tients with a short anterograde bypass tract refrac-
tory period in whom AF occurs with a rapid
ventricular response associated with hemodynamic
instability. (Level of Evidence: B)
3. Intravenous procainamide or ibutilide is recom-
mended to restore sinus rhythm in patients with
WPW in whom AF occurs without hemodynamic
instability in association with a wide QRS complex
on the ECG (greater than or equal to 120-ms dura-
tion) or with a rapid preexcited ventricular re-
sponse. (Level of Evidence: C)
Class IIa
Intravenous flecainide or direct-current cardioversion
is reasonable when very rapid ventricular rates occur
in patients with AF involving conduction over an
accessory pathway. (Level of Evidence: B)
Class IIb
It may be reasonable to administer intravenous quini-
dine, procainamide, disopyramide, ibutilide, or amiod-
arone to hemodynamically stable patients with AF
involving conduction over an accessory pathway. (Level
of Evidence: B)
Class III
Intravenous administration of digitalis glycosides or
nondihydropyridine calcium channel antagonists is not
recommended in patients with WPW syndrome who
have preexcited ventricular activation during AF.
(Level of Evidence: B)
Although the most feared complication of AF in patients with
WPW syndrome is ventricular fibrillation and sudden death
resulting from antegrade conduction of atrial impulses across
a bypass tract, this actually occurs infrequently. The inci-
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dence of sudden death ranges from 0% to 0.6% per year in
patients with WPW syndrome (460,634,823,859). In contrast,
a large population-based study in Olmsted County, Minne-
sota, found 4 newly diagnosed cases of WPW syndrome per
100 000 people per year. There were only 2 sudden deaths
over 1338 patient-y of follow-up, however. Among 113
patients with WPW syndrome, 6 had documented AF and 3
had atrial flutter. Patients with WPW syndrome at high risk of
sudden death are those with short antegrade bypass tract
refractory periods (less than 250 ms) and short R-R intervals
during preexcited AF (180 plus or minus 29 ms) (178,860). In
patients prone to ventricular fibrillation, there is also a higher
incidence of multiple pathways (178).
When a patient with a preexcited tachycardia is clinically
stable, intravenous procainamide may be given to convert AF
to sinus rhythm. It is critically important to avoid agents with
the potential to increase the refractoriness of the AV node,
which could encourage preferential conduction over the
accessory pathway. Specifically, administration of AV nodal
blocking agents such as digoxin, diltiazem, or verapamil is
contraindicated. Beta blockers are ineffective in this situation,
and their administration via the intravenous route may have
adverse hemodynamic effects.
Flecainide can slow the ventricular rate in patients who
have AF associated with a very rapid tachycardia due to an
accessory pathway and may terminate AF (861–864) by
prolonging the shortest preexcited cycle length during AF.
Propafenone seems less effective in this respect (861).
For patients with preexcitation syndromes and AF who
have syncope (suggesting rapid heart rate) or a short antero-
grade bypass tract refractory period, immediate direct-current
cardioversion followed by catheter ablation of the accessory
pathway is the preferred therapy (865). Ablation of the bypass
tract does not necessarily prevent AF, however, especially in
older patients, and additional pharmacological therapy may
be required. Once the accessory pathway has been eliminated,
the selection of pharmacological therapy can parallel that for
patients without preexcitation.
8.4.4. Hyperthyroidism
RECOMMENDATIONS
Class I
1. Administration of a beta blocker is recommended to
control the rate of ventricular response in patients
with AF complicating thyrotoxicosis, unless contra-
indicated. (Level of Evidence: B)
2. In circumstances when a beta blocker cannot be
used, administration of a nondihydropyridine cal-
cium channel antagonist (diltiazem or verapamil) is
recommended to control the ventricular rate in
patients with AF and thyrotoxicosis. (Level of Evi-
dence: B)
3. In patients with AF associated with thyrotoxicosis,
oral anticoagulation (INR 2.0 to 3.0) is recom-
mended to prevent thromboembolism, as recom-
mended for AF patients with other risk factors for
stroke. (Level of Evidence: C)
4. Once a euthyroid state is restored, recommendations
for antithrombotic prophylaxis are the same as for
patients without hyperthyroidism. (Level of Evi-
dence: C)
AF occurs in 10% to 25% of patients with hyperthyroid-
ism, more commonly in men and elderly patients than in
women or patients younger than 75 y (866). Treatment is
directed primarily toward restoring a euthyroid state,
which is usually associated with a spontaneous reversion
to sinus rhythm. Antiarrhythmic drugs and direct-current
cardioversion are generally unsuccessful while the thyro-
toxic condition persists (867,868). Beta blockers are effec-
tive in controlling the ventricular rate in this situation, and
aggressive treatment with intravenous beta blockers is
particularly important in cases of thyroid storm, when high
doses may be required. Nondihydropyridine calcium chan-
nel antagonists may also be useful (869). Although specific
evidence is lacking in AF caused by hyperthyroidism, oral
anticoagulation is recommended to prevent systemic em-
bolism (870).
Several reports suggest that patients with AF in the
setting of thyrotoxicosis, which is often associated with
decompensated HF, are also at high risk (418,419,422),
although the mechanism underlying this enhanced embolic
potential is not clear (203,416,423). The notion of in-
creased thromboembolic risk in thyrotoxic AF has been
challenged on the basis of comparison with patients in
sinus rhythm, and logistic regression analysis found age
the only independent predictor of cerebral ischemic events
(319). Although 13% of patients with AF had ischemic
cerebrovascular events (6.4% per year) compared with 3%
of those in normal sinus rhythm (1.7% per year),
(203,268,320) there was no adjustment for duration of
observation or time to event. When TIAs are discounted,
the increased risk of stroke in patients with AF reached
statistical significance (p  0.03) (319). Although it re-
mains controversial whether patients with AF associated
with thyrotoxicosis are at increased risk of thromboem-
bolic cerebrovascular events (421), the authors of these
guidelines favor treatment with anticoagulant medication
in the absence of a specific contraindication, at least until
a euthyroid state has been restored and HF has been cured.
8.4.5. Pregnancy
RECOMMENDATIONS
Class I
1. Digoxin, a beta blocker, or a nondihydropyridine
calcium channel antagonist is recommended to con-
trol the rate of ventricular response in pregnant
patients with AF. (Level of Evidence: C)
2. Direct-current cardioversion is recommended in
pregnant patients who become hemodynamically
unstable due to AF. (Level of Evidence: C)
3. Protection against thromboembolism is recom-
mended throughout pregnancy for all patients with
AF (except those with lone AF and/or low thrombo-
embolic risk). Therapy (anticoagulant or aspirin)
should be chosen according to the stage of preg-
nancy. (Level of Evidence: C)
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Class IIb
1. Administration of heparin may be considered during
the first trimester and last month of pregnancy for
patients with AF and risk factors for thromboembo-
lism. Unfractionated heparin may be administered
either by continuous intravenous infusion in a dose
sufficient to prolong the activated partial thrombo-
plastin time to 1.5 to 2 times the control value or by
intermittent subcutaneous injection in a dose of
10 000 to 20 000 units every 12 h, adjusted to pro-
long the mid-interval (6 h after injection) activated
partial thromboplastin time to 1.5 times control.
(Level of Evidence: B)
2. Despite the limited data available, subcutaneous
administration of low-molecular-weight heparin
may be considered during the first trimester and last
month of pregnancy for patients with AF and risk
factors for thromboembolism. (Level of Evidence: C)
3. Administration of an oral anticoagulant may be
considered during the second trimester for pregnant
patients with AF at high thromboembolic risk.
(Level of Evidence: C)
4. Administration of quinidine or procainamide may
be considered to achieve pharmacological cardiover-
sion in hemodynamically stable patients who develop
AF during pregnancy. (Level of Evidence: C)
AF is rare during pregnancy and usually has an identifiable
underlying cause, such as mitral stenosis (875), congenital
heart disease (876), or hyperthyroidism (877). A rapid ven-
tricular response to AF can have serious hemodynamic
consequences for both the mother and the fetus.
In a pregnant woman who develops AF, diagnosis and
treatment of the underlying condition causing the arrhythmia are
the first priorities. The ventricular rate should be controlled with
digoxin, a beta blocker, or a nondihydropyridine calcium chan-
nel antagonist (878–880). All currently available antiarrhythmic
drugs have the potential to cross the placenta and enter breast
milk and should therefore be avoided if possible. Quinidine
(879), sotalol (881), flecainide (881), and amiodarone (870,876–
878) have all been used successfully during pregnancy, how-
ever, in relatively small numbers of cases. Quinidine has the
longest record of safety in pregnant women and remains the
agent of choice for pharmacological cardioversion of AF in this
situation (497,879). In the event of hemodynamic embarrass-
ment, direct-current cardioversion can be performed without
fetal damage (879).
The role of anticoagulation to prevent systemic arterial em-
bolism has not been systematically studied in pregnant patients
with AF, but the arrhythmia is frequently associated with
conditions that carry a high risk of thromboembolism, including
congenital or valvular heart disease. Consideration should be
given to avoiding warfarin because it crosses the placental
barrier and is associated with teratogenic embryopathy in the
first trimester and with fetal hemorrhage in the later stages of
pregnancy (880–886). Heparin is the preferred anticoagulant
because it does not cross the placenta. The safety and efficacy of
subcutaneous unfractionated heparin or low-molecular-weight
heparin in preventing ischemic stroke in patients with AF during
pregnancy have not been proved, and experience with these
agents mainly involves patients with prosthetic heart valves or
venous thromboembolism. In patients with prosthetic valves
who have AF, unfractionated heparin can be administered either
by continuous intravenous infusion or by twice-daily subcuta-
neous injections in a dose between 10 000 and 20 000 units
adjusted to prolong the mid-interval activated partial thrombo-
plastin time to 1.5 times the control value. The same strategies
are proposed for patients without prosthetic valves who have AF
and risk factors for thromboembolism (887,888).
8.4.6. Hypertrophic Cardiomyopathy
RECOMMENDATIONS
Class I
Oral anticoagulation (INR 2.0 to 3.0) is recommended
in patients with hypertrophic cardiomyopathy who
develop AF, as for other patients at high risk of
thromboembolism. (Level of Evidence: B)
Class IIa
Antiarrhythmic medications can be useful to prevent
recurrent AF in patients with hypertrophic cardiomy-
opathy. Available data are insufficient to recommend
one agent over another in this situation, but (a) diso-
pyramide combined with a beta blocker or nondihydro-
pyridine calcium channel antagonist or (b) amiodarone
alone is generally preferred. (Level of Evidence: C)
Opinions differ regarding the clinical significance of AF in the
setting of HCM. In a retrospective series of 52 patients studied
between 1960 and 1985, 89% of those patients who developed
AF experienced hemodynamic deterioration that was amelio-
rated by restoration of sinus rhythm (889). In a multivariate
analysis of a population-based cohort of 37 patients with HCM
who experienced an annual cardiac mortality rate of 5%, AF was
associated with decreased survival (402). A lower annual mor-
tality rate (1.3%) was observed in a single-center retrospective
study of 277 patients with HCM. The prevalence of AF was
18%. Among the 50 cases with AF, 15 deaths were recorded, a
third of which were attributed to stroke (890). The natural
history of HCM is better defined by the combined experience of
3 large centers following 717 cases for a mean of 8 plus or minus
7 y, during which there were 86 deaths (12%), 51% of which
were sudden (mean age 45 plus or minus 20 y). Death was
attributable to HF in 36% of the patients (mean age 56 plus or
minus 19 y) and to stroke in 13% (mean age 73 plus or minus
14 y). Although most sudden deaths were attributed to ventric-
ular arrhythmias, cardiogenic embolism may have been under-
estimated as a contributory mechanism. Ten of 11 fatal strokes
were associated with AF. In a study of 480 patients the
prevalence of AF was 22% over 9 y. AF was associated with an
increased risk of HCM-related death (odds ratio 3.7) due to
excess HF-related mortality but not sudden cardiac death. AF
patients were at increased risk for stroke (odds ratio 17.7) and
severe functional limitation (odds ratio for NYHA Class III or
IV 2.8) (891).
Studies of patients with HCM and AF (892) have consis-
tently reported a high incidence of stroke and systemic
embolism (871–874). These retrospective longitudinal stud-
ies report stroke or systemic embolism in 20% to 40% of
patients with HCM and AF followed up for a mean of 4 to
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11 y, for a thromboembolism rate of 2.4% to 7.1% per year.
In addition to AF, other factors associated with systemic
embolism in patients with HCM include advanced age (874),
hypertension (872), mitral annular calcification, and LA
enlargement (872). By multivariate analysis, age and AF
were independent predictors of thromboembolism (874).
Although no randomized studies of anticoagulant therapy
have been reported, the incidence of thromboembolism in
patients with HCM and AF is high, warranting consideration
of anticoagulant medication when AF persists for longer than
48 h or when recurrence is likely.
There have been no systematic studies of the treatment of
AF in patients with HCM, but various antiarrhythmic agents,
including disopyramide, propafenone, and amiodarone, have
been used. Deedwania et al (738) advocate administration of
amiodarone both to prevent episodes of AF and to modulate
the rate of ventricular response. The use of electrical pacing
to prevent AF has not been studied.
8.4.7. Pulmonary Diseases
RECOMMENDATIONS
Class I
1. Correction of hypoxemia and acidosis is the recom-
mended primary therapeutic measure for patients who
develop AF during an acute pulmonary illness or
exacerbation of chronic pulmonary disease. (Level of
Evidence: C)
2. A nondihydropyridine calcium channel antagonist
(diltiazem or verapamil) is recommended to control
the ventricular rate in patients with obstructive
pulmonary disease who develop AF. (Level of Evi-
dence: C)
3. Direct-current cardioversion should be attempted in
patients with pulmonary disease who become hemody-
namically unstable as a consequence of AF. (Level of
Evidence: C)
Class III
1. Theophylline and beta-adrenergic agonist agents are
not recommended in patients with bronchospastic
lung disease who develop AF. (Level of Evidence: C)
2. Beta blockers, sotalol, propafenone, and adenosine
are not recommended in patients with obstructive
lung disease who develop AF. (Level of Evidence: C)
Supraventricular arrhythmias, including AF, are common in
patients with COPD (893,894). AF has adverse prognostic
implications in patients with acute exacerbations of COPD
(895). Treatment of the underlying lung disease and correc-
tion of hypoxia and acid-base imbalance are of primary
importance in this situation. Theophylline and beta-
adrenergic agonists, which are commonly used to relieve
bronchospasm, can precipitate AF and make control of the
ventricular response rate difficult. Beta blockers, sotalol,
propafenone, and adenosine are contraindicated in patients
with bronchospasm. Rate control can usually be achieved
safely with nondihydropyridine calcium channel antagonists
(896); digoxin offers no advantage over calcium channel
antagonists in this situation. Pharmacological antiarrhythmic
therapy and direct-current cardioversion may be ineffective
against AF unless respiratory decompensation has been cor-
rected. Intravenous flecainide may be efficacious in restoring
sinus rhythm in some patients (508), however, and direct-
current cardioversion may be attempted in hemodynamically
unstable patients. In patients refractory to drug therapy, AV
nodal ablation and ventricular pacing may be necessary to
control the ventricular rate. Although anticoagulation has not
been studied specifically in patients with AF due to pulmonary
lung disease, the general recommendations for risk-based anti-
thrombotic therapy apply.
8.5. Primary Prevention
Although measures aimed at the primary prevention of AF have
not been widely investigated, it has been suggested that atrial or
AV synchronous pacing may reduce the incidence of subsequent
AF in patients with bradycardia compared with ventricular
pacing (807,808). On the other hand, studies in patients with
intermittent atrial tachyarrhythmias failed to illustrate a general
benefit of atrial pacing (808,822,897). Another potential avenue
for primary prevention has been suggested following secondary
analysis of placebo-controlled trials of treatment with ACE
inhibitors (36,749). In the LIFE (41) and CHARM (898) trials,
the angiotensin receptor antagonists losartan and candesartan
reduced the incidence of AF in hypertensive patients with LVH
(41) and symptomatic HF (40,898), respectively. These results,
together with their favorable safety profile compared with
antiarrhythmic agents, suggest a role for ACE inhibitors or
angiotensin receptor antagonists for primary prevention of initial
or recurrent episodes of AF associated with hypertension, MI,
HF, or diabetes mellitus. An overview of 11 clinical trials
involving more than 56 000 patients with different underlying
cardiovascular diseases suggests that ACE inhibitors or angio-
tensin receptor blockers may reduce the occurrence and recur-
rence of AF (43).
Yet inadequately explored, the use of statins has also been
suggested to protect against AF, (335,899) and dietary lipid
components may influence the propensity of patients to
develop AF (900). In 449 patients with CAD followed for 5 y,
statin therapy reduced the incidence of AF—an effect not
observed with other lipid-lowering drugs (899). In a canine
sterile pericarditis model, atorvastatin prevented atrial elec-
trophysiological and structural changes associated with in-
flammation and reduced the incidence of AF (119). Insuffi-
cient data are available at this time to permit
recommendations for primary prevention of AF in popula-
tions at risk using dietary interventions, pharmacological
interventions, or pacing or other devices.
9. Proposed Management Strategies
9.1. Overview of Algorithms for Management of
Patients With Atrial Fibrillation
Management of patients with AF requires knowledge of its
pattern of presentation (paroxysmal, persistent, or perma-
nent), underlying conditions, and decisions about restoration
and maintenance of sinus rhythm, control of the ventricular
rate, and antithrombotic therapy. These issues are addressed
in the various management algorithms for each presentation
of AF (see Figs. 13, 14, 15, and 16).
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9.1.1. Newly Discovered Atrial Fibrillation
It is not always clear whether the initial presentation of AF is
actually the first episode, particularly in patients with minimal or
no symptoms related to the arrhythmia. In patients who have
self-limited episodes of AF, antiarrhythmic drugs are usually
unnecessary to prevent recurrence unless AF is associated with
severe symptoms related to hypotension, myocardial ischemia,
or HF. Regarding anticoagulation, the results of the AFFIRM
study (296) indicate that patients with AF who are at high risk
for stroke on the basis of identified risk factors generally benefit
from anticoagulation even after sinus rhythm has been restored.
Therefore, unless there is a clear reversible precipitating factor
for AF, such as hyperthyroidism that has been corrected, the
diagnosis of AF in a patient with risk factors for thromboembo-
lism should prompt long-term anticoagulation.
When AF persists, one option is to accept progression to
permanent AF, with attention to antithrombotic therapy and
control of the ventricular rate. Although it may seem reasonable
to make at least one attempt to restore sinus rhythm, the
AFFIRM study showed no difference in survival or quality of
life with rate-control compared with rhythm-control strategies
(296). Other trials that addressed this issue reached similar
conclusions (293,294,343,344). Hence, the decision to attempt
restoration of sinus rhythm should be based on the severity of
arrhythmia-related symptoms and the potential risk of antiar-
rhythmic drugs. If the decision is made to attempt to restore and
maintain sinus rhythm, then anticoagulation and rate control are
important before cardioversion. Although long-term antiarrhyth-
mic therapy may not be needed to prevent recurrent AF after
cardioversion, short-term therapy may be beneficial. In patients
with AF that has been present for more than 3 mo, early
recurrence is common after cardioversion. In such cases, antiar-
rhythmic medication may be initiated before cardioversion (after
adequate anticoagulation) to reduce the likelihood of recurrence,
and the duration of drug therapy would be brief (e.g., 1 mo).
9.1.2. Recurrent Paroxysmal Atrial Fibrillation
In patients who experience brief or minimally symptomatic
recurrences of paroxysmal AF, it is reasonable to avoid
antiarrhythmic drugs, but troublesome symptoms generally
call for suppressive antiarrhythmic therapy. Rate control and
prevention of thromboembolism are appropriate in both
situations. In a given patient, several antiarrhythmic drugs
may be effective, and the initial selection is based mainly on
safety and tolerability (see Fig. 15). For individuals with no
or minimal heart disease, flecainide, propafenone, or sotalol
is recommended as initial antiarrhythmic therapy because
these drugs are generally well tolerated and carry relatively
little risk of toxicity. For patients with recurrent episodes of
symptomatic AF who tolerate these agents, an as-needed,
pill-in-the-pocket approach may reduce the risk of toxicity
compared with sustained therapy. When these drugs prove
ineffective or are associated with side effects, the second- or
third-line choices include amiodarone, dofetilide, disopyr-
amide, procainamide, or quinidine, all of which carry greater
potential for adverse reactions. As an alternative to treatment
with amiodarone or dofetilide when first-line antiarrhythmic
drugs fail or are not tolerated, PV isolation or LA substrate
modification may be considered. When a consistent initiating
scenario suggests vagally mediated AF, drugs such as diso-
pyramide or flecainide are appropriate initial agents, and a
beta blocker or sotalol is suggested for patients with adren-
ergically induced AF. In particularly symptomatic patients,
nonpharmacological options such as LA ablation may be
considered when antiarrhythmic drug treatment alone fails to
control the arrhythmia.
Many patients with organic heart disease can be broadly
categorized into those with HF, CAD, or hypertension. Other
types of heart disease can be associated with AF, and the
clinician must determine which category best describes the
individual patient. For patients with HF, safety data support
the selection of amiodarone or dofetilide to maintain sinus
rhythm. Patients with CAD often require beta blocker medi-
cation, and sotalol, a drug with both beta-blocking activity
and primary antiarrhythmic efficacy, is considered first,
unless the patient has HF. Amiodarone and dofetilide are
considered secondary agents, and the clinician should con-
sider disopyramide, procainamide, or quinidine on an indi-
vidual basis.
The selection of antiarrhythmic drugs for patients with a
history of hypertension is confounded by the dearth of
prospective, controlled trials comparing the safety and effi-
cacy of drug therapy for AF. In patients with hypertension
without LVH, drugs such as flecainide and propafenone,
which do not prolong repolarization or the QT interval, may
offer a safety advantage and are recommended first. If these
agents either prove ineffective or produce side effects, then
amiodarone, dofetilide, or sotalol represents an appropriate
secondary choice. Disopyramide, procainamide, and quini-
dine are considered third-line agents in this situation. Hyper-
trophied myocardium may be prone to proarrhythmic toxicity
and torsades de pointes ventricular tachycardia. Amiodarone
is suggested as first-line therapy in patients with LVH
because of its relative safety compared with several other
agents. Because neither ECG nor echocardiography reliably
detects LVH as defined by measurement of myocardial mass,
clinicians may face a conundrum.
The scarcity of data from randomized trials of antiarrhyth-
mic medications for treatment of patients with AF applies
generally to all patient groups. Accordingly, the drug-
selection algorithm presented here has been developed by
consensus and is subject to revision as additional evidence
emerges.
9.1.3. Recurrent Persistent Atrial Fibrillation
Patients with minimal or no symptoms referable to AF who
have undergone at least one attempt to restore sinus rhythm
may remain in AF after recurrence, with therapy for rate
control and prevention of thromboembolism as needed. Al-
ternatively, those with symptoms favoring sinus rhythm
should be treated with an antiarrhythmic agent (in addition to
medications for rate control and anticoagulation) before
cardioversion. The selection of an antiarrhythmic drug should
be based on the same algorithm used for patients with
recurrent paroxysmal AF. If patients remain symptomatic
with heart rate control, and antiarrhythmic medication is
either not tolerated or ineffective, then nonpharmacological
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therapies may be considered. These include LA ablation, the
maze operation, and AV nodal ablation and pacing.
9.1.4. Permanent Atrial Fibrillation
Permanent AF is the designation given to cases in which
sinus rhythm cannot be sustained after cardioversion of AF
or when the patient and physician have decided to allow
AF to continue without further efforts to restore sinus
rhythm. It is important to maintain control of the ventric-
ular rate and to use antithrombotic therapy, as outlined
elsewhere in this document, for all patients in this
category.
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APPENDIX III: Abbreviations
ACE angiotensin-converting enzyme
ACT activated clotting time
ACTIVE-W Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events
ADONIS American-Australian Trial with Dronedarone in Atrial Fibrillation or Flutter Patients for Maintenance of Sinus Rhythm
AF atrial fibrillation
AFASAK Copenhagen Atrial Fibrillation, Aspirin, Anticoagulation
AF-CHF Atrial Fibrillation and Congestive Heart Failure
AFFIRM Atrial Fibrillation Follow-up Investigation of Rhythm Management
AFI Atrial Fibrillation Investigators
ALFA Etude en Activité Libérale sur la Fibrillation Auriculaire
ANP atrial naturetic peptide
APT Ablate and Pace Trial
ARCH Amiodarone Reduction in Coronary Heart
ATRIA Anticoagulation and Risk Factors in Atrial Fibrillation
AV atrioventricular
BAATAF Boston Area Anticoagulation Trial for Atrial Fibrillation
BNP B-type natriuretic peptide
CABG coronary artery bypass
CAD coronary artery disease
CAFA Canadian Atrial Fibrillation Anticoagulation
CAPRICORN Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction trial
CHADS2 Cardiac Failure, Hypertension, Age, Diabetes, Stroke Doubled
CHAMP Combined Hemotherapy and Mortality Prevention Study
CHARM Candesartan in Heart failure, Assessment of Reduction in Mortality and morbidity
CHF-STAT Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure
CI confidence interval
CIBIS Cardiac Insufficiency Bisoprolol Study
COMET Carvedilol Or Metoprolol European Trial
CONSENSUS Co-operative North Scandinavian Enalapril Survival Study
COPERNICUS Carvedilol Prospective Randomized Cumulative Survival
COPD Chronic obstructive pulmonary disorder
CRP C-reactive protein
CTGF connective tissue growth factor
CVF-1 type 1 collagen volume fraction
DIAMOND Danish Investigations of Arrhythmias and Mortality on Dofetilide
DIAMOND-MI Danish Investigations of Arrhythmia and Mortality on Dofetilide–Myocardial Infarction
EAFT European Atrial Fibrillation Trial
ECG electrocardiogram
ELAT Embolism in the Left Atrial Thrombi
EMERALD European and Australian Multicenter Evaluative Research on Atrial Fibrillation Dofetilide study
EP electrophysiological
ERK-2-mRNA extracellular signal-regulated kinase messenger-RNA
ERP effective refractory period
ESPS II European Stroke Prevention Study II
EURIDIS European Trial in Atrial Fibrillation or Flutter Patients Receiving Dronedarone for Maintenance of Sinus Rhythm
FFAACS The French Fluindione-Aspirin Combination in High Risk Patients With AF
GESICA Grupo Estudio de la Sobrevida en la Insufficienca Cardiaca en Argentina (V)
GUSTO-1 Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries
HCM hypertrophic cardiomyopathy
HF heart failure
HOT CAFÉ How to Treat Chronic Atrial Fibrillation
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APPENDIX III: Continued
HRV heart rate variability
IMP-2 atrial insulin-like growth factor-II mRNA-binding protein 2
INR international normalized ratio
IRAF immediate recurrence of atrial fibrillation
IVC inferior vena cava
LA left atrium
LAA LA appendage
LASAF Low-dose Aspirin, Stroke, Atrial Fibrillation
LIFE Losartan Intervention For End Point Reduction in Hypertension study
LMWH low-molecular-weight heparin
LV left ventricle
MERIT-HF Metropolol CR/XL Randomized Intervention Trial in Congestive Heart Failure
MI myocardial infarction
MMP-2 matrix metalloproteinase 2
NASPEAF National Study for Prevention of Embolism in Atrial Fibrillation
PAFAC Prevention of atrial fibrillation after cardioversion
PAPABEAR Prevention of Arrhythmias that Begin Early after Revascularization, Valve Replacement, or Repair
PATAF Prevention of Arterial Thromboembolism in Atrial Fibrillation
PAVE Post AV Node Ablation Evaluation
PIAF Pharmacological Intervention in Atrial Fibrillation
PV pulmonary veins
RA right atrium
RAAS renin-angiotensin-aldosterone system
RACE Rate Control vs. Electrical cardioversion for persistent atrial fibrillation
RV right ventricular
SAFE-T Sotalol Amiodarone Atrial Fibrillation Efficacy Trial
SAFIRE-D Symptomatic Atrial Fibrillation Investigative Research on Dofetilide
SEC spontaneous echo contrast
SIFA Studio Italiano Fibrillazione Atriale
SOLVD Studies of Left Ventricular Dysfunction
SOPAT Suppression of paroxysmal atrial tachyarrhythmias
SPAF Stroke Prevention in Atrial Fibrillation
SPINAF Stroke Prevention in Nonrheumatic Atrial Fibrillation
SPORTIF Stroke Prevention using an Oral Direct Thrombin Inhibitor In Patients with Atrial Fibrillation
SRAF subacute recurrence of atrial fibrillation
STAF Strategies of Treatment of Atrial Fibrillation
SVC superior vena cava
TEE transesophageal echocardiography
TGF-beta1 transforming growth factor-beta1
TIA transient ischemic attack
TRACE Trandolapril Cardiac Evaluation
UK-TIA The United Kingdom transient ischaemic attack aspirin trial
Val-HeFT Valsartan Heart Failure Trial
VF ventricular fibrillation
WPW Wolff-Parkinson-White
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